Characterization of NS1 glycosylation mutant viruses as a potential vaccine candidate for West Nile virus by Whiteman, Melissa Christine
CHARACTERIZATION OF NSI GLYCOSYLATION MUTANT 
VIRUSES AS A POTENTIAL VACCINE CANDIDATE FOR
WEST NILE VIRUS
Thesis submitted in accordance with the requirements o f the 
University o f Liverpool for the degree o f Doctor in Philosophy
by
M elissa Christine Whiteman
February 2008
“ Copyright © and Moral Rights for this thesis and any 
accompanying data (where applicable) are retained by the 
author and/or other copyright owners. A copy can be 
downloaded for personal non-commercial research or study, 
without prior permission or charge. This thesis and the 
accompanying data cannot be reproduced or quoted 
extensively from without first obtaining permission in 
writing from the copyright holder/s. The content of the 
thesis and accompanying research data (where applicable) 
must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the 
copyright holder/s. When referring to this thesis and any 
accompanying data, full bibliographic details must be given, 
e.g. Thesis: Author (Year of Submission) "Full thesis title", 
University of Liverpool, name of the University Faculty or 
School or Department, PhD Thesis, pagination.” 
ABSTRACT
W est N ile virus (WNV) is a mosquito-borne flavivirus that has N-linked glycosylation 
sites on the premembrane (prM) envelope (E) and nonstructural 1 (NS1) proteins. NS1 
contains three glycosylation (asparagine-X-threoine [NXT]) sites at NS 1130, NS 1175, 
and NS 1207. The first aim o f the thesis was to attenuate WNV through the ablation of 
the NS 1 glycosylation sites, individually and in all combinations, initially by replacing 
the asparagine (N) with alanine (A) in the glycosylation m otif using site-directed 
mutagenesis o f a WNV infectious clone. Two o f the mutants were greatly attenuated, 
up to 50,000-fold, for lethal neuroinvasiveness in mice, had reduced viraemia at two 
and three days post-infection relative to the parental strain, but multiplied similarly to 
the parental strain in Vero cells. Although these viruses were highly attenuated, the 
m ost attenuated NS1 mutant virus reverted to virulence and reversion at the first NS1 
glycosylation site (NS 1130) was seen in mice that succumbed to infection. The second 
aim was to diminish reversion. Thus, the first NS1 glycosylation site was mutated 
such that it contained two or three amino acid substitutions in the NS 1130 glycosylation 
m otif (NNT—►SVT; NNT—>QQA), while the second and third glycosylation sites 
remained a single N to A amino acid change. These viruses were highly attenuated 
for mouse neuroinvasiveness and neurovirulence, > 100,000-fold and 3,000-fold, 
respectively, compared to the parental strain and did not revert to virulence. 
M ultiplication kinetics o f the attenuated viruses in mice showed a decrease in 
m ultiplication compared to the parental strain and a small plaque phenotype. The 
third aim was to examine a functional role for the NS1 protein using these mutant 
viruses. Electron microscopy studies o f the most attenuated NS1 glycosylation mutant 
virus revealed changes in the virus-induced structures compared to the parent virus- 
infected Vero cells that may suggest involvement o f the NS 1 protein in the formation 
o f these structures. Cytokine expression experiments showed several down-regulated 
cytokines in the sera o f parent and attenuated NS1 mutant virus-infected mice 
compared to mock-infected serum suggesting that immune evasion by the suppression 
o f cytokines may contribute to the WNV virulence phenotype. Therefore, mutations in 
the NS1 glycosylation sites were hypothesized to modify virus replication and the host 
response to infection leading to a mouse attenuated phenotype. Construction o f a 
virus w ith mutations ablating the glycosylation site in the E protein together with the 
ablation o f the three NS1 glycosylation sites completely attenuated this virus for 
mouse neuroinvasiveness with an ipLD5o >100,000 PFU. It was hypothesized that 
the ablation o f the prM glycosylation site would also attenuate WNV. Contrary to 
previous studies, however, the ablation o f the prM glycosylation site did not attenuate 
the virus and multiplication kinetics in cell culture revealed that this mutant virus 
multiplied to higher titres at all time points when compared to the parental strain. 
U tilization o f the mutant viruses generated in this thesis may have potential as 
effective components o f future vaccine candidates.
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CHAPTER 1 : INTRODUCTION
1
1.1 General introduction to W est Nile virus
W est Nile virus (WNV) was discovered in the 1930’s when it was isolated from the 
blood o f a  febrile woman in Africa (Smithbum et al., 1940). This virus was originally 
classified as a group B arbovirus due to its cross neutralization with Japanese 
encephalitis (JE), S t Louis encephalitis (SLE), Murray Valley encephalitis (MVE), 
Kunjin (KUN), Kokobera (KOK), Stratford and Alfuy (ALF) viruses (De M adrid and 
Porterfield, 1974). Subsequently, the group B arboviruses have been classified as the 
genus Flavivirus in the family Flaviviridae. The Flaviviridae is a diverse family, 
including three genera: Pestivirus that includes Bovine virus diarrhea and classical 
swine fever viruses, Hepacivirus that includes hepatitis C virus (HCV) and the genus 
Flavivirus. The latter consists o f more than 70 viruses, including mosquito-bome 
viruses such as dengue (DEN) and yellow fever (YF), tick-borne viruses such as tick- 
bome encephalitis (TBE) and no known vector-borne viruses such as Entebbe bat 
(ENT). Currently, WNV is classified in the JE group, which contains ALF, Cacipore, 
Koutango, JE, MVE, Usutu (USU), WN and Yaounde viruses. Kunjin virus, found in 
Australia, is classified as a subtype o f WNV.
Following the initial isolation in Uganda, the next isolates o f WNV were obtained 
over a decade later from healthy children (M elnick et al., 1951). After this time, 
isolates collected from several outbreaks suggested that the virulence o f this virus 
varied somewhat. In 1997, one study examined the phylogenetics o f 20 WNV 
isolates collected from several outbreaks in Africa and France and showed that WNV 
strains were divided in to two separate lineages (lineage I and lineage II) and that the 
Australian KUN virus belonged to lineage I as a  WN subtype (Berthet et al., 1997; 
Lanciotti et al., 1999) (Figure 1-1). W hile many WNV strains cause asymptomatic to
2
m ild infections in humans, recent outbreaks, since the mid-1990s, in Europe and the 
Americas were associated w ith severe neuroinvasive disease resulting from highly 
virulent strains. Currently, WNV is found in Africa, Asia, Europe, the M iddle East, 
A ustralia (KUN) and recently in North and South America (Figure 1-2). In the United 
States (US) all 48 contiguous states, except Maine, have documented human WNV 
infections. Since its introduction into the US in 1999, WNV has been responsible for 
at least 1,045 human fatalities and almost 11,000 cases o f diagnosed neuroinvasive 
(encephalitis/ meningitis) disease (CDC, Arbonet). There are currently four lisenced 
equine vaccines in the US: a  whole cell formalin inactivated vaccine (Ng et al., 2003), 
a recombinant canarypox containing the prM  and E o f WNV (Minke et al., 2004; 
Siger et al., 2004), a recombinant plasmid DNA containing the prM and E o f WNV 
(Davis et al., 2001) and a WNV/YF17D chimera containing theprM  and E o f WNV 
(Arroyo et al., 2004). However, to date no vaccine or antiviral is available for human 
use.
1.2 History of West Nile virus
1.2.1 History o f disease
W est N ile virus was first isolated in 1937 from a febrile woman in the W est Nile 
district o f Uganda (Smithbum et al, 1940). It was nearly 15 years later that the first 
epidem ic o f WNV was reported in Israel (Bemkopf et al., 1953). During this time, a 
four year study o f the upper Nile region examined the prevalence o f WNV in humans, 
arthropods and birds. It was concluded that o f nearly 80,000 different arthropods 
collected, WNV was isolated from the Culex species o f mosquitoes only and o f the 
420 birds examined, neutralizing antibodies were found in 65% o f crows, 42% o f
3
sparrows and virus was isolated from a sick pigeon. It was also demonstrated that 
approximately 60% of the human population possessed WNV antibodies (Taylor et 
al., 1956). A serological survey o f animals during these outbreaks indicated that a 
wide range o f animals had been also infected by WNV and it was hypothesized that 
horses may be involved in the amplification o f the virus (Murgue et al., 2001). In 
fact, more than 50% o f horses possessed WNV antibodies (Schmidt and El Mansoury, 
1963), although experimentally infected horses elicited little to no viraemia (Taylor et 
al., 1956). Based on the above, WNV was considered to be an arthropod-borne virus 
(arbovirus) that was transmitted by Culex mosquitoes to birds, who were the 
amplifiying vertebrate hosts. Humans and horses were considered “dead-end” hosts as 
the viraemia was not sufficient to infect mosquitoes.
Human cases were noted as febrile illnesses and it was not until 1957 that the first 
WNV cases including neurological manifestations were reported (Spigland et al., 
1958). During this time WNV was not commonly associated with neuroinvasive 
disease, rather it was associated with either asymptomatic or mild flu-like illness. 
Hypothesizing that the immune response to WNV infection may prevent other 
diseases, terminal cancer patients were infected w ith WNV in the hopes o f inhibiting 
neoplasms. Ninety patients were given high doses o f WNV either intramuscularly or 
intravenously, the patients observed and virem ia was recorded (Southam and Moore, 
1951; Southam and Moore, 1954). Interestingly, this study gave insight into the 
pathogenesis o f human WNV infection. Many patients did not develop any clinical 
signs o f infection other than fever, though a few patients developed encephalitic 
manifestations. Viremia was found 24 hours post-infection and lasted for six days or 
more. It was noted that there was a direct correlation between the longevity o f the
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virem ia and the severity o f disease. In most cases, WNV antibodies were detected 
three weeks post-infection.
Between 1950 and 1998, several outbreaks o f WNV were documented (Figure 1-3). 
The first recorded outbreak o f WNV occurred in 1951 in Israel. During this time 123 
cases o f WN fever were recognized with no fatalities. It was noted that the majority 
o f cases were among children younger than six years with the highest morbidity in 
children less than three years old (Bemkopf et al., 1953). Two more outbreaks 
occurred in Israel in 1957 and 1962 and it was at this time that the first clinical cases 
associated w ith neurological manifestations were noted (Spigland et al., 1958; 
Pruzanski and Altman, 1962). Also in 1962, WNV appeared in France causing an 
epizootic resulting in 30% mortality in horses that exhibited neurological 
m anifestations (Joubert et al., 1970). Severe encephalitis in humans was also reported 
at this time and one human fatality occurred in 1964 (Panthier et al, 1968). W est Nile 
outbreaks were seen in South Africa in 1974 and 1983-84, and WNV was isolated 
from the brains o f children who succumbed to encephalitis in Russia, Romania, Spain 
and India during this time (Georges et al., 1987). The first large, severe outbreak of 
WNV was seen in 1996 in Bucharest, which was also the first time an outbreak 
occurred in an urban setting, leading to a high number o f cases associated with WNV 
infection (Tsai et al., 1998). Also at this time, an outbreak in Morocco was associated 
w ith one human encephalitic case while 45% o f horses clinically affected by WNV 
succumbed to infection (Tber, 1996; El Harrack et al., 1997). In the fall o f 1997 an 
outbreak in Tunisia resulted in eight human fatalities, this time the majority being >60 
years old (Triki, 2001). Two outbreaks in  1998 occurred in Italy and Israel, which 
were again associated with human and animal encephalitis (Murgue et al., 2001).
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1.3 The summer of 1999: WNV impacts the new world
1.3.1 Introduction o f WNV in to the US and expansion throughout the Americas
Until 1999, WNV was confined to the Eastern Hemisphere, including parts o f Asia, 
Africa, Europe, Australia (KUN) and the Middle East. In the summer o f 1999, the 
first cases o f WNV were seen in New York City, including nine deaths. It was 
unclear what impact this newly introduced pathogen would have in subsequent years, 
or if  this virus would be able to overwinter given the cold climate in the Northeast o f 
the United States (US). In the years following the introduction o f WNV into New 
York, it was clear that the virus continued to thrive by inhabiting more naïve areas 
while still being maintained in areas affected in the previous years (Figure 1-4). 
Although the initial WNV outbreak in New York was confined to the immediate area, 
by the next year expansion o f the virus epidemic was apparent. By the summer o f 
2000, WNV had spread along the Eastern Seaboard o f the US, including 12 states, yet 
only two deaths were associated w ith WNV infection. In 2001,16 more states 
reported WNV cases, including nine deaths. Although WNV infection had spread 
geographically in the US, the number o f deaths did not rapidly increase; however, 
WNV continued to be isolated from mosquitoes, birds and horses. By 2002, more 
than 4,000 human cases o f neuroinvasive encephalitis/meningitis disease and WN 
fever, and 284 deaths were documented, and the virus had spread across the US to 
C alifornia According to the CDC, this was the largest encephalitic arboviral 
epidemic in recorded history in the W estern Hemisphere. In 2003, the number o f 
WNV cases and deaths were similar to the previous year, and WNV was now found in 
alm ost every state o f the US. During 2004 and 2005, the number o f WNV cases and 
deaths was reduced by more than half compared to 2003, while 2006 saw a small
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increase in the documented human cases with 177 deaths. To date (November 13, 
2007), there have been 3,304 WNV cases, including 93 deaths during 2007. The 
decline in the incidence o f WNV infection is probably due to many contributing 
factors, including higher prevalence o f protective antibodies in the human, bird and 
animal populations versus the naive population in earlier years.
1.3.2 Veterinary impact o f WNV
W est Nile virus also had a great impact on veterinary disease in North America. In 
1999 birds, including crows, were found dead due to the virulence o f this virus in 
birds. In fact, dead birds became an indicator o f WNV activity in many areas, since 
high levels o f the virus could be found in these animals. Thousands o f dead birds 
tested positive for WNV infection between 1999 and 2000, including at least 75 
species (Hayes, 2001). The migratory pattern o f birds has been implicated in the 
spread o f WNV across the US, into Canada, and Central and South America (Figure 
1-5). In fact, a popular but unproven hypothesis for the introduction o f WNV into the 
US proposes that a bird infected with WNV got lost on a migratory flyway, crossing 
the Atlantic to land in New York. It is also possible that an infected bird whose 
migratory route spans from regions where WNV is epidemic to the United States, 
such as the Arctic Tern, introduced WNV to the US (Figure 1-6). It has also been 
proposed that an infected human travelling from endemic areas to the US was 
responsible for the 1999 outbreak. However, humans may not produce the high 
viraemia necessary to transmit the virus to a mosquito. It has been demonstrated 
experimentally that the viraemia in birds may reach up to 12 loglO PFU/ml while one 
study found that o f humans that donated blood in 2002, the highest titre was 3.2 loglO 
PFU/ml (Komar et al., 2003; Hayes et ah, 2005).
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Early in the US outbreak it was also apparent that many other incidental hosts 
succumbed to WNV disease, including horses. Horses were highly susceptible to 
infection and death due to exposure to virus-infected mosquitoes. Approximately 
20% o f horses infected with WNV presented clinical signs o f encephalitis, such as 
hind limb paralysis and muscle tremors (W ard et al, 2006). In later years, it was 
reported that many other animals were succumbing to WNV, possibly through non- 
mosquito-bome transmission, including turkeys, geese and alligators (CDC, 
2003;Austin et al, 2004; Jacobson et al, 2005). Non-mosquito-bome transmission 
o f WNV for alligators and birds has been shown experimentally through close 
contact, though not documented in nature (Komar et al, 2003; Klenk et al, 2004).
1.4 Epidemiology of WNV
1.4.1 Transmission cycle o f WNV
W est Nile virus is a mosquito-bome flavivirus transmitted prim arily by various Culex 
species o f mosquitoes. The WNV transmission cycle includes birds as the reservoir 
host, which amplifies die virus to high titres (Figure 1-7). Naïve mosquitoes feed on 
these birds becoming infected with the virus via the bite o f the infected mosquito and 
subsequently pass the virus onto naïve birds and the cycle repeats. Many incidental or 
dead end hosts have been identified for WNV, including humans and animals such as 
horses. These incidental hosts are thought not to contribute to the biology o f the virus 
since most infections do not result in high viraemia, however, high titres o f the virus 
have been found in experimentally infected mammals (Hayes, 2001). Non-viraemic 
transmission o f WNV has also been shown experimentally where non-infected 
mosquitoes that feed in close proxim ity to infected mosquitoes could become infected,
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although the significance o f this transmission in nature is undetermined (Higgs et al., 
2005).
1.4.2 Mosquito vectors
As mentioned in above, Culex mosquito species had been implicated as the major 
transmission vectors in early outbreaks o f WNV. This was also true in the 1996 
Bucharest epidemic, which included 17 human deaths where Culex pipiens pipiens 
comprised 96% o f all mosquitoes that tested positive for WNV (Campbell et al., 
2001).
Although the major mosquito vector involved in the transmission o f WNV in the US 
also includes Culex spp., the virus has been isolated from over 60 different species of 
mosquitoes, 10 o f which may be important in the transmission o f the virus (Hayes et 
al., 2005). After feeding on WNV-infected birds, mosquitoes harbour virus particles 
in the salivary gland where it can be transmitted to an amplification or dead end host 
when the mosquito takes a blood meal.
W est Nile virus transmission has been detected in the United Kingdom (UK) where as 
many as 50% o f birds analyzed were positive for WNV antibodies (Buckley et al., 
2003). Although the mosquito transmission vector and amplification bird host exist in 
the UK, WNV has not been implicated as a human pathogen in this part o f the world 
presumably due to a combination o f factors that may include: herd immunity o f birds 
w ith previous exposure to WNV, less virulent virus and/or lack o f bridging vectors.
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1.4.3 Non-mosquito transmission o f  WNV
Although humans are most commonly infected with WNV by the bite o f a virus- 
infected mosquito, non-mosquito transmission o f WNV has proved to be an important 
route o f transmission, especially for immunocompromised individuals in the US. 
Non-vector-bome transmission o f WNV was first recognized in 2002 when transplant 
patients became particularly susceptible to serious infection. It was estimated that 
40%  o f transplant patients infected w ith WNV were at risk o f developing serious 
neuroinvasive disease versus approximately 1% for the general public (Kramer et al., 
2007). Other non-vector-bome transmission routes o f WNV infection for humans 
includè: blood transfusions, breast m ilk and intrauterine transmission (Kramer et al., 
2007). Nonetheless, non-mosquito transmission o f WNV is rare. Increased screening 
reduces the risk o f WNV infection for transfusion and transplantation patients, and the 
vast majority o f cases remain vector-borne.
1.4.4 Risk factors
As noted above, children appeared to be more at risk for WNV infection until the 
1990’s, when it was evident that WNV infections had become more associated with 
neurological involvement among the elderly. Chilren were more susceptible than 
adults in past outbreaks probably because many children had not yet been exposed to 
the virus and therefore, did not possess antibodies towards the virus. However, it was 
noted during an outbreak in Isreal that children presented m ild clinical signs such as 
fever, lymphadenopathy and rash, while the immunocompromised, or elderly, had 
increased neurologic involvement (Goldblum, 1959; Spigland et al., 1958). In this
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case, age appeared to be a risk factor for severe WN disease. Similarly in the US, the 
elderly, or immunocompromised, have the greatest risk for neuroinvasive disease, 
while children and healthy adults are at a  low risk o f acquiring severe clinical 
manifestations (Hayes and O’Leary, 2004).
The greatest risk factor for WNV infection is increased exposure to infected 
mosquitoes due to areas o f residence and the seasons. In the US, all states have 
experienced WNV cases since 1999, while outbreaks in Europe and Africa have 
continued to occur in specific regions. The seasons also contribute as a risk factor in 
that temperate climates typically seen in the summer months correspond to greater 
increases o f cases seen worldwide. This is due, in part, to the transmission cycle of 
the virus. As mentioned above, the virus is transmitted by mosquitoes, which may 
accumulate not only at tim es o f mild weather, but also may be highest in the rainy 
seasons.
1.5 Pathology of WNV
1.5.1 Clinical symptoms o f WNV
Humans infected with WNV exhibit a  range o f disease manifestations from 
asymptomatic to severe morbidity and mortality. Asymptomatic cases account for 
about 80% o f human infections (M ostashari et al., 2001). A mild infection or West 
N ile fever (WNF) consists o f a  febrile illness including: fever, headache, fatigue, 
m alaise, muscle pain and weakness and may involve gastrointestinal symptoms and 
m acular rash on extremities (Hayes et al., 2005; Hayes, 1989; Watson et al., 2004).
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In some instances (<1% o f those infected), neuroinvasive disease occurs (Hayes et al., 
2005). In these cases patients develop meningitis, encephalitis or paralysis, and 
symptoms involve a range o f clinical manifestations, including: mild disorientation, 
severe tremors, asymmetric flaccid paralysis, respiratory failure, coma and death 
(Pepperell et al., 2003; Sejvar et al., 2003a; Jeha et al., 2003; Sejvar et al., 2003b; Li 
et al., 2003; Hayes etal., 2005).
1.5.2 Gross pathology o f human WNV infection
W est Nile encephalitis infection causes inflammation, necrosis and loss o f neurons 
mostly in the brainstem and spinal cord (Kleinschmidt-Demasters et al., 2004; 
Guamer et al., 2004). West Nile virus was not isolated from human post-mortem 
tissues until 2001 and only isolated from immunocompromised patients containing a 
high viral load (Hayes et al., 2005). Viral antigen was seen within the neurons and 
throughout the CNS in immunocompromised patients (Guamer et al., 2004), yet the 
virus was rarely seen by EM and only detected in the ER o f neurons. Depletion of 
the motor neurons o f the anterior hom o f the spinal cord was commonly found upon 
autopsy caused by WNV infection and may be linked to paralysis (Kramer et al., 
2007). Lack o f damage to other sections o f the spinal cord may provide clues into the 
pathogenesis o f neuroinvasive infection (Kramer et al., 2007).
1.5.3 Diagnosis o f  WNV
Infection o f WNV may be identified in the serum or CSF by enzyme immunoassays 
(EIA) that detect immunoglobulin (Ig) M (Hayes et al., 2005). W est Nile virus IgM 
antibody is typically detected by eight days post-infection in the serum or CSF o f 
patients with neuroinvasive disease (M artin et al., 2002). Although persistent
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infections are rare, IgM may be detected in the serum or CSF at one year post­
infection and a positive result may not exclude previous infections (Campbell et al., 
2002; Roehrig et al., 2003; Kapoor et al., 2004). Due to the cross-reactivity o f 
antibodies to the envelope (E) glycoprotein o f related flaviviruses, EIA may not be 
accurate and, therefore, other assays such as a  microsphere assay incorporating a 
nonstructural protein appear to discriminate between WN antibodies and antibodies 
from SLE, dengue (DEN), JE vaccine and YF vaccine infection (Wong et al., 2004). 
W est Nile virus can also be detected in the serum, CSF and tissues by RT-PCR, which 
can be used for diagnostic purposes to distinguish between flaviviruses (Bhatnagar et 
al., 2007). The most specific test to date remains the plaque reduction neutralization 
assay, which is used to detect four-fold or greater differences between acute and 
convalescence phase in serum samples. This assay is often used in combination with 
other serological assays.
1.5.4 Treatment o f WNV infection
To date there are no antiviral therapies to combat WNV infection. Reduced viral
replication has been seen in cell culture studies with some candidate WNV treatments,
although many therapies have not been effective in preclinical studies in animal
models or human trials (Kramer et al., 2007). Potential therapeutics include
phosphorodiamidate-morpholino-oligomers (PMO’s), which have been shown to
inhibit WNV replication in cell culture (Deas et al., 2005) and show some protection
in m ice against WNV disease (Kramer et al., 2007). Interferon-a2(5 treatment o f
patients with WNV meningoencephalitis demonstrated considerable recovery of
neurologic functions in the small number o f patients that received this treatment, yet
the efficacy in a large study has not been determined (Sayao et al., 2004). Another
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treatm ent that has shown some efficacy in humans is the administration o f intravenous 
immunoglobulin containing high titers o f WNV antibody; however, this treatment has 
also not been widely studied in humans (Shimoni et al., 2001).
1.6 Molecular Virology
1.6.1 Virion
W est Nile virus is a small enveloped positive sense RNA virus whose genome is 
approximately 11 kb in length. The surface o f the virion contains the envelope (E) 
and membrane (M) proteins surrounding the nucleocapsid and core that encompasses 
the nonstructural proteins (Figure 1-8). The mature virus appears as a  smooth 
spherical particle, icosohedral symmetry, that measures approximately 500 A in 
diameter (Kuhn et al., 2002; Nybakken et al.,2006). The outer layer o f the virion 
contains 180 copies o f the E protein arranged in a herringbone pattern and the same 
am ount o f M protein anchored by the C-terminal ends (Kuhn et al., 2002). In 
contrast, the immature virus particle is larger in size (600 A) due to the precursor 
premembrane protein (prM ) and E heterodimers (Zhang et al., 2003).
The genome encodes 10 genes; three structural proteins (capsid (C), prM/M and E) 
in the 5’ quarter o f the genome and the rem ainder o f the genome encodes the seven 
nonstructural (NS) proteins (NS1-NS5). The gene order is 5’-C-M -E-NSl-NS2A- 
NS3-NS4A-NS4B-NS5-3’. The genome is flanked by a short 117 nucleotide 5’ 
untranslated region (5’UTR) and a longer but variable (300-600 nucleotides)
3’UTR. The genome is translated as one polyprotein that is co- and post- 
translationally modified by viral and cellular enzymes to yield the 10 proteins 
(Figure 1-9).
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1.6.2 WNV structural proteins
W est N ile virus contains three structural proteins including the C, prM/M and E 
proteins. The structural proteins are involved in various steps o f the replication cycle 
and comprise the virion.
Capsid protein
The flavivirus nucleocapsid core contains the C protein and viral RNA. The electron 
dense core displays differential symmetry by cryoelectron microscopy suggesting that 
the C protein and viral RNA assemble randomly (Patkar et al., 2007). Also, the viral 
membrane shows no apparent connectivity with the nucleocapsid suggesting the C 
protein does not interact with the M and E proteins. The C protein is a small (~12 kD) 
basic protein that binds viral RNA and is not highly conserved among flaviviruses 
(Khromykh and Westaway, 1996; Patkar et al., 2007). The C-terminal end o f the C 
protein serves as a signal sequence involved in the translocation o f the prM  protein to 
the lumen o f the endoplasmic reticulum (ER), which is proteolytically cleaved by the 
NS2B-NS3 viral protease (Amberg et al., 1994; Yamshchikov and Compans, 1994; 
Zhang et at, 2003). This mature form o f the C protein is found in the virion and 
associated w ith intracellular membranes by a conserved internal hydrophobic 
sequence (M arkoff et at, 1997). The C protein has been found associated with the 
ER, w ithin die cytoplasm and in the nucleus (W ang et at, 2002). Kunjin virus- 
infected Vero cells showed C protein interactions with the perinuclear membranes and 
within the nucleus (W estaway et al., 1997). The translocation o f the C protein to the 
nucleus has an undetermined role in the replication cycle o f the virus.
prM /M  protein
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The larger prM protein is the precursor to the small M protein. The prM and E 
proteins form heterodimers that translocate to the ER. The C-terminal sequence o f the 
C protein is required for prM  translocation, and the processing o f the prM protein 
occurs with the cleavage o f this signal sequence (Amberg et al., 1994). The flavivirus 
prM  protein contains one to three putative N-linked glycosylation sites in the N- 
term inal region (Chambers et al., 1990). The glycosylation sites, as well as six 
conserved cysteine residues involved in disulfide formation, are cleaved to form the 
mature M protein (Nowak and Wengler, 1987). The C-terminal end o f the prM 
protein is involved in membrane anchoring, containing two transmembrane domains 
(M arkoff et al., 2003).
The prM  protein is associated with immature virus particles and is likely to protect E 
protein from inactivation due to the low pH during transport through the intracellular 
vesicles (Heinz and Allison, 2000). The prM protein also elicits a chaperone-like 
function preventing conformational changes in the E protein within the low pH 
secretory pathway (Guirakhoo et al., 1992). The prM  protein is cleaved by furin or a 
furin-like protease after the virus leaves the trans-Golgi network, but before the 
release o f the virus, to reveal the mature form o f the virus (Murray et al., 1993;
Stadler et al., 1997).
The M  protein is much smaller than the prM  protein that existis in the mature form o f 
the virus after prM cleavage. Few studies have investigated the role o f the M protein. 
A single mutation at M5 for JE virus increased plaque size and infectivity in cell 
culture, but did not affect virulence in mice. Since this mutation was shown to 
inactivate the virus at low pH, it has been hypothesized that the M protein may
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function to stabilize the E protein dimers at neutral pH from forming trimers (Maier et 
al., 2007).
E protein
The E protein is the major surface viral protein involved in receptor binding and 
fusion. The X-ray crystallographic structure o f the E protein for TBE, DEN-2 and 
WN viruses revealed some similarities including three domains; the N-terminal 
domain 1, elongated dimerization domain II containing the fusion peptide and an 
immunoglobulin-like domain III (Rey et al., 1995; Modis et al., 2003; Zhang et al., 
2004; Nybakken et al., 2006) (Figure 1-10). Flavivirus E protein may contain up to 
four N-linked glycosylation sites and WNV strains have either one or no glycosylation 
sites. The crystal structure for WNV is based on the NY99 strain, which contains one 
glycosylation site at E154 (Nybakken et al., 2006). A mutation at the N-linked 
glycosylation site affects the virulence o f WNV in mice, decreases infectivity in cell 
culture and influences particle assembly (Beasley et al., 2005; Hanna et al., 2005).
The glycosylation sites for DEN viruses have been proposed to modulate receptor 
binding through intercellular adhesion molecule (ICAM)-3 mediated adhesion 
(Navarro-Sanchez et al., 2003). The putative receptor binding domain III for 
mosquito-borne flaviviruses, including JE, YF and WN viruses, contain an RGD/RGE 
integral binding recognition m otif yet mutations in this m otif did not abolish YF virus 
binding to the cell, suggesting the use o f a non-integrin receptor (van der M ost et al., 
1999).
The E protein is involved in fusion utilizing a  class II fusion process (Figure 1-11). 
A fter receptor-mediated endocytosis, a pH change occurs that triggers a
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conformational change o f the E dimers and the domain II moves toward the host cell 
membrane. The hinge region, now exposed, inserts into the host cell membrane 
resulting in the formation o f E protein trimers followed by the movement o f domain 
III resulting in the hemifusion o f the lipid membrane. This enables a trim er formation 
bringing the transmembrane regions and fusion peptide in close proximity 
(Mukhopadhyay et al., 2005).
The E protein undergoes yet another conformational change in its replication cycle 
during maturation. Before the release o f the virus, 60 trim ers o f the prM and E 
heterodimer on the surface o f the virus disassociate to 90 E homodimers after the 
furm-mediated cleavage o f the prM protein in a low pH induced manner. This 
dissociation causes a  conformational change in the E protein from the hinge between 
domains I and II (Mukhopadhyay et al., 2005).
The E protein also elicits neutralizing antibodies. Neutralizing antibodies against the 
E protein are important for protective immunity and are involved in the clearance of 
viral infection.
1.6.3 WNV nonstructural proteins
W est Nile virus synthesizes seven nonstructural (NS) proteins inside virus-infected 
cells, including NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. These proteins are 
necessary for virus replication.
NS1 protein
The flavivirus NS1 protein is highly conserved and all members contain conserved N-
linked glycosylation sites (asparagine-X-serine/threonine [NXS/T]). For the JE
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serogroup, all members, except JE virus, contain three glycosylation sites with the 
asparagine residue at NS1130, NS1175 and N SI207 (Bakonyi et al., 2004; Blitvich et al., 
2001; Chambers et al., 1990; Sumiyoshi et al., 1987). Other mosquito-borne 
flaviviruses contain two glycosylation sites at N S li30 and N SI207 (N S l2os YF) while 
non-vector-bome ENT bat virus has four predicted N-linked glycosylation sites 
(Dalgamo et al, 1986; Pryor and W right, 1994; Flamand et al., 1992; Kuno and 
Chang, 2006). The glycosylation sites have been linked with virulence o f the virus 
and showed attenuation in mice and reduced infectivity in cell culture for DEN-2 and 
YF viruses (Crabtree et al., 2005; Pryor and W right, 1994; Pletnev etal, 1993).
The NS1 protein forms dimers and is found in different forms within the cytoplasm, 
associated with the plasma membrane, and is secreted (Blitvich et al., 2001; Flamand 
etal., 1999; Mason, 1989; Schlesinger etal., 1990; Post etal., 1991; W inkler etal., 
1988; W inkler et al., 1989; Crooks et al., 1994). Although the function o f this protein 
has yet to be identified, the NS 1 protein has been identified as essential for replication 
as large in-frame amino acid deletions w ithin NS1 were deficient in negative-strand 
RNA synthesis; however, replication could be restored by supplying this protein in 
trans (Lindenbach and Rice, 1997). The NS1 protein has extensive identity and 
homology between different flaviviruses, yet the NS 1 protein functions in a virus- 
specific manner (Lindenbach and Rice, 1999). The NS 1 protein interacts with other 
proteins necessary for replication, including the NS2A and NS4A proteins 
(Lindenbach and Rice, 1999; Kümmerer and Rice, 2002).
The NS1 protein has been implicated to possess immunomodulatory capabilities.
High levels o f circulating NS1 protein has been linked to serious DEN infection,
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which may lead to potentially lethal DHF infection (Alcon et al., 2002; Young et al., 
2000, Libraty et al., 2002; Macdonald et al., 2005; Avirutnan et al., 2006). The role 
o f secreted NS 1 protein is unclear, but it is thought to be involved in the immune 
complex formation (Young et al., 2000), induction o f autoreactive antibodies against 
extracellular matrix proteins (Chang et al., 2002), and enhanced viral production (con- 
LePoder et al., 2005). Recently, the cell surface associated NS1 protein for WNV has 
been shown to bind regulatory protein factor H, inhibiting complement activation, 
which may prevent complement-dependent lysis o f infected cells (Chung et al., 2006). 
This is contrary to studies with DEN virus where NS1 appears to activate complement 
(Avirutnan etal., 2006), suggesting a novel function for WNV NS1. Finally, 
antibodies to NS1 have no neutralizing activity but do induce protective immunity, 
probably by antibody dependent cellular cytoxicity and elicit passive protection in 
mouse and monkey models (reviewd by Gibson et al., 1988)
The NS1 protein forms a hexamer, heat-labile homodimer and a short-lived monomer 
and can be found inside the cell, associated with membranes, and as a soluble secreted 
protein (B litvichetal., 2001; Flam andetal., 1999; Mason, 1989; Schlesinger etal., 
1990; W inkler et al., 1988; W inkler et al., 1989; Crooks et al., 1994). Many forms o f 
the protein have been shown to exist due to alternative cleavage sites, formation of 
heterodimers with E or NS2A, or differences in glycosylation status (Blitvich et al., 
1995; Blitvich et al., 1999; Falgout & Markoff, 1995; Mason et al., 1987; 
Nestorowicz et al., 1994). Previous studies with other flaviviruses have established 
that glycosylation o f NS1 is not required for dimerization but does affect dimer 
stability (Pryor and Wright, 1993; Pryor and W right, 1994). Furthermore, it has been
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suggested that dimerization may not be necessary for either the secretion o f NS1 or 
viral replication (Hall et al., 1999).
The NS1 protein has been shown to contain two distinct isoforms in cell culture, 
referred to as NS1° and NS1’ (Mason, 1989; Blitvich et al., 1995; Poidinger et al., 
1996). Although the cleavage site generating these isoforms is unclear, studies have 
found that the NS3 protease is not required, and that the NS1’ isoform contains a 
portion o f the NS2A protein (Mason et al., 1987; Chambers et al., 1990; Blitvich et 
al., 1999). The function(s) o f these isoforms are unclear and it is not understood if  
the internal cleavage o f the protein is required for NS 1 function. A study with JE 
virus-infected cells showed that N S1’ may be involved in RNA dependent RNA 
polymerase activity and that NS3 coprecipitated w ith N S1’ (Satchidanandam et al., 
2006).
NS2A protein
The NS2A protein is a small (~22 kD), hydrophobic protein. The N-terminus is 
located within the endoplasmic reticulum (ER) and C-terminus w ithin the cytoplasm 
(Preugschat et al., 1990). The C-terminus o f the NS2A is cleaved by the viral 
protease (Preugschat et al., 1990) while the N-terminus is cleaved in the ER by an 
unidentified host protease (Falgout and Markoff, 1995). An internal viral cleavage 
site resulting in the formation o f NS2Aa and NS1’ is necessary for the production of 
infectious virus (Kummerer and Rice, 2002).
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The NS2A protein is required for assembly and has been shown to contribute to the 
virulence o f the virus in mice (Liu et al., 2003; Liu et al., 2006). An isoleucine to 
asparagine mutation at NS2A59 for KUNV resulted in a complete block o f virus 
production, but wild-type NS2A supplied in trans restored the replication o f infectious 
virus. This same study found that packaging o f replicon RNA was impaired due to 
this m utation (Liu et al., 2003). A single mutation in the NS2A protein, changing an 
alanine to a  proline at NS2A30, reduced the inhibition o f interferon-beta promoter- 
driven transcription in cell culture and was highly attenuated for neuroinvasiveness 
and neurovirulence in 3-week-old mice (Liu et al., 2006). Surprisingly, this mutant 
was also partially attenuated in LFN-aPy receptor knockout mice suggesting it may 
play an additional immunomodulatory role (Liu et al., 2006).
NS2B protein
The NS2B protein is a hydrophobic protein that contains a 40 residue central region 
that is a cofactor o f the NS3 serine protease and is necessary for the activation o f the 
protease (Mastrangelo et al., 2007; Chambers et al., 1993; Leung et al., 2001). 
Cleavage o f the NS2B/NS3 complex is necessary for replication (Chambers et al.,
1995). The NS2B protein also may be involved in the cleavage o f the C protein 
(Amberg and Rice, 1999).
NS3 protein
NS3 protein contains an N-tenninal serine protease and C-terminal helicase, with
nucleoside 5 '-triphosphatase (NTPase) and 5'-terminal RNA triphosphatase (RTPase)
activities (M astrangelo et al., 2007). It is thought that the NTPase may be required for
the helicase to unwind viral RNA and the RTPase may be involved in the formation of
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the 5’ cap (Brinton, 2002). The protease is responsible for the proteolytic cleavage o f 
the N-terminal/C-terminal regions o f the C protein, NS2A/NS2B, NS2B/NS3, 
NS3/NS4A, NS4A/NS4B and NS4B/NS5 junctions (Nowak et al, 1989; Speight 
and W estaway, 1989).
Both positive- and negative-stand RNA transcripts contain highly structured 
secondary structures especially in the 5’UTR and 3’ UTR. Therefore, it is a 
necessary function o f the helicase to unwind nascent transcripts during transcription. 
The helicase aids in the initial negative strand synthesis by unwinding the 
polyprotein at the highly structured 3’UTR (Takegami et al, 1995).
The NS3 protein may also be involved in host cell apoptosis through the recruitm ent 
o f caspase-8 (Ramanathan et al, 2006).
NS4A protein
The NS4A protein is a small hydrophobic protein, approximately 16kD in size, 
involved in  the replication complex. Cleavage o f this protein may be regulated since 
two precursors, NS3/NS4A and NS4A/NS4B, are found within the cell (Chambers et 
al, 1990; Preugschat et al, 1990). The cleavage o f the NS4A/NS4B junction 
liberates a transmembrane signal peptide from the N-terminus o f NS4B named 2K 
(Lin et al, 1993; Preugschat and Strauss, 1991). The NS4A interacts with the NS 1 
protein in an undetermined fashion possibly essential for replication (Lindenbach and 
Rice, 1999).
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The NS4A protein function has been recently implicated in the formation o f virus- 
induced replication structures. The NS4A protein, in the absence o f the 2K fragment, 
was shown to induce vesicle formation similar to the convoluted 
membrane/paracrystalline array (CM/PC) structures for KUN NS4A synthesized via 
the Semliki Forest virus expression system. However, the structures lacked the tightly 
dense structure appearance seen in virus-infected cells suggesting other factors are 
involved in the formation o f virus-induced structures (Roosendaal et al., 2006). In 
addition, the NS4A protein has been implicated in the formation o f virus-induced 
structures for an NS4A DEN-2 T7 polymerase based expression system. Different 
from the KUN study, the NS4A protein lacking the 2K fragment induced internal 
structural changes similar to those seen in virus-infected cells (M iller et al., 2007). 
Both these studies were limited in their findings and suggested the NS4A protein may 
be involved in the formation o f virus-induced structures necessary for replication, 
although the NS4A protein function may differ between flaviviruses.
NS4B protein
The NS4B is a small hydrophobic protein o f approximately 27 kD, which may 
participate in the replication cycle and immune evasion. The NS4B protein shows 
only 35% homology between DEN, WN and YF viruses (Umareddy et al., 2006), 
however, members o f die family Flaviviridae share common ER and cytoplasmic 
regions and transmembrane domains (M iller et al., 2006) that may indicate similarities 
in the function o f this protein between viruses.
The NS4A/NS4B precursor is cleaved by the viral protease and the resulting 
2K/NS4B protein is further cleaved by a host signalase to generate the mature NS4B
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protein (Chambers et al., 1989; Lin etal., 1993; Cahour et al., 1992; Preugschat and 
Strauss, 1991). The NS4B protein for HCV and DEN-2 viruses localize in the ER 
within foci that may represent the viral replication complex (Lundin et al., 2003). The 
expression o f mature NS4B protein, but notNS4A/NS4B, leads to the formation o f 
membranous webs in cell culture suggesting its involvement in ultrastructural 
membrane changes (Egger et al., 2002; Konan et al., 2003).
The NS4B protein contains three to five transmembrane domains with an N-terminus 
portion that localizes to the lumen o f the ER and a C-terminus portion in the 
cytoplasm in DEN-2- and HCV-infected cells (Lundin et al., 2003; M iller et al.,
2006). A portion o f the NS4B protein has also been shown to translocate to the 
nucleus in KUN virus-infected Vero cells (W estaway et al., 1997).
M utations within die central hydrophobic region of the NS4B protein have been 
identified in several attenuated and passage-adapted flavivirus strains, including: 
chimeric WN/DEN-4 and DEN-2/DEN-4 viruses, passage adapted DEN-4 virus, JE 
vaccine strain, YF vaccine strain and hamster passage adapted YFV strain, and a 
WNV mouse attenuated strain (Pletnev etal., 2002; Blaney Jr., 2003; Ni etal., 1995; 
Hahn etal., 1987; Wang etal., 1995; McArthur et al., 2003; W icker etal., 2006).
The NS4B protein also elicits immunomodulatory capabilities, specifically the 
inhibition o f interferon. The first 125 amino acids o f the mature NS4B protein have 
been shown to be crucial in the inhibition o f ST ATI phosphorylation for DEN-2, YF 
and WN viruses (Munoz-Jordan et al., 2003; Munoz-Jordan et al., 2005). Mutations 
w ithin the NS4B protein have also been identified in interferon-resistant HCV
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replicons (Namba et al, 2004). Therefore, immune evasion may be a conserved 
function o f the NS4B protein.
NS5 protein
The NS5 protein is approximately 100 kD in size and the largest flaviviral protein. 
This protein is highly conserved among flaviviruses, containing a methyltransferase 
activity in the N-terminus, which is utilized in 5’ capping, and a 3’ viral RNA- 
dependent RNA polymerase (RdRp) required for replication (Khromykh et al, 1999). 
The phosphorylation o f serine residues o f the DEN-2 virus NS5 leads to the formation 
o f the NS3/NS5 complex, which is also required for polymerase activity (Kapoor et 
al, 1995). The NS5 protein is found within the cytoplasm but translocates to the 
nucleus via a signal sequence in conjunction with a host cellular nuclear import 
receptor (Johansson et al, 2001). Approximately 20% o f the RdRp activity resides in 
the nucleus o f WN, DEN or JE virus-infected cells (Uchil et al, 2006).
Recently, the NS5 protein has been shown to elicit immunomodulatory capabilities, 
specifically in interferon inhibition. The NS5 protein o f Langat and JE virus inhibits 
Jak-STAT phosphorylation via activation o f cellular protein tyrosine phosphatases 
(Best et al, 2005; Lin et al, 2006).
1.6.4 WNV untranslated regions
The WNV genome contains 5’ and 3’ untranslated regions (UTR) located at the 
extreme 5’ and 3’ends o f the virus genome. The 5’ and 3’UTR form secondary 
structures that are essential for replication and translation. Mosquito-bome 
flaviviruses including DEN, YF and JE viruses, show similar 5’ stem loop structures
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whereas TBE virus shows somewhat different 5’UTR secondary structure (Thumer et 
al., 2004). The 5’UTR is not conserved among members o f the family Flaviviridae as 
the hepaciviruses contain an internal IRES, while the flaviviruses contain a type 1 cap 
structure for translation (Brinton and Dispoto, 1988; Pestova et al., 1998). The 
3 ’UTR contains three cyclization sequences that interact with the 5’ cyclization 
sequence, located in the N-terminal portion of the C protein, approximately 40 
nucleotides downstream o f the start codon (Markoff, 2003). In the absence o f a  poly 
A tail, the 3’UTR is essential for viral replication (Markoff, 2003) and may be 
involved in translation or genome packaging (Li and Brinton, 2001; Mandl, 2005). It 
has been shown for DEN virus that the cyclization o f the 5’ and 3’UTR’s , but not the 
RNA cap-dependent mechanism, are required for translation (Edgil and Harris,
2006). Highly conserved regions o f the 3’UTR contain two stem loop regions, 
however, the regions downstream o f the stop codon are variable (Brinton et al., 1986).
M utations or deletions in the 3’UTR have been shown to reduce RNA replication 
(Khromykh et al., 2003; Lo et al., 2003; Elghonemy et al., 2005; Hanley et al., 2004). 
A DEN virus vaccine candidate has been proposed based on a mutant virus containing 
a 30 nucleotide deletion within the 3’UTR, which shows reduced replication in 
monkeys and induces a protective immune response (Hanley et al., 2004).
1.6.5 Viral life cycle and replication
As with other flaviviruses, the WNV life cycle begins w ith binding o f the virus to the 
host cell through the interaction o f the E  protein on the surface o f the virus with 
cellular receptors. Although these cellular receptors have yet to be identified, 
attachment factors, such as heparin sulfate, alpha-v-beta-3 integrin and DC-SIGN may
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be involved in the entry o f the virus (Mandl et al., 2001; Kroschewski et al., 2003; 
Chu and Ng, 2004; Davis et al., 2006).
Virus is taken up into the cell via receptor mediated endocytosis into clathrin-coated 
pits before subsequent transport o f the virus to prelysosomal endocytic compartments 
(Chu and Ng, 2004). A rearrangement o f E dimers to trim ers, which occurs due to the 
low pH within these compartments (Allison et al, 1995) is necessary for the fusion o f 
the viral membrane with the endosomal membrane (Heinz and Allison, 2003). This 
results in the release o f the viral nucleocapsid into the cytoplasm o f the cell and 
uncoating o f the viral RNA genome. The input RNA is translated to yield a 
polyprotein that is subjected to co-and post-translational processing to generate the 
individual proteins. Replication o f the viral genome is initiated through transcription 
o f the input positive-strand genomic RNA to produce a negative-strand RNAs, which 
serves as a template for synthesis o f new positive-strand RNA that are used for further 
translation o f viral proteins and progeny genomes. The next steps in the replication 
cycle are not as well understood, but involve packaging o f genome RNA by the capsid 
protein and assembly o f the virus through the budding o f the nucleocapsid into the ER 
(Figure 1-12). This immature particle results from the association o f the prM and E 
heterodimers and is not infectious (Elshuber et al., 2003). Transport o f the immature 
virus particles occurs via the host secretory pathway and cleavage o f the prM in acidic 
vesicles o f the late trans-Golgi network by host cell protease furin, which produces the 
mature form o f the virus (Stadler et al., 1997). The mature particles are released from 
the cell following fusion o f the transport vesicles to the plasma membrane (Figure 1 - 
13).
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1.7 Immunology
1.7.1 Immune response to WNV
The use o f rodent models has provided insight into the immune response to WNV 
infection. Early post-infection, WNV replicates in the Langerhan dendritic cells, 
which migrate to the draining lymph node causing viremia and subsequent infection 
o f organs such as the kidney and spleen (Samuel and Diamond, 2006). Although the 
mechanism o f invasion o f the CNS is unknown, viral load and a cytokine involvement 
may facilitate the virus crossing the blood brain barrier (Figure 1-14).
Innate and humoral immune responses to WNV infection have been elucidated using 
rodent models. Interferons have been shown to inhibit WNV replication when given 
before infection, although the same is not true after infection (Anderson and Rahal, 
2002; Crance et al., 2003; Samuel and Diamond, 2005). Gene knockout mice lacking 
IFN-y showed increased viral burden, earlier entry into the CNS, and a higher 
mortality rate suggesting IFN-y has an antiviral function in controlling WNV infection 
( Shrestha et al., 2006; Wang et al., 2003). Complement, a group o f proteins in the 
serum involved in the destruction o f non-self particles, has also been shown to be 
essential for protection from lethal WNV infection in mice (Mehlhop and Diamond, 
2006).
Although the role o f cellular immunity is less well characterized, it is thought that 
macrophages may control WNV infection through production o f nitric oxide 
intermediates, direct viral clearance, enhanced antigen presentation and the secretion 
o f cytokine and chemokines (Ben-Nathan et al., 1996; Kreil and Eibl, 1996; Lin et al., 
1997). Helper T cells play an important role in antiviral immunity, especially
29
cytotoxic T cell response, which axe important in controlling WNV infection through 
cytokine production and T-cell priming (Samuel and Diamond, 2006). Although the 
E protein elicits a T-cell response, the nonstructural proteins, especially NS1 and NS3, 
have shown to be primary targets o f protective T-cells (Aihara et al., 1998; Kurane et 
al., 1991; Mathew et al., 1996,1998; Zeng et al., 1996; Co et al., 2002; Kumar et al., 
2003). In fact, when a dominant T-cell eliciting antigen, such as NS 1, is present, the 
E protein does not enduce a strong cell-mediated response (Konishi et al., 1995; Desai 
et al., 1995; Kumar et al., 2003). The NS1 protein has been shown to stimulate 
cytolytic antibodies in mice (Lin et al., 1998) and were found to be the major target o f 
IFN-y-producing T-cells in  humans (Co et al.,2002).
Humoral immunity has also proved to be a critically important aspect o f the immune 
systems response to WNV infection, and neutralizing antibody is considered the key 
component o f protective immunity. Recent studies showed B-cell deficient mice died 
from WNV infection but passive transfer o f immune sera was able to protect mice 
from infection (Diamond et al., 2003).
1.7.2 Immune evasion o f WNV
The efficiency o f WNV replication may, in part, be permitted through evasion o f the 
host immune system. The nonstructural NS2A, NS4A and NS4B proteins for DEN-2 
virus have been shown to suppress the host immune response through the down 
regulation o f IFN-P gene expression (Munoz-Jordan et al., 2003). Similarly, the 
nonstructural proteins o f KUN virus, the Australian subtype o f WNV, inhibit viral 
spread through the activation o f the ERF-3 pathway (Fredericksen et al., 2004). In 
this case, when the NS2A, NS2B, NS3, NS4A and NS4B proteins were individually
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expressed, STAT2 translocation into the nucleus was inhibited. Recently, the NS5 
protein has also been shown to inhibit Jak-STAT phosphorylation (Best et al, 2005). 
Inhibition o f the IFN-a pathway was not inhibited when NS1 was expressed (Liu et 
al, 2005). It has also been shown that WNV replication hinders the phosphorylation 
and activation o f Tyk2 and JAK1 ( Guo et al, 2005).
1.7.3 Antibody-dependent enhancement
Following infection, neutralizing antibodies, mainly against the E protein, are 
important for the clearance o f the viral infection. However, subneutralizing 
antibodies, which may enhance infection, has been implicated in DHF. Referred to as 
antibody-dependent enhancement (ADE), concentrations o f antibodies below the 
neutralization threshold may enhance infection through Fc-y receptor engagement and 
enhancement o f Fc-y receptor-expressing cells (Mehlhop et al., 2007; Pierson et al, 
2007). Previously, ADE had been shown experimentally in vitro for several 
flaviviruses including JE, YF, WN and DEN viruses (Cardosa et al, 1986; Gould and 
Buckley., 1989; Halstead, 1989; W allace et al, 2003). Recently, evidence o f this 
phenomenom has been demonstrated in mice infected with Murray Valley 
encephalitis and WNV (Mehlhop et al, 2007; W allace et al, 2003), however, ADE 
has not been verified in humans.
A recent study examined ADE in mice given subneutralizing antibodies o f JE and 
subsequent challenge with MVE (Wallace et al, 2003). This study found that 
viream ia and mortality was increased in these mice. This study, and others like it,
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suggest the possibility o f ADE and is a concern for vaccines. Since ADE has yet to be 
shown in humans, this hypothesis remains controversial; however, severe infections 
subsequent to the administration o f some formalin-inactivated viral vaccines have 
been attributed to ADE (Iankov et al., 2006; Ponnuraj et al., 2003; Porter et al., 1972; 
Prabhakar and Nathanson,1981). It is important to consider the possibility o f ADE 
when designing a vaccine candidate and therefore, a robust antibody response to 
vaccine should be achieved.
1.7.4 Vaccine development
Currently, no WNV vaccine or antiviral is available for human use. Three vaccines 
are currently licensed for equine use in the United States: a whole virus formalin 
inactivated vaccine (Ng et al., 2003), a recombinant canarypox virus containing the 
WN prM  and E proteins (Minke et al., 2004; Siger et al., 2004) and a recombinant 
plasm id DNA containing the WN prM  and E proteins, which is also in human clinical 
trials (Davis et al., 2001). Various other vaccine candidates have been evaluated in 
mice or monkeys including live-attenuated strains, live-attenuated chimeric virus 
strains and recombinant virus strains (Yamshchikof et al., 2004; Ledizet et al.,2005; 
Qiao et al.,2004; Arroyo et al., 2004 ; M onath et al., 2006 ;Pletnev et al., 2003; 
Despres et al., 2005; Iglesias et al., 2006).
A preclinical trial o f a chimeric WN/DEN-4 virus has been evaluated in mice and
non-human primates (Pletnev et al., 2003). This live-attenuated virus was derived
using reverse genetics from the DEN-4 Dominican Republic strain lacking 30
nucleotides in the untranslated region and contains the prM and E protein from the
WNV NY99 strain. This recombinant virus showed decreased infectivity titres in
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neuroblastom a cells compared to the parental strains and following inoculation with 
the vaccine virus, WN/DEN4A30, monkeys displayed little to no viraemia. Although 
all monkeys elicited neutralizing antibodies, a two-fold reduction in the neutralizing 
antibody titre was seen in monkeys that had previous immunity to DEN virus.
Recently, an attenuated recombinant WNV vaccine candidate was evaluated in a small 
clinical trial (Monath et al., 2006). This vaccine was derived by reverse genetics from 
the YF17D vaccine strain, replacing the prM and E proteins with the corresponding 
WNV proteins containing attenuating mutations in the E protein. The resulting 
recom binant vaccine virus, ChimeriVax-WN02, has been tested for safety and 
immunogenicity in preclinical and clinical trials in non-human primates and humans 
(M onath et al., 2006). Neutralizing antibody titres after the first dose were low with 
plaque reduction neutralization assay (PRNT50) values in mice and monkeys o f <50 
four weeks post- infection and <100 14-days post-infection, respectively. After 
challenge, the neutralizing antibody titres in monkeys increased with PRNT50 values > 
640 (Arroyo et al., 2004). O f the 45 subjects in the phase I clinical trial, one did not 
seroconvert, while the others displayed neutralizing titres by 28 days post- 
subcutaneous inoculation o f the vaccine. The vaccine was well tolerated in healthy 
women and men aged 18-40 years old (Monath et al., 2006). A larger Phase II trial 
investigation o f the safety, immunogenicity and efficacy o f this vaccine has yet to be 
performed.
Although several vaccine candidates exist for WNV, some lacked high neutralizing 
antibody titres and the efficacy o f these candidates has not proceeded beyond 
preclinical development.
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1.8 Aims of the thesis
The impact o f WNV and lack o f a vaccine for human use represents the need for 
additional vaccine candidates to control this disease. A cDNA infectious clone exists 
for this virus (Beasley et al., 2005) that provides an important tool to investigate 
molecular determinants o f attenuation that may be used to generate a live-attenuated 
vaccine candidate.
The NS1 protein is a unique viral protein in that this nonstrucutural protein is 
glycosylated and is found within the cell as well as secreted through the secretory 
pathway. Studies have yet to identify the function(s) o f this protein although it is 
thought be involved in several aspects o f the viral replication cycle and may affect the 
host immune response to infection. Since the glycosylation sites o f the NS 1 protein 
are highly conserved, these sites are hypothesized to contribute to the function o f the 
protein and therefore, may affect the virulence o f the virus. Previous studies o f the 
NS1 glycosylation sites with DEN-2 and YF viruses revealed reduced infectivity in 
cell culture and attenuation in mice (Pryor and Wright, 1994; M uylaert et al., 1996; 
Pletnev et al., 1993; Crabtree et al., 2005), however, these studies were limited to 
mouse neurovirulence studies. Also, these viruses possessed only two o f the three 
glycosylation sites that WNV contains, lacking the NS 1175 site.
The objective o f this thesis was to investigate a rational approach to utilizing NS1 
mutations to contribute towards generation o f a candidate live-attenuated WNV 
vaccine while investigating a functional role for the NS1 protein. The following 
specific aims were undertaken to achieve these objectives.
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Specific Aim 1 : Attenuation o f WNV through the deglvcosvlation o f the NS1 protein. 
Hypothesis: The ablation o f one or more NSI N-linked glycosylation site (s) will 
attenuate the mouse virulence phenotype o f WNV.
Rationale: This was accomplished through site-directed mutagenesis to generate 
mutant viruses lacking the NSI glycosylation site(s) in all possible combinations. 
These viruses were used to compare infectivity in cell culture and attenuation in mice 
compared to the parental strain. The mouse model for WNV mimics natural infection 
o f neuroinvasive disease, therefore, may be used to study the neuroinvasiveness of 
N SI glycosylation mutant viruses.
Specific Aim 2: Derive a candidate live-attenuated vaccine candidate virus for WNV 
including multigenic attenuating mutations. Hypothesis: Attenuating mutations in the 
NS1 combined with attenuating mutations in other proteins will attenuate the mouse 
virulence phenotype, be replication competent in cell culture and elicit protective 
antibodies.
Rationale: M utations in the glycosylation sites o f prM  and E proteins and a conserved 
residue in NS4B were examined, together with attenuating N SI glycosylation 
mutations, to determine if  these mutations, alone or in combination, would enhance 
attenuation o f a live-attenuated vaccine candidate.
Specific Aim 3: Utilize the NS1 protein mutant viruses to examine a functional role 
for the NS1 protein. Hypothesis: Mutations in the conserved NSI glycosylation sites 
will alter the function o f the protein affecting various steps o f the replication cycle and 
immune response to infection.
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Rationale: The ultrastructure o f cells infected with the NS1 mutant virus was 
hypothesized to differ from cells infected with the parental virus due to the NS 1 
protein being involved in the formation o f virus-induced replication structures inside 
infected cells. Also, the immune responses to the mutant viruses were assessed in 
mice with the hypothesis that infection with the attenuated viruses would alter the 
immune response to infection compared to mice inoculated with the parental strain.
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Figure 1-1. Phylogenetics of WNV strains. Sequencing o f WNV strains from across the 
world fell into two distinct lineages (Lineage I and Lineage 2). Lineage 1 included the New 
York 1999 strain and the Australian Kunjin virus among others. (Adapted from Lanciotti et 
al., 1999).
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Figure 1-3. Outbreaks o f WNV from 1951-2000. (Adapted from Murgue et 
al., 2001)
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Figure 1-4. Distribution of human WNV cases in the US 1999-2006. (Adapted
from CDC, Arbonet)
40
Figure 1-5. Migratory flight patterns o f birds. The flyways in the Americas shows how 
different routes travel across the US, Canada and South America (Adapted from Gubler, 
2007).
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Figure 1-7. Transmission cycle of WNV. (Adapted from CDC, Arbonet)
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Figure 1-8. Structure of West Nile virus. West Nile virus structure appears as a 
round, spherical shape with iscosohedral symmetry. The E and M protein reside 
on the surface of the protein that contains the nucleocapsid and core containing 
the viral RNA (Adapted from Mukhopadhyay et al, 2003)
44
Fi
gu
re
 1
-9
. S
ch
em
at
ic
 o
f W
es
t N
ile
 v
iru
s 
ge
no
m
e.
 (
Pr
ov
id
ed
 b
y 
A
D
T.
 B
ar
re
tt)
45
N
S2
B
-N
S3
 p
ro
te
as
e 
sit
e
Figure 1-10. X-ray crystallographic structure of West Nile virus E 
protein. The E protein is comprised of three domains: domain I in red, 
domain II in yellow and domain III in blue. West Nile virus E contains 
one N-linked glycosylation site at E l 54. (Adapted from Kanai et al., 
2006)
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Figure 1-11. Class II fusion process. The fusion peptide o f the E protein is buried 
within the dimer (1) the E protein binds via the receptor and is internalized in the 
endosome (2) a conformational change is caused by low pH. The fusion peptide, 
now exposed, inserts itself into the host membrane (3) The E protein folds back 
bringing the viral membrane closer to the host membrane (4) Domain III moves 
closer to domain II resulting in hemifusion of the membrane (5) where the trimer 
forms moving the transmembrane and the fusion peptide are in close proximity 
(6). (Adapted from Mukhopadhyay et al., 2005 )
1 2 3
6
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Figure 1-12. Flavivirus life cycle overview. The steps involved in the 
assembly of the virus remain vague, although proposed to be within the 
Golgi. (Adapted from Mukhopadhyay et al., 2005).
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Figure 1-13. Flavivirus replication cycle. After binding and fusion, the capsid and 
viral RNA are exsposed leading to RNA replication begining with translation and 
polyprotein processing followed by the synthesis of a negative strand RNA 
intermediate. Newly synthesized positive RNA leads to viral morphogenesis in 
intracellular vesicles before maturation and release (Adapted from Solomon and 
Barrett in Nash and Burger (Eds) Clinical Neurovirology Marcel Decker 2003).
b  Envelope Protein
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Figure 1-14. Dissemination o f West Nile virus from mosquito bite to neuroinvasion. 
West Nile virus from the saliva o f a mosquito travels from Langerhans dendritic cells 
to the draining lymph node resulting in viraemia. Virus crosses the blood brain barrier 
possibly aided by TNFa and infects the neurons. (Adapted from Samuel and 
Diamond, 2006).
Langerhans 
dendritic cells
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CHAPTER 2 : MATERIALS AND METHODS
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2.1 Buffers aud reagents
GTE resuspension buffer 
50mM Glucose 
25mM Tris-Cl 
lO m M ED TA
Alkaline lysis buffer (SDS/NaOHl 
0.2 N  NaOH 
1% SDS
3M KOAc pH 4.8 
60ml 5M KOAc
11.5 ml glacial acetic acid
28.5 ml dH20
TE-RNase A buffer
lOul o f stock RNase A (10mg/ml)
0.5ml TE buffer
PAGE running buffer (10x1
Glycine 144g 
Tris 30g 
SDS 20g 
1L dH20
Western blot wet transfer buffer (10x1
Tris 30.3g 
Glycine 144g 
lL d H 20
Luria-Betani (LB) broth and agar 
20g LB powder 
Add dH20  to 1L
For agar add 15g Bacto agar per liter
0.1 M cacodylate buffer
Dissolve 21.4 g sodium cacodylate trihydrate in ca. 800 ml deionized water 
Titrate with 12N HCL to pH 7.2 
Add water to total volume 1,000 ml 
Filter and store
PFGPA stock solution
200ml 0.1 M cacodylate buffer heat to 60°C for 10 min
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Add 12g paraformaldehyde powder, cover with aluminum foil and continuing heating 
while stirring until solution becomes clear
Remove from hot plate and cool at least 15 minutes
Add 0.04g trinitrophenol (picric acid)
Adjust pH to 7.3
PFGPA.l fixative (TOOmlf
To 40ml stock solution add 0.2 ml 50% glutaraldehyde 
Add 59.8 ml dH20 
Add 0.03g CaCl2 
Adjust pH to 7.3
PFGPA.1 fixative (final concentration')
2.5% formaldehyde
0.1% glutaraldehyde
0.03% picric acid (trinitrophenol)
0.03% CaCl2
0.05 M cacodylate buffer pH 13-1A
0.1 M maleate buffer HOOP mlt
Dissolve 5.8g maleic acid in ca. 900ml dH20
Add 2.2g NaOH
Titrate pH to 5.2 with IN NaOH
Add dH20  to 1000 ml
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1% uranylacetate (UA) in 0.1 M maleate buffer U 00m It
Dissolve 0.58g maleate acid in ca. 90 ml dH20
Add 0.2g NaOH
Adjust pH to 6.0 with IN NaOH
Dissolve IgU A
2.2 Site-directed mutagenesis
A cDNA infectious clone designed from WNV NY99 (382-99) was used for these 
experiments (Beasley et a l, 2005). Briefly, the clone consists of a two plasmid 
system containing the WNV 5’untranslated region (UTR), the structural genes and the 
natural nt-2495 NgoMTV site o f the NS1 gene in one plasmid (designated pWN-AB), 
and the NgoMTV through the 3’ UTR in the second plasmid (pWN-CG). An Xbal site 
was engineered after the NgoMTV site o f the 5’ plasmid and at the end of the 3’UTR in 
the second plasmid. The vector plasmid (Kinney et a l, 1997) is a modification of 
plasmid pBR322 containing a T7 bacteriophage promotor upstream of the WNV 5’ 
UTR.
The NSI glycosylation mutants were derived using site-directed mutagenesis 
(Stratagene Quikchangell XL). Nucleotide AA to GC mutations were engineered at 
genomic nucleotide positions 2857-2858, 2292-2293 and 3088-3089 in pWN-CG to 
change the asparagine to an alanine (N—>A) for N S Ibo, N S I175, andN SI207 (Table 2- 
1). Nucleotide A to G mutation was engineered in pWN-CG at 2858 to change the 
asparagine to serine (N—>S) at N S Ibo, 2858-2862 ACAAC—»GCGTG to change 
asparagine, asparagine to serine, valine (NN—>SV) at N S Ibo-b i, 2857-2859 
AAC—»GAG to change the asparagine to glutamine (N—>Q) at N S Ibo and 2857 to
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2865 AACAACACC—►CAGCAGGCG to change asparagine, asparagine, threoine to 
glutamine, glutamine, alanine (NNT—>QQA) at NS 1130-132 (Table 2-1). The prM and 
E glycosylation sites were also ablated by changing the asparagine to serine (N—>S) 
with nucleotide changes at 508-510 (TCG—>AAT) for the prMis mutant and at 1427 
(A—>G) for the E 154 mutant (Table 2-1).
2.3 Large scale plasmid DNA extraction
Plasmid DNA o f the WN cDNA infectious clone was extracted using a large scale 
plasmid extraction protocol. Either broth containing a bacterial colony or the bacterial 
colony from a  plate streaked with bacterial culture broth was used to grow the bacteria 
in 200 ml LB broth with 200 pi o f a 50 mg/ml stock o f ampicillin overnight. The 
culture broth was centrifuged for five minutes at 6,000 rpm to pellet the cells. Next, 
the cells were resuspended in 6 ml o f cold GTE, the cells lysed with 9 ml SDS/NaOH 
for five minutes on ice before the addition o f 9 ml o f 3M KOAc. The cellular debris 
and chromosomal DNA was then pelleted by centrifugation for 10 minutes at 10,000 
rpm. The liquid was aspirated and added to 16 ml ispropanol, mixed, and centrifuged 
for 15 minutes at 10,000 rpm to reveal a  pellet. The liquid was discarded and 500 pi 
TE buffer was added to dissolve the pellet and RNase A was added. This mixture was 
placed at 37°C for 30 minutes to one hour before phenol chloroform and chloroform 
extractions. Ethanol was added to the tube and a pellet was formed after 
centrifugation for 10 mintues at 14,000 rpm at 4°C. The ethanol was discarded and 
500 pi o f TE was added to dissolve the pellet. This crude DNA prep was further 
purified using the Qiagen PCR purification kit. Concentrations o f DNA were
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determined by running one microliter o f sample on a gel with DNA loading buffer 
(NEB).
2.4 In vitro ligation
The two plasmids (Fig. 2-1) were prepared for in vitro ligation by digesting 
approximately lpg o f each 5’ pWN-AB and 3’ pWN-CG plasmid with NgoMTV and 
Xbal. The 5’ and 3’ DNA fragments were purified by agarose gel electrophoresis 
and ligated using T4 DNA ligase (NEB) overnight at 4°C, after which the ligase was 
heat inactivated for 10 minutes at 70°C. Ligated DNA containing full-length WNV 
genome was linearized by Xbal, treated with proteinase K, extracted twice with 
phenol/chloroform/isoamyl alcohol and once with chloroform, and then ethanol 
precipitated. The pelleted DNA was rehydrated in 10 pi o f TE buffer pH 8.0 
(Invitrogen) and used as template for transcription, incorporating A cap analog (NEB) 
and using the Ampliscribe T7 transcription kit (Epicentre). After two hours o f 
incubation at 37°C, 2 pi o f the transcription reaction was analyzed by agarose gel 
electrophoresis to ensure that transcription had taken place. The remaining 
transcription reaction was mixed with 3.3xl06 Vero cells in 500 pi of phosphate 
buffered saline (PBS; Gibco), placed in a 0.2-cm electrode gap cuvette (Bio-Rad), and 
pulsed twice at 1.5 kV, 25 pF, and oo ohms using a Gene Pulser electroporator (Bio- 
Rad). The electroporated cells were incubated at room temperature for 10 minutes, 
then added to 35 ml o f minimal essential medium (MEM-Gibco) supplemented with 
8% BGS (Hyclone), 100 units/ml o f penicillin and 100 pg/ml o f streptomycin 
(Gibco), 0.1 mM non-essential amino acids (Sigma), and 2 mM L-glutamine (Gibco) 
in a 75-cm2 tissue culture flask (Costar), and incubated in 5% CO2 at 37°C. Virus was
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harvested when cytopathic effects (CPE) were apparent. The cell debris was pelleted 
by centrifugation, and the supernatant medium was stored in 1 ml aliquots at -80°C.
2.5 RT-PCR
RNA was extracted from a sample o f each mutant virus using the QiaAmp Viral RNA 
Mini kit (Qiagen), and a cDNA fragment containing the NS 1 gene was amplified by 
RT-PCR (Roche Titan One Step RT-PCR kit) and sequenced to confirm the presence 
o f the introduced mutation(s). Primers used for genome and protein fragment 
sequencing are outlined in Table 2-2 and the RT-PCR conditions used are as follows:
Reverse transcriptase 50°C 30 min
Denaturing 94 °C 2 min
Annealing 55 °C 30 sec >-
Extension 68 °C 2 min J
Denaturing 94 °C 15 sec
Annealing 55 °C 15 sec >■
Extension 68 °C 2 min J
Denaturing 94 °C 15 sec
"\
Annealing 60 °C 15 sec >■
Extension 68 °C 2 min A5sec >
Hold 4 °C
xl
x9
x25
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2.6 Cell culture
2.6.1 Passaging virus
Viruses were passaged in Vero cells before subsequent use. Supernatant from 
transfected cells were added to a confluent monolayer o f Vero cells, left for 30 
minutes at room temperature before adding maintenance media containing 2% BGS 
(Hyclone) MEM supplemented with glutamine, penicillin/streptomycin and non- 
essential amino acids. Supernatant was collected two days later, centrifuged and 
frozen at -80 °C.
2.6.2 Plaque titration
Infectivity o f each virus was measured by plaque titration using 6-well tissue culture 
plates (Costar-3506) containing confluent Vero cell monolayers. The virus was 
added to the cells in ten-fold dilutions and left at room temperature for 30 minutes, 
rocking the plates every five minutes. After this time, 4 ml o f 2% agarose/MEM 
overlay was added to the cells and the plates were placed at 37 °C. For temperature 
sensitivity assays, an additional plate was prepared in parallel and incubated at 39.5 
°C. Two days later, a  second 2 ml overlay containing 2.4% neutral red (Sigma) was 
added. Plaques were visualized over the next two days. A temperature-sensitive 
phenotype was evidenced by reduced viral plaque titre at 39.5 °C compared to 37°C.
2.6.3 Plaque reduction neutralization tests
Neutralizing antibody titres were determined by PRNT50. Mice inoculated 
intraperitoneally (ip) with either NY99 or attenuated mutant viruses were bled 21 days
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post-inoculation and the serum collected. Serum was diluted 1:5 in PBS and heat 
inactivated at 56°C for 30 minutes. The serum was then diluted 1:5 in PBS before 
preparing two-fold dilutions in 100 pi o f 2% MEM. The NY99 virus was diluted to 
200 PFU/100 pi and 100 pi o f virus was added to 100 pi o f serially diluted serum, 
mixed and placed at 4°C overnight. One hundred microlitres o f the serum/virus 
mixture was added to confluent Vero cells in 6 well plated (Costar). Back titrations o f 
the virus were also plated at 10'1 to 10'2, or 100,10, and 1 PFU respectively, to test the 
dilutions. Plaques were counted and the PRNT50 was determined by a 50% reduction 
in plaques.
2.7 Multiplication in cell culture
Viral replication kinetics were analyzed in monkey kidney Vero (ATCC CCL 81) 
mouse macrophage-like P388 D1 (ATCC CLL-46) and mouse neuroblastoma Neuro 
2A (ATCC CCL-131) cells. Virus was adsorbed at am oi o f 0.1 to confluent 
monolayers o f cells for 45 minutes at room temperature. The inoculum was aspirated, 
cells washed with PBS and maintenance MEM medium containing 2% BGS was 
added. Triplicate monolayers were infected for each virus, and samples were 
collected at 12,24, 36 ,48 ,60 ,72  and 96 hours post-infection for Vero and P388 D1 
cells and at 12,24,48, 72, and 96 hours for Neuro 2A cells, centrifuged to pellet cell 
debris, and frozen at -80°C until analyzed by plaque titration in Vero cells. Some of 
the mutant viruses were combined into one large experiment and the data was 
subsequently separated; therefore, the NY99 replication curve may be repeated in 
more than one chapter.
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2.8 Western Blot
Confluent Vero cells in 100 mm tissue culture petri dishes were inoculated with 
mutant virus or the parental strain. After adsorbing for 30 minutes, the virus inoculum 
was removed, the cells were washed twice with PBS, and 10 ml o f MEM containing 
2% BGS and supplemented as above was added. The plates were incubated for two 
days at 37°C, after which the culture medium was collected, concentrated to 250 pi 
by using an Amicon lOkd filter, and mixed with an equal volume o f RIP A lysis buffer 
(Eliceiri et al., 1998). Whole cell lysates were also collected. Laemmli loading dye 
containing 0.5M Tris pH 6.8, 6% glycerol and bromophenol blue was added to the 
culture medium extract, and samples were boiled for five minutes. Similarly, 
Laemmli loading dye containing 0.6 M DTT (Sigma) was added to the whole cell 
lysate samples. Five to 25 pi o f each sample was loaded onto a 10% polyacrylamide 
gel (Bio-Rad), and western blotting was performed by using a transblot (Bio-Rad) 
according to the manufacturer’s instructions. After wet transfer, the blots were 
blocked overnight in 5% milk (Sanalac) in Tris buffered saline (TBS). Next, the 
blocking buffer was removed, anti-NSl monoclonal antibody (Chung et ah, 2006) 
was added at a dilution of 1:200, and the blots were incubated for 30 minutes at 37°C. 
The primary antibody was removed by three five- minute washes with TBS. 
Secondary anti-mouse whole IgG antibody containing horseradish peroxidase (HRP- 
Sigma) and diluted 1:5,000 in blocking buffer was added for 30 minutes at room 
temperature. The secondary antibody was removed with three five-minute washes of 
TBS, and chemiluminescent reagent was added (Super Signal - Pierce). 
Audoradiographs were developed to visualize the protein.
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Some western blots used to visualize the NS1 protein were re-probed in order to 
visualize the E protein. In these cases, the blots were stripped using Restore Western 
Blot Stripping Buffer (Pierce). Approximately 25 ml o f buffer was added to the blot 
with rocking for 10 minutes to remove the chemiluminescence and antibodies. The 
blot was then washed with TBS three times to remove the stripping buffer before 
blocking in milk. The primary (anti-EDIH) and secondary (anti-mouse-HRP) 
antibody and chemiluminescence were added as described above for the NS1 
antibody.
2.9 Confocal microscopy
In vitro fluorescent conjugate antibody probing was used to examine differences in the 
E and NS1 protein staining pattern o f the attenuated E i54S, NS1130-132QQA/175A/207A and 
E154S/NS1130A175A/207A mutant versus the parental NY99 strain and mock-infected cells. 
A coverslip containing a confluent monolayer o f Vero cells was infected with either 
mutant or parental WNV at a moi o f 0.1. The viruses were left to adsorb for 30 
minutes at room temperature, the inoculum removed and the coverslips washed with 
PBS twice before 2% serum containing medium was added and left at 37°C for 48 
hours. The coverslips were then fixed in acetone and dried. A double staining 
technique was used to probe the E and NS1 protein by adding a rabbit anti-E domiain 
III antibody to the coverslips, left for one hour at 37°C, then wash three times with 
PBS. The second primary antibody, a mouse anti-NSl, was added and left at 37°C for 
45 minutes, then wash three times with PBS. The two secondary anti-rabbit and anti­
mouse alexoflour conjugate antibodies were then added (Molecular Probes) diluted to 
10 pg/ml and left at 30 minutes at 37°C then washed three times with PBS. The 
coverslips were mounted on slides with DAPI containing Prolong Gold mounting
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media (Molecular Probes). The slides were viewed using a Ziess confocal and the 
images visualized using Zeiss LSM image browser. All slides were analyzed using 
the same gain.
A similar technique was used to visualize the endoplasmic reticulum (ER). A 
confluent monolayer o f Vero cells was infected with either NSI130-132QQA/175A/207A or 
parental N Y 99 strain at an moi of 0.1 or mock-infected as above. Cells were fixed, 
stained and visulaized as above, except the primary antibody, mouse anti-ER antibody 
diluted 1:200, was used (Molecular Probes).
2.10 Electron microscopy
The parental NY99, attenuated NS1 glycosylation mutant viruses and mock-infected 
cells were used for electron microscopy (EM) to visualize the virus within the cell.
T25 flasks containing a confluent monolayer o f Vero cells were infected with a moi of 
0.1, virus left to adsorb for 30 minutes and then washed with PBS before adding 2% 
MEM media. Forty-eight hours post-infection the cells were washed with PBS and 
fixed with PFGPA. 1 fixative (see reagents) for two hours at room temperature. Next, 
the cells were washed with 0.1 M cacodylate buffer three times for 10 minutes at 
room temperature. After washing the cells were scraped, placed into an eppendorf 
tube and centrifuged for 10 minutes at 8,000 rpm to pellet cells. At this time the cell 
pellet was divided into two separate tubes to complete the procedure for transmission 
electron microscopy (TEM) and transmission immuno-EM (TEEM).
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2.10.1 TEM post-fixation and embedding procedure
Post-fixation, 1% 0 s0 4  in 0.1 M cacodylate buffer was added to the cell pellet and 
left for 1 hour at room temperature followed by three washes with 0.1 M cacodylate 
buffer for 10 minutes each, then one wash in 0.1 M maleate buffer at pH 5.2 for 10 
minutes. Next, en block staining consisting o f 1% UA in 0.1 M maleate buffer was 
performed for 30 minutes at 60°C followed by four 10 minute washes with 0.1 M 
maleate buffer at a pH o f 5.2 at room temperature, then the pellet was left in 0.1 M 
maleate buffer overnight at 4°C. The next day the pellet was dehydrated with several 
ethanol washes including 50% ethanol wash for 10 minutes, 75% ethanol for 10 
minutes, 95% ethanol for 10 minutes and three washes with 100% ethanol for 10 
minutes each. Infiltration o f the pellet with propylene oxide (PO) was performed next 
two times for 10 minutes each followed by two 1 hour infiltration steps, PO:Poly/Bed 
812= 50:50 and 25:75 , with rocking and then pure Poly/Bed 812 was added twice for 
one hour with rocking. Embedding followed by placing the cell pellet in Poly/Bed 
812 into polyethylene capsules to polymerize overnight at 60°C. The embedded cell 
pellet was then cut into thin sections and placed on disks for visualization on the 
electron microscope.
2.10.2 TIEMpost-fixation and embedding procedure
Post-fixation, en bloc staining for TIEM consisted o f one wash in 1% UA in 0.1 M 
maleate buffer, making sure the pellet was away from the wall o f  the tube, for 20 
minutes at 60°C. Four consecutive washes with 0.1 M maleate buffer at a pH of 5.2 
for 10 minutes each was followed by one wash in the same buffer overnight at 4°C. 
Dehydration o f the pellet was performed by two 10 minute washes with 50% ethanol,
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two 10 minutes washes with 75% ethanol and one 1 hour wash in the dark with a 1:2 
dilution of 75% ethanol and LR white. Three more consecutive washes with LR 
white were performed first for 1 hour at room temperature and then overnight 
followed by one more 1 hour wash. The cell pellet LR white mixture was embedded 
into small gelatin capsules for polymerization for 24 hours at 60°C. Following 
polymerization, thin sections were cut and placed onto disks.
2.10.2.1 Antibody staining
Petri dishes lined with parafilm were used to wash and stain the disks. The buffers 
and antibodies were syringe filtered, drops were added to the parafilm and the disks 
were placed face down onto the drops. The cells were blocked in BSA-G buffer for 
15 minutes before placed onto the primary antibody. The primary antibodies were 
diluted 1:2 for the rabbit a-EDIII and 1:10 for the mouse a-NS 1 (17 NS 1: Chung et 
al. 2006) in BSA-G, combining both, and left for one hour in a moist chamber and 
then overnight at 4°C. The next day the unbound primary antibodies were removed 
with five washes in BSA-G for three minutes each and then placed onto 20 pi o f the 
secondary antibodies containing a 1:20 dilution o f the a-rabbit and a-mouse gold 
particles in 1% BSA for one hour at room temperature in a moist dark chamber. The 
unbound secondary antibodies were then removed by another five washes o f BSA-G 
for three minutes each and followed by three TBS buffer washes for five minutes each 
and one wash with water for five minutes. Next 2% aqueous GA was added for five 
minutes and then washed with water three times for five minutes each. A five m inu te  
staining in 2% UA followed and was washed three times for five minutes each in 
water and then left to air dry before the final Pb-citrate step for 30 seconds. The disks 
were then visualized in the electron microscope.
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2.11 Mouse studies
2.11.1 Ip and ic inoculations
To determine the mouse virulence phenotype o f the mutant viruses, groups o f five 3-4, 
3- or 5-week-old female NIH Swiss mice (Harlan Sprague-Dawley) were inoculated 
via intraperitoneal (ip) and intracerebral (ic) routes with serial 10-fold dilutions of 
virus. Due to the lack o f availability o f mice, some experiments contained 3-5 week- 
old-mice. Differences in the LD50 o f weanling- and adult-infected mice were 
undertaken in Chapter 9. The parental NY99 strain derived from the infectious clone 
was used as a positive control in each experiment, and PBS was used as a negative 
control. Mice were observed for 21 days and 50% lethal dose was calculated for each 
group. Some of the mutant viruses were combined into larger experiments and the 
data subsequently separated; therefore, the parental NY99 control may be repeated in 
more than one chapter.
2.11.2 Multiplication kinetics
To study the in vivo replication kinetics o f the attenuated viruses compared to the 
parental strain, groups o f mice were inoculated ip with 100 PFU of either 
NS1 130A/207A, NS 1 i 3oa/175a /207Aj or clone-derived parental NY99 virus. Three mice 
were sacrificed each day post-infection for six days, and brains and blood were 
collected. Blood samples were centrifuged in a microtainer tube containing a serum 
separator before collecting the serum and storing at -80°C. Each brain was 
homogenized in 500 pi o f 2%MEM and frozen at -80°C. All samples were plaque 
titrated in Vero cells.
66
2.11.3 Serum collection
Whole blood was collected from mice via tail bleeds. Blood was collected in 
mictrotainer tubes containing a serum separating gel (BD- 365956) and left at room 
temperature for at least 30 mintues to coagulate. After this time the tubes were 
centrifuged at 6,000 rpm for 90 seconds and serum was transferred to a new tube.
The serum was stored at -80 °C until subsequent use.
2.11.4 Isolating and sequencing virus from the brain
Brains from moribound and dead mice were collected and homogenized in 2% BGS 
MEM. The RNA was extracted either from the brain homogenate or from culture 
supernatant from Vero cells infected with brain homogenate.
2.12 Cytokine/chemokine analysis
2.12.1 Cytokine membrane
Whole blood was collected at one and three days post-infection from mice inoculated 
ip with the parental NY99 strain or PBS inoculated mice. The blood was allowed to 
coagulate, the serum separated (see serum collection section) and frozen before use 
with RayBiotech’s Mouse Cytokine Antibody Array III membranes (Fig. 2-2). The 
protocol supplied with the kit was followed and the membranes were analyzed using a 
densitometer.
2.12.2 Bioplex
Serum collected from 3-, 5- and 3-5-week-old mice inoculated ip with the parental
NY99, NS 1130A/175A/207A* NS 1130-1 32Qqa ; i 75A/207A or PBS on days one and three post-
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infection was used for cytokine/chemokine expression anlysis using the Bioplex kit 
and equipment (BioRad). The mouse 23- and/or 9-plex beads (Table 2-3) and the 
standard controls were utilized according to manufacturer’s instructions. Triplicate 
samples were analyzed on 96-well plates read using the Plex-200 machine. Student’s 
t-test was used to determine the significance o f up- or down-regulation compared to 
the mock-infected samples.
2.13 Statistical significance
Statistical significance was determined for mouse average survival time and the 
cytokine assays. Significance was determined by Student’s t-test (p<0.05) for all 
experiments. The mouse average survival time significance was determined by 
comparing the parental NY99 strain to the mutant strains and the significance o f the 
cytokine data was determined by comparing the virus-infected samples to the mock- 
infected samples. No outliers were visualized by a box and whiskers plot.
Significance was also determined for the immuno-EM studies. Six fields were 
counted for the mock and NY99-infected cells for both E and NS1 gold particles. The 
background staining for the mock-infected cells was significantly less than the 
infected cells (p<0.01) by Student’s t-test.
2.14 Research statement
The experimental work contained in this thesis was the work o f the author. The 
laboratory research in this thesis was conducted at the University o f Texas Medical
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Branch in Galveston,TX under the supervision of Professor Alan Barrett (UTMB) and 
Professor Tom Solomon (Liverpool).
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Table 2-1. Mutagenesis primers
prM15S
CTAACTTCCAAGGGAAGGTGATGATGACGGTATCGGCTACT
GACG
E l54S GTCGCACGGAAGCTACTTCCACACAGGTTGG
NS1130A CCAGAACTCGCCGCCAACACCTTTGTGG
NSI175A GGT CAGAGAGAGCGCCACAACT GAAT GT GACTCG
NS1207A GGATTGAAAGCAGGCTCGCTGATACGTGGAAGC
NSI130Q
GCACCAGAACTCGCCCAGAACACCTTT GT GGTT GAT GGTCC 
GG
NS1130s CCAGAACTCGCCAGCAACACCTTTGTGGTTG
NS 1130-131 sv CAGAACT CGCCAGCGT GACCTTT GT GGTT G
NS1130-132QQA
GCACCAGAACTCGCCCAGCAGGCGTTTGTGGTTGATGGTCC
GG
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Figure 2-1. Drawing o f WNV genome: mutagenesis to transfection. The WNV 
cDNA infectious clone exists as a two plasmid system. Mutagenesis was performed to 
either plasmid according to the location o f the desired mutation. The two plasmids 
were ligated together before transfection into Vero cells.
5’UIK C prM H NS I w \  NS2B NS3 SS4A NUB NS5 3'U(R
Cut withNgoMV and Xbal 
ligate with T4 ENA ligase 
linearize with Xbal
1 5'UIR c prM MSI \S 2 \  \S2B NSIA NS4B NS5
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Table 2-2. NY99 infectious clone primers
WN-1272- CAACGGCTGCGGACTATTTGG
cWN-2500- GCCGGCT GAT GTCTAT GGCAC
WN-2495- GCCGGCAAGAGCT GAGAT GT G
cWN-3795- CGCTTTGAGAAACGATGCCACC
WN-3739- GGAGACGTGGTACACTTGGCGC
cWN-5248- GGCCT CTTT GAT GAT CT GT GGCAG
WN-5199- CGGCGCCGGTAAAACAAGG
cWN-6701- CCAATGCCCTTCCGCTGC
WN-6640- GCCTTATT GAGT GT GAT GACCAT GG
cWN-8155- GCT CTT CAACCT CAGCACTT GACG
WN-8086- CCTT CT GAGT GTT GT GACACCCTCC
cWN-9592- CC AC AT CAT CT GGGCCAAT CAC
WN-9511- GCCCTAAACACTTTCACCAACCTGG
cWN-11029- AGATCCTGTGTTCTCGCACCACC
WN=sense primer 
cWN=antisense primer
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CHAPTER 3 : REMOVING THE GLYCOSYLATION MOTIF(S) 
IN THE NS1 PROTEIN BY CHANGING THE ASPARAGINE
TO ALANINE
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3.1 Introduction
The flaviviral NS1 protein contains two to four highly conserved N-linked 
glycosylation motifs. All members o f the JE serogroup, with the exception o f JE virus, 
contain three glycosylation motifs at asparagine (N) residues NS 1130, NS 1175, and 
NS1 207 (Bakonyi d  ctl., 2004, Bli tvi ch et ¿7/., 2001, Chambers fit fl/-, 1990, Sunuyoshi 
et al., 1987) . Other mosquito-bome flaviviruses, including JE and DEN viruses, 
contain two glycosylation motifs at positions N S I130 and N SI207, while YF, SEP and 
YOK viruses have two motifs at positions N Slno and N SI208, and ENTV contains 
four potential sites at N S I106, N S I130, N SI208 and N SI326 (Dalgamo et al., 1986; Pryor 
& Wright, 1994; Flamand et al., 1992, Kuno and Chang, 2006). Although the 
functions o f NS1 are not well defined, it appears to be involved in multiple steps of 
the replication cycle (Lindenbach & Rice, 1997; Mackenzie et al., 1996; Westaway et 
al., 1997). It has also been suggested that the NS1 protein o f DEN-2 virus induce 
autoreactive antibodies against extracellular matrix proteins, which may play a role in 
the development o f dengue hemorrhagic fever (Chang et al., 2002; Falconar, 1997).
Studies involving the ablation o f NS1 glycosylation sites have been performed for
other mosquito-bome flaviviruses, including DEN-2, DEN-4 and YF viruses
(Crabtree et al., 2005; Muylaert et al., 1996; Pletnev et al., 1993; Pryor & Wright,
1994 ;Pryor et al., 1998). In contrast to WNV, these viruses contain only two
glycosylation sites in NSI (NS1130 and N SI207) and phenotypic studies were limited to
replication in cell culture and mouse neurovirulence studies. Overall, these published
studies showed that nonglycosylated NS1 mutant viruses have impaired replication
and, with a couple of exceptions, displayed a decrease in mouse neurovirulence.
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In this chapter, ablation o f the WNV NS1 glycosylation sites was achieved by 
changing the asparagine o f the glycosylation motif to an alanine by site-directed 
mutagenesis. Alanine was chosen due to its small size and ability to reside inside or 
outside o f the protein. The mutation of a specific amino acid is denoted by the single 
letter amino acid code after the amino acid in question. A total o f seven glycosylation 
mutants were generated using all possible combinations of mutations including: 
N S W  N S W  N SI207A , NSI130A/175A, NS1 i3oa/207a> NS 1175A/207A and
N S1130A/175A/207A-
3.2 Results
3.2.1 In vitro characterization o f mutant viruses
The studies in the PhD utilize an infectious clone o f prototype strain New York 1999 
(NY99) o f WNV. This infectious clone has the WNV genome contained in two 
plasmids; the 5’ half and 3’ half and was obtained from Dr. Richard Kinney o f the 
United States Centres for Disease Control and Prevention in Fort Collins Colorado. 
The details o f the infectious clone can be found in Chapter 2, Materials and Methods, 
section 2.2. The mutant viruses were generated by site-directed mutagenesis o f the 
infectious clone, as described in Materials and Methods, section 2.2-2.4. All studies 
compare mutant viruses generated by site-directed mutagenesis to the “parental” 
NY99 strain generated from the infectious clone via transfection o f Vero cells with in 
vitro generated RNA. Previous studies (Beasley et al., 2005) have shown that the 
phenotype of the NY99 virus appears identical to that generated from the NY99 
infectious clone.
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Seven glycosylation mutants were rescued as infectious virus following transfection 
of Vero cells with in vitro generated RNA as described in Materials and Methods 
section 2.4. Neither the parental NY99 strain nor any of the mutant viruses derived 
from it were temperature sensitive at 39.5° C except for NS 1 boa, which was slightly 
temperature sensitive (20-fold reduction in infectivity titre at 39.5° C; Table 3-1) and 
the plaque morphology of each of the mutants was not altered from that o f parental 
NY99 virus.
The NS1 gene o f each mutant was sequenced and confirmed the integrity o f the 
introduced mutation(s) and that no additional, possibly compensatory, mutations had 
arisen in the gene. Full length genome sequencing was performed for the NS 1 b o a /207a  
and NS1 b o a /175a /207A mutant viruses, which showed the greatest attenuation in mice 
(see below). The N S 1 b o a /207a  mutant contained one unexpected silent change at 
nucleotide 10221 in the NS5 gene, while N S 1 b o a / 175a / 207a  contained only the 
engineered mutations compared to the NY99 cDNA infectious clone.
3.2.2 Western Blot
NS1 is normally a secreted protein. Accordingly, polyacrylamide gel electrophoresis
and western blot analysis were performed on concentrated culture media collected
from NY99 and NS1 mutant virus-infected Vero cells, at 48 hours post-infection.
This was undertaken to determine whether or not the NS1 protein of each
glycosylation mutant was secreted, and to assess the difference in the apparent
molecular weight o f each mutated NS1 protein, compared to that o f the parental NY99
virus, resulting from the loss o f single or multiple NS1 glycosylation sites (Fig. 3-1 A).
Anti-NSl monoclonal antibody 17NS1 (Chung et al., 2006) detected NS1 protein in
the culture medium o f cells infected with clone-derived WNV NY99 and all of the
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mutants, indicating that the loss in glycosylation did not significantly affect NS1 
protein secretion. Variable levels o f glycosylation were putatively confirmed by the 
observed differences in migration between the parental NY99 NS1 protein and the 
NS1 o f each single, double, and triple glycosylation mutant (Fig. 3-1 A). The 
monomeric form of the NS1 triple mutant NS I 130A/175A/207A migrated faster than that o f 
the double mutants NS1 bo a / h s a , NS1 i75A/207Aand N S 1 i 30a /207a , which in turn migrated 
faster than the monomeric NS1 o f single mutants N S 1 i 30a ,  N S I h s a  and NS1207A- 
Samples separated in the absence o f reducing agent revealed E-NS1 dimers and 
monomeric states o f NS1, as has been previously documented for other flaviviruses 
(Blitvich et al., 1995; Flamand, et al., 1999; Mason, 1989). The NS1-NS1 dimer is 
readily converted to monomer after boiling, and therefore was not detected (Winkler 
et al, 1988; Blitvich et al, 1995). The NS1 monomer appeared as a cluster of bands, 
probably due to the different cleavage products o f this protein (Mason, 1989; Blitvich 
et al., 1995). The presence o f multiple NS1 bands was likely more pronounced in the 
glycosylation mutant samples because o f the decrease in NS1 size due to the loss of 
glycosylation at one, two, or three sites (Fig. 3-1A). Western blotting was also 
performed for whole cell lysate samples o f NS 11 3oa/ i 75A/207A, NY99, N S I b o a ,  N S I175A, 
and N S I207A mutant virus-infected cells boiled in the presence of dithiothreitol (DTT) 
to analyze the reduced form o f the NS1 protein (Fig. 3-1B). Two major isoforms of 
NS1, a  larger NS1’ band and a smaller NS1° band, were detected by anti-NSl 
monoclonal antibody 17NS1. These two NS1 isoforms have been described 
previously for JE and MVE viruses (Mason, 1989; Blitvich et al., 1995; Blitvich et al 
1999.) (Fig. 3-1B).
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3.2.3 Multiplication kinetics o f  mutant viruses in cell culture
Multiplication characteristics o f the parental clone-derived NY99 virus and mutant 
viruses were compared in mouse neuroblastoma Neuro 2A, monkey kidney Vero cells 
and mouse macrophage-like P388 D1 cells. Confluent monolayers were infected at an 
moi o f  0.1, the supernatant collected in triplicate at 12,24,48,72 and 96 for Neuro 2A 
cells and 12, 24, 36,48, 60, 72 and 96 hours post-infection for Vero and P388 D1 
cells. The infectivity titres were determined in Vero cells.
3.2.3.1 Neuro 2A cells
No differences were seen between the parental NY99 infectious clone virus and the 
triple glycosylation mutant NS 1130A/175A/207A virus in the Neuro 2A cells (Fig. 3-2A). 
Other NS1 mutant viruses were not studied.
3.2.3.2 Vero cells
The triple (NS 1130A/175A/207A) and the double (NS 1130A/207A) mutant viruses and the 
parental NY99 strain were compared in Vero cells to determine the multiplication 
kinetics in cell culture. No differences were seen in multiplication kinetics o f the 
parental virus and the double or triple NS1 glycosylation mutants in Vero cells (Fig. 
3-2B)
3.2.3.3 P388D1 cells
Multiplication curves in P388 D1 cells exhibited modest differences in infectivity 
titres, with the double and triple NS1 glycosylation mutant viruses (N SI130A/207A and
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NSI i 3oa/175a/207a )  having a lower infectivity titre compared to the parental strain at the 
12 and 48 hour time points (Fig. 3-2C).
3.2.4 Mouse virulence phenotype o f mutant viruses
All seven NSI glycosylation mutant viruses were examined for mouse 
neuroinvasiveness through inoculation by the ip route. Glycosylation mutant viruses 
(NS 1 130A/207A and NS 1 i 3oa/175a /207a )  were also examined for neurovirulence through 
inoculation by the ic route. Attenuation was determined by the L D 50 comparison o f the 
mutant viruses to the parental NY99 strain.
3.2.4.1 Neuroinvasiveness and neurovirulence o f mutant viruses
The mouse neuroinvasive phenotype (i.e., the ability to invade the brain following 
inoculation by a peripheral route) was examined following ip inoculation o f 3-4 week 
old female NIH Swiss mice. Only one o f the single glycosylation mutants, N S I175A, 
was attenuated (500-fold) compared to clone-derived parental NY99 virus, while the 
double mutants N S I130A/175A and N S I175A/207A were attenuated 800- and 200-fold, 
respectively (Table 3-2). The two most attenuated mutants by this route were 
NS1130A/207A and N S I130A/175A/207A, which was attenuated 3,200-fold and 50,000-fold, 
respectively, compared to the parental NY99 strain.
Mouse neurovirulence (i.e., the ability o f virus to cause disease following direct 
inoculation into the brain) was assessed for three o f the viruses: clone-derived parental 
NY99 virus and glycosylation mutants N S I130A/207A and N S I130A/175A/207A (Table 3-2). 
Following ic inoculation, the N S I130A/207A and N S I130A/175A/207A mutants were 
attenuated 50-fold and 160-fold, respectively, compared to NY99 virus.
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3.2.4.2 Sequence analysis o f viral RNA isolatedfrom mouse brains
RNA was isolated from the brains o f mice that succumbed to ip inoculation with 
1,000, 100 or 10 PFU of each o f the seven mutant viruses, and the WNV NS1 gene 
was amplified by RT-PCR and sequenced. In one study, all five mice that 
succumbed to infection following ip N S I130A/175A/207A inoculation, and two mice that 
succumbed to infection following ip inoculation o f each NS 1 boa, N S Ihsa, N SI207A, 
NS1B0A/175A, NS1130A/207A or N S I175A/207A mutant were analyzed. Only the 
NS1130A/175A/207A virus showed a mutation in the NS1 gene and this was a reversion, 
which occurred only at the asparagine (N) o f the NS 1130 site (i.e., A -> N). The frill- 
length genomic consensus sequence was determined for one N S I130A/175A/207A mutant 
virus isolated from the brain o f a mouse that succumbed to infection following ip 
inoculation with 1,000 PFU. A reversion to N at the N S I130 site, as well as two 
additional mutations in domain II of the E protein at E-M204v and E-E237G were 
identified (Fig 3-3). This “revertant” virus was observed to have a highly 
neuroinvasive phenotype o f <0.1 PFU/LD50, following ip inoculation. The mutations 
at E204 and E237 were introduced individually into the NY99 infectious clone, and a 
variant virus was generated for each mutation. Mice infected with these viruses 
showed an ipLDso of 20 PFU for the E204 mutant and 2 PFU for the E237 mutant.
In a second study, viral RNA was isolated from the brains of a total o f 6 mice that 
succumbed to N S  I130A/175A/207A virus infection during different experiments, and the E 
and N S 1 genes were amplified by RT-PCR and sequenced. Viral RNA from two of 
these mice contained the same two E-M204V and E-E237G mutations as well as the 
reversion at N S I1 3 0 .  Three o f the six viruses contained no mutations in either E or
82
NS1 other than the engineered mutations. One o f the six had no mutations in E but 
the NS 1130 changed to Aspartic acid.
In a third study, viral RNA was isolated from the brains o f four mice that succumbed 
to infection with mutant virus NSI130A/175A/207A containing reversion at NS 1130 (A -> 
N )  plus E-M204V and E - E237G mutations ( E 2o4v /237g - N S 1 175a /207a )- Analysis o f these four 
brains showed that the reversion at NS 1130 and the E204 and E237 mutations were 
retained in viral RNA from the brains o f all four mice.
3.2.4.3 Multiplication in vivo
Examination o f the multiplication o f clone-derived parental W N V  and the two most 
attenuated mutant viruses, N S 1 i3oa/207a  and NSI130A/175A/207A, following ip inoculation 
(three mice per group per time point) o f 100 PFU revealed all three viruses were 
cleared from the serum after the third day post-infection (Fig. 3-4A). The attenuated 
strains encoding the mutations at N S  1130A/207A and N S  1130A/175A/207A showed a delay in 
the onset o f viraemia when compared to the parental N Y 99 virus. The parental N Y 99 
virus was detected in the brain of one mouse at day 4 post-inoculation and in all mice 
by the fifth day post-inoculation, whereas neither N S 1 i 3oa/207a  nor NSI130A/175A/207A  
mutant viruses were detectable in the brain by 6 days post-infection, as determined by 
plaque titration (Fig 3-4B). The level o f detection was 50 PFU/brain. This result was 
confirmed by RT-PCR of the N S 1 gene where both N S li30A/207Aand NS1i3oa/i75a/207a 
groups were negative for detection o f viral R N A  in the brains o f all three mice on 
days 4, 5 and 6 post-inoculation, while the N Y 99 samples that showed infectious virus 
were also positive by RT-PCR (Fig 3-5).
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In an effort to investigate a possible correlation between level of viraemia and 
mortality of the animals, groups o f 5 mice were inoculated ip with one o f the two 
attenuated mutants, N S 1 i 30a/207a  or N S 1 i 30a / i 75a/207a , at a dose o f either 1 ,0 0 0  or 1 0 0  
PFU in order to achieve groups o f mice that either succumbed to or survived infection, 
respectively. Additional groups o f mice were inoculated ip with either 100 or 10 
PFU of infectious clone-derived NY99 virus. Mice were bled on days 2 and 3 post­
infection to measure viraemia. Brains were harvested from moribund mice following 
euthanasia and from mice that died, and homogenized before passaging once in Vero 
cells for isolation and sequencing o f the virus. In general, a peak viraemia > 200 
PFU/ml at 2 or 3 days post-inoculation correlated with a fatal outcome (Table 3-3). 
The level o f viraemia was significantly reduced on both day 2 and day 3 post­
infection in the mice infected with either o f the two attenuated viruses, compared to 
mice infected with the parental NY99 strain. The highly attenuated phenotype of the 
NS1 i 3oa/ i 75a/207a  mutant virus correlated with the greatest reductions in viraemia, 
morbidity, and mortality. In the case o f the parental NY99 strain, only one mouse, 
given 10 PFU of virus, showed no detectable viraemia and did not succumb to 
infection. However, this surviving mouse did not survive secondary ip challenge with 
100 PFU of the NY99 virus. This is consistent with the lethal dose o f NY99 virus 
being approximately equivalent to the infectious dose (i.e., LD50 = ID5o).
Only one mouse survived infection with the N S 1 i 30a/207a  mutant at each inoculum of 
100 or 1,000 PFU (Table 3-3). However, the apparent survivor at the 1,000 PFU dose 
had a viraemia o f 3,500 PFU/ml on day three, which was higher than most mice that 
succumbed to infection in this group, and this mouse exhibited encephalitic 
manifestations o f permanent hind limb paralysis, and was euthanized. In the case of
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the NSI 130A/175A/207A group given 1,000 PFU, two animals had a viraemia greater than 
1,000 PFU/ml and subsequently died. Viral RNA isolated from the brains of these 
mice encoded a reversion to N at NS 1130, as had been observed in the original 
experiments to investigate reversion (section 3.2A.2.). Another mouse in the 100 PFU 
dose N S I i3oa/175A/207A group succumbed to infection without detectable viraemia. 
However, viral RNA isolated from the brain o f this mouse also showed the reversion 
to N at the NS1130 site.
3.3 Discussion
Previous studies o f the attenuating effects o f mosquito-borne flavivirus NS1 
deglycosylation have focused on YF, DEN-2 and DEN-4 viruses, which have two 
glycosylation sites in NS1. West Nile virus NS1 contains three glycosylation sites, 
and this study determined that WNV utilizes all three glycosylation sites in the NS 1 
protein (see Figure 3-1). The NSI glycosylation sites were ablated in various 
combinations to generate seven mutants, and phenotypic properties o f these mutants 
were investigated.
Despite ablation o f all three NSI glycosylation sites of WNV, the triple 
NS 1 boa/175a/207a  mutant exhibited apparent genetic stability in vitro, as demonstrated 
by its containing the expected genomic nucleotide sequence and its robust 
multiplication in cell culture (Fig. 3-2). This contrasts with the NSI glycosylation 
mutant viruses for DEN-2 virus where the dual (complete) deglycosylation of the NS1 
protein o f a  DEN-2 virus was unable to produce infectious virus and the engineered 
mutation at NS 1207 acquired secondary mutations to enable replication in mosquito 
C6/36 or monkey kidney LLC-MK2 cell culture (Crabtree et al, 2005).
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The triple NS1 glycoslyation mutant ( N S 1 i 30a/ i 75a /207a )  that included three amino 
acid changes and the parental NY99 virus were initially chosen to compare 
multiplication kinetics in Neuro 2 A cells. Plaque titration in Vero cells o f triplicate 
samples per time point revealed similar infectivity titres for both the parental strain 
and the mutant containing the most amino acid mutations, despite attenuation for 
neuroinvasiveness and neurovirulence o f this mutant virus. Similar multiplication 
kinetics were also seen in Vero cells for the parental NY99 strain, double N S 1 i 30a /207a  
and triple NSI 1 30a /175a /207a mutant viruses. Unlike Neuro 2A and Vero cells, the triple 
glycosylation mutant (N SI130A/175A/207A) showed some reduction in multiplication in 
the mouse macrophage-like derived P388 D1 cell line compared to the parental NY99 
strain, particularly at the 12 and 48 hour time points. The double ( N S 1 i 30a/207a ) 
mutant virus showed a reduction in infectivity titre similar to the triple 
NSI 130A/175A/207A mutant virus in the P388 D1 cells. This is consistent with a previous 
report o f  delayed replication for NS 1 glycosylation mutants of YF virus (Muylaert et 
al, 1996). Since macrophages are infected early after inoculation o f mice by the ip 
route, this impediment to multiplication may explain, in part a reduced viraemia, 
earlier clearance o f the virus from the blood, and the observed inability o f this virus to 
replicate to high enough titres to invade the brain.
The data in this chapter indicated that all three NSI glycosylation sites contribute to 
the mouse virulence phenotype o f W N V, with the triple mutant virus showing the 
greatest attenuation o f the mutants that were engineered. The additional NS 1175 
glycosylation site that is found only in W N V and other viruses belonging to the JE 
serogroup, except JE virus, was shown to play an important role in the mouse 
neuroinvasive phenotype o f W NV N Y 99. Ablation o f glycosylation at NSI175
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attenuated this mutant compared to the parental strain, whereas ablation o f either the 
N S I130 or N SI207 site alone had much less effect on the neuroinvasive phenotype. 
The degree o f attenuation that was observed depended on the particular NS1 mutation 
or combination o f NS1 mutations incorporated into the viral mutant The NS1130A/207A 
and NS1130A/175A/207A mutants were consistently attenuated more than 200-fold, 
compared to the parental NY99 virus when inoculated ip into 3-4 week-old mice. 
Interstingly, the double N S I175A/207A mutant was not as attenuated as the single 
N S I175A mutant virus in mice. Disparate phenotypic effects o f deglycosylation at 
different NS1 loci have been previously reported for a chimeric TBE/DEN-4 virus in 
which deglycosylation o f the DEN-4 N S I130 site attenuated the mouse neurovirulence 
o f the chimeric virus, whereas deglycosylation o f the N SI207 site actually increased 
mouse virulence (Pletnev et al., 1993).
Previous studies with other flaviviruses have shown that mutation o f the first 
(N SI130) or both (N Sli3o/207-or-208) glycosylation sites by replacing the asparagine with 
an alanine, isoleucine or glutamine in the NS 1 protein cause variable attenuation of 
mouse neurovirulence (Crabtree et al.,2005; Muylaert et al., 1996; Pletnev et al., 
1993). Although for WNV the ablation o f the first N S I130 glycosylation site alone did 
not attenuate the virus, this site appeared to be important for the ability o f the virus to 
replicate efficiently in vivo when the other two glycosylation sites were ablated as 
well (N SI130A/175A/207A mutant). Many o f the viruses that were isolated from the brains 
o f mice that had succumbed to infection with the N S I130A/175A/207A mutant showed an 
A -> N  reversion at the NS 1130 site. Given the high frequency o f occurrence o f this 
reversion in viruses recovered from the brains o f  mice infected ip with the 
NS 1 i3oa/i75a/207a mutant, the increased neuroinvasiveness o f the N S I130A/175A/207A
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mutant virus in certain instances o f virus-induced mouse morbidity and mortality was 
partially attributed to reversion at the N S I130 site, which rendered the virus 
neuroinvasive. Although both NS 1130A/207A and NS 1130A/175A/207A mutants replicated to 
measurable viremic titres in virus-infected mice, neither virus replicated to detectable 
levels in the brain, suggesting that in the absence o f reversion at NS 1130 or the absence 
of other virulence enhancing mutations, these viruses generally lacked 
neuroinvasiveness. The decreased icLDso values o f the N SI130A/207A and 
N S  1130A/175A/207A mutants, relative to the NY99 virus, indicated that attenuation of 
neurovirulence also contributed to the overall attenuated phenotypes o f  these two 
viruses, despite the similarities o f their multiplication kinetics compared to the 
parental NY99 virus in mouse neuroblastoma cells.
Interestingly, some NS 1130 revertants had two additional substitutions at residues 204 
and 237 in domain II o f the E protein (Fig 3-3). The role of these E protein mutations 
is not clear. However, their presence in the revertants suggested a possible interaction 
between E and NS1 under the selective pressure o f replication in vivo. The amino 
acid at E204 appears to reside buried inside the protein while E237 is a surface 
accessible amino acid (VIPERdb http://viperdb.scripps.edu/) and resides close to an 
antibody epitope (Oliphant et al., 2006). Individually, each o f these E mutations 
either did not significantly alter (E 237) or slightly attenuated (E204) the mouse 
neuroinvasive phenotype o f parental WNV. Although it is not understood why the 
NS 1130 site was the only site o f reversion observed in this study, it has been shown for 
the related MVE virus that this glycosylation site contains a complex carbohydrate 
and is suggested to lie outside the interface o f the NS1 dimer (Blitvich et al., 2001; 
Hall et al., 1999). N-linked carbohydrate groups have been implicated to function in
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several ways such as protein folding, secretion rates and stability in the endoplasmic 
reticulum (Varki 1998). This study demonstrated that glycosylation o f at least one of 
the glycosylation sites of the NS 1 protein was important for viral multiplication in 
vivo. The NS 1 no glycosylation site, which exhibited significant attenuation in synergy 
with the other two glycosylation loci in the N S li3oA/207Aand NS 1 i 30a/ 17sa/207a  mutants, 
appears to play a critical role in the function o f the protein and the biology of the 
virus.
Finally, this study showed that the removal o f the three glycosylation sites o f the NS 1 
protein generated a viable W NV that replicated robustly in cultures o f several 
mammalian cell types, and the triple mutant was significantly attenuated for both 
neuroinvasiveness and neurovirulence in a mouse model. Overall, this study is 
consistent with previous studies suggesting that the structural protein genes are not the 
only genes that contribute to the neuroinvasive phenotype o f flaviviruses (Pletnev et 
al, 1993). However, this is the first study to clearly demonstrate that mutations in the 
nonstructural N S1 protein are sufficient to attenuate the neuroinvasive phenotype in 
the mouse model.
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Table 3-1. Temperature sensitivity o f all seven NS1 alanine mutant viruses and 
parental NY99 virus.
V irus
37°C
(LoamPFU/mll
NY99 6.6
NSI130A 6
NSI175A 8 .1
NSI207A 7
NS1130A/175A 7.9
N S 1130A/207A 7.9
NS1-I75A/207A 7.8
NS1130A/175A/207A 8 .2
39.5°C
(LoamPFU/mll
A 37°C- 39.5°C 
(Loam PFU)
6.5 0.1
4.7 1.3
7.4 0.7
6.6 0.4
7.6 0.3
7.5 0.4
7.3 0.5
8.3 -0.1
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Figure 3-1. Non-reducing western blot o f NS1 protein from supernatant of all 
seven alanine mutants and NY99 (A), and from cell lysates o f the single and triple 
mutants and NY99 treated with a reducing agent (B) collected from Vero-infected 
cells at an moi o f 0 .1 .
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Figure 3-2. Multiplication kinetics o f parental NY99 and NS1i30a/175a/207a mutant 
viruses in mouse neuroblastoma Neuro 2A cells (A) and parental NY99, NS1i30a/207a 
and N S1 i30a/i75a/207A mutant viruses in monkey kidney Vero cells (B) and mouse 
macrophage-like P388 D1 cells (C) at an moi o f 0.1. Each time point represented by 
mean + SD of triplicate samples.
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Table 3- 2. Mouse neuroinvasiveness (ip) and neurovirulence (ic) o f NSI glycosylation 
alanine mutant viruses and the parental NY99 strain.
ipLDso icLDso
Virus (PFU) AST * SD* p-Valuet (PFU)
NY99 0.1 7.7 +.0.8 NA 0.5
N S 1 -I3 0 A 2 10.0+1.9 <0.05 nd
N S 1 i7 5 A 50 10.0 + 1.2 <0.05 nd
N S 1 2 0 7 A 1.3 7.4 + 0.9 >0.05 nd
NS1130A/175A 80 9.0 + 1.2 >0.05 nd
N  S1130A/207A 320 9.5+ 1.7 >0.05 25
N  S1175A/207A 20 7.8 + 1.0 >0.05 nd
NS1130A/175A/207A 5,000 9.0+ 1.4 >0.05 80
*=Average standard survival time (days) at dose of 1,000 PFU
p-valuet= significance of difference between AST of mutant virus and that of the NY99 virus 
(Student’s t-test)
nd = not determined
93
Fi
gu
re
 3
-3
.T
op
 v
ie
w
 o
f W
N
V
 E
 g
ly
co
pr
ot
ei
n 
sh
ow
in
g 
th
e 
E2
04
 a
nd
 E
23
7 m
ut
at
io
ns
. C
ol
or
s 
re
pr
es
en
t d
iff
er
en
t d
om
ai
ns
: R
ed
-D
om
ai
n 
I, 
Y
el
lo
w
-D
om
ai
n 
II,
 B
lu
e-
D
om
ai
n 
III
94
In
fec
tiv
ity
 (
Lo
g1
0 P
FU
/br
ain
) 
In
fec
tiv
ity
 (
Lo
g1
0 P
FU
/m
l)
Figure 3-4. Multiplication kinetics o f parental NY99 and attenuated NS1 
glycosylation alanine mutant viruses in mouse serum (A) and brain homogenates 
(B) 1-6 days post-inoculation. Each time point is mean o f three mice + SD.
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Days post-infection
Days post-infection
NY99
N S 1 130a /207A
N S 1 i 3oa/175A/207A
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Figure 3-5. Conformation o f the WNV NS1 gene by RT-PCR o f viral RNA present 
in brain homogenates in the parental NY99-infected mice but not in the attenuated 
NS1 mutant-infected mice from samples 4-6 days post-ip inoculation used in Fig. 3- 
4 .
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Table 3-3. Infectivity titre o f mouse serum collected two and three days post-inoculation 
by the ip route with either parental NY99 or attenuated NSI glycosylation mutant viruses
NSli30A/207A NS 1 i 30A7175A/207A
(10 PFU ip) (100 PFU ip) (100 PFU ip)
2 dpi 3 dpi 2 dpi 3 dpi 2 dpi 3 dpi
Mouse (PFU/mll (PFU/mll (PFU/mll (PFU/mll (PFU/mll (PFU/mll
1 <50 15,000* 50 600* <50 <50
2 <50 <50 <50 <50 <50 <50*$
3 2,000 150,000* 1,000 5,000* <50 <50
4 4,000 50,000* 2,000 5,000* <50 <50
5 2,500 300,000* 50 200* <50 <50
NY99 NSli30A/207A NSI J30A/175A/207A
(100 PFU ip) (1,000 PFU ip) (1,000 PFU ip)
2 dpi 3 dpi 2 dpi 3 dpi 2 dpi 3 dpi
Mouse (PFU/mll (PFU/mll (PFU/mll (PFU/ml) (PFU/mll (PFU/mll
1 5,000 2,000* 1,500 600* 50 <50
2 6,500 3,000* 100 3,500f 100 100
3 10,000 5,000* 100 1,100* <50 <50
4 4,000 10,000* 500 600* 50 4,500*$
5 <50 12,500* 250 1,000* 400 1,500*$
*Mice that succumbed to infection 
tPartially paralyzed and euthanized
^Reversion of Ala to Asn at NS1130
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CHAPTER 4 : CHANGING NS1i30 TO A SERINE AND TWO 
AMINO ACIDS IN THE GLYCOSYLATION MOTIF
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4.1 Introduction
In Chapter 3, the three NSI N-linked glycosylation sites (NXT) o f WNV were ablated 
by changing the asparagine o f the glycosylation motif to an alanine (NXT —► AXT). 
Alanine was chosen because it is a small uncharged amino acid that is hypothesized to 
not disrupt the conformation or function o f the protein. It was demonstrated in 
Chapter 3 that the triple glycosylation mutant (NS1i3oa/175a/207a) was unstable in mice. 
Many viruses isolated from the brains o f mice that succumbed to this virus had one or 
more mutations, including reversion at one o f the glycosylation sites (NS1 oo) plus 
two mutations in the E protein. Although this virus was highly attenuated, several 
mice that died following ip inoculation had one or more o f these amino acid 
substitutions.
Accordingly, it was hypothesized that complete attenuation o f neuroinvasiveness in 
mice would be achieved if  the mutations incorporated in the NS1 protein would not 
revert the glycosylation status to wild-type at the NS 1 no site. Since the NS 1 no 
glycosylation motif contains two asparagines in the first and second position o f the 
glycosylation motif (NNT), both asparagines were mutated by changing the first 
asparagine to a serine and the second asparagine to a valine (NNT—>-SVT). In this 
way the glycosylation site could not be restored either by reversion at NS1 no or by 
shifting the glycosylation motif using the second asparagine that could result from a 
mutation in the fourth position to a serine or threonine (i.e. SNTF —» SNTT). In 
addition, a  mutant virus was generated containing only a single amino acid mutation 
at NS1 no by changing the asparagine to a serine (NNT->SNT) in order to determine 
what effects, if  any, the specific amino acid change would have at this site. Serine 
was selected because it is a mutation in the E glycosylation site o f WNV isolates
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found in nature (Beasley et al., 2005) and its molecular structure resembles asparagine 
(Fig 4-1).
A total o f four new mutant viruses were generated, including NS 1 bos, NS1 bo-13isv, 
NS1 bos/175a/207a and NS1B0-131SV/175A/207A- Multiplication kinetics in cell culture and 
the neuroinvasiveness and neurovirulence phenotype in mice were examined by 
comparing the mutant viruses to the parental NY99 strain.
4.2 Results
4.2.1 In vitro characterization o f mutant viruses
Five days post-transfection, all four mutant viruses were harvested, samples frozen 
and then passaged once in Vero cells before subsequent experiments were performed. 
The NS1 gene was sequenced for all mutant viruses and no mutations were identified 
other than the engineered mutations. Plaque titration o f NS 1 bos and NS 1 bo-131sv 
revealed a typical NY99 plaque morphology while the NS 1 bos/175a/207a and NS 1 bo- 
i31sv/i75A/207A mutant viruses displayed a small plaque morphology (<lmm) compared 
to the parental strain (2mm) (Fig. 4-2). A temperature sensitivity (ts) assay at 39.5°C 
indicated that the serine mutant viruses NS 1 bos, NS1 bo-131sv and NS1130S/175A/207 were 
not ts (Table 4-1). The NS1bo-131sv/175a/207a mutant virus, having a 1.6 logio reduction 
in infectivity titre, was considered somewhat ts given that a >2 logio reduction in 
infectivity is normally used to define a ts phenotype (Table 4-1).
4.2.2 Western blot analysis
All four mutant viruses were analyzed by western blot after infection o f Vero cells at a 
moi o f 0.1, incubation for 48 hours followed by concentration o f the viral culture
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supernatant. The maximum allowed volume of protein sample (25 pi) was loaded on a 
PAGE gel following wet transfer and probing with a  NS 1 monoclonal antibody 17 
NS1 (Chung et al., 2006) and chemilumenescence (Fig. 4-3A). TheN Sl protein for 
the single glycosylation mutant viruses (NS 1130s and N S1130-msv) migrated faster 
than the NS 1 protein for the parental NY99, and the NS 1 protein for the triple 
glycosylation mutants (N Sli30s/i75A/207Aand N S I130-131SV/175A/207A) migrated faster than 
the single glycosylation mutants, indicating a loss in glycosylation (Fig. 4-3 A). The 
western blot used to identify the NS1 protein was stripped and reprobed with a 
recombinant E  domain III antibody as a loading control. The results from this blot 
indicated that the relative amounts o f E protein for each sample were similar for the 
parental NY99 and serine glycosylation mutants NS 1130s, N S Ioo-bisv,
NS1 l30S/175A/207Abut not NS1130-131SV/I75 A/207A (Fig. 4-3B).
An overlay o f the E and NS1 probed blots shows the differences in migration o f the 
two proteins (Fig. 4-3C). The larger protein, E, migrates slower than the smaller NS1 
protein. Overall, the western blots indicated a reduction o f secreted NS1 protein in 
the glycosylation mutant viruses.
4.2.3 Multiplication kinetics o f  mutant viruses in cell culture
Multiplication kinetics of the glycosylation mutant viruses and parental NY99 virus 
derived from the infectious clone were compared in mouse macrophage P388 D l, 
monkey kidney Vero and mouse neuroblastoma Neuro2A cells. Cells were infected at 
a moi o f  0.1 in triplicate, cell culture supernatant was collected for each virus at 12 ,
24,48, 72 and 96 hours post-infection and infectivity was determined by titration in
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Vero cells. Figure 4-4A-C shows the multiplication curves with mean infectivity 
values for each time point and standard deviation.
4.2.3.1 Vero cells
Since no differences were seen in the mouse attenuated triple alanine mutant virus 
(NS1 i3oa/175a/207a) in Vero cells (Fig. 3-2B), only the triple serine mutant virus 
(NS1130-131SV/175A/207A) and parental NY99 strain were analyzed in this cell line (Fig. 4- 
4A). The parental NY99 WNV increases in infectivity titre up to 48 hours post­
infection in Vero cells, whereas the NS I130-131SV/175A/207A mutant virus increases until 
96 hours post infection. At 12 hours post-infection the infectivity titre o f the mutant 
virus compared to the parental strain were similar. However, at 24 and 48 hours post­
infection there was up to a 100-fold decrease in infectivity compared to the parental 
NY99 strain. Infectivity levels were similar to NY99 virus at the 72 and 96 hour time 
points.
4.2.3.2 Neuro2A cells
Since WNV shows tropism for the brain, mouse neuroblastoma Neuro2A cells were 
selected to investigate differences in the multiplication o f the NS 1130-131SV and NS 1 no- 
131 sv/i 75A/207A mutant viruses compared to the NY99 parental strain. Unlike 
multiplication in Vero cells, the parental NY99 strain and serine mutant viruses 
NS1 i3o-i3isv and NS 1130-131SV/175A/207A increased in infectivity titre until 72 hours post­
infection and subsequently began to decrease at 96 hours post-infection. Although 
both mutants displayed a reduction in infectivity titre at all time points compared to 
NY99 virus, the N S 1 i 30-i 3 isv / 175a/207a  mutant showed the greatest reduction in
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infectivity titre (approximately 70-100-fold) compared to the parental strain (Fig. 4- 
4B).
4.2.3.3 P388D1 cells
As macrophages are infected early in the infection process following ip inoculation of 
mice, the mouse macrophage cell line P388 D1 was used to investigate differences in 
multiplication kinetics between the parental NY99 and serine mutant viruses, 
including NS loos, NSloo-msv and NSI130-131SV/175A/207A mutants (Fig. 4-4C). The 
NY99 strain increased in infectivity titre until 48 hours post-infection followed by a 
small decrease in infectivity titres at subsequent time points (Fig. 4-4C). The mutant 
viruses followed a similar trend in multiplication with all three mutant viruses,
NS 1 n o s ,  NS 1131-131SV and NS1o o -i3 isv /i75A /207A , showing a reduction in infectivity titre 
compared to the parental strain at all time points; at least 100-fold and up to 10,000- 
fold reduction for NS1 i30-msv/i75A/207Aat 96 hours post-infection.
4.2.4 Mouse virulence phenotype o f mutant viruses
To determine whether or not the serine mutants were attenuated for mouse virulence, 
3-4 week female outbred NIH Swiss mice were inoculated by the ip route to 
determine the neuroinvasive phenotype and by the ic route to determine the 
neurovirulence phenotype o f all four mutant viruses (NS loos, NS1 oo-msv,
NS1 130S/175A/207A and NS1 o o -131s v /17sa /207a )  compared to the parental NY99 strain and 
the NS 1 o o a / i 75a /207a  mutant. Serial 10-fold doses o f each virus were inoculated into 
groups o f mice and lethality and survival times were calculated (Tables 4-2 and 4-3).
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4.2.4.1 Neuroinvasiveness and neurovirulence o f mutant viruses
As hypothesized, the NS 1130 serine mutants showed a greater level o f attenuation of 
neuroinvasiveness than the alanine mutant viruses (Chapter 3). However, the serine 
mutants exhibited an unexpected level o f attenuation o f neuroinvasiveness as 
increasing the number o f amino acid mutations did not necessarily correlate with 
attenuation. The single glycosylation mutant viruses, NS1130s and N S1130-msv 
exhibited a similar level of attenuation o f neuroinvasiveness with ipLDso values of 
1,300 and 2,000 PFU respectively (Table 4-2). Interestingly, both viruses were 
attenuated at least 130-fold for neuroinvasiveness compared to the parental NY99 
strain, which was more than the triple alanine mutant virus NS 1130A/175A/207A (Table 4- 
2). The triple serine mutant viruses, NS 1130S/175A/207A and NS 1130-131SV/175A/207A5 
showed inconsistent mouse neuroinvasive phenotypes in that the mutant with the most 
amino acid mutations, the NSI 130-131SV/175A//207Amutant virus, was less attenuated than 
the NS 1 i3os/i75A/207A mutant virus with an ipLDso values o f 80 and >100,000 PFU, 
respectively. In this experiment the NS 1130A/175A/207A triple alanine mutant virus was 
attenuated 50-fold for neuroinvasiveness compared to the parental NY99 strain, which 
was less attenuated than three o f the four serine mutant viruses, excluding NS1130-
131SV/175A/207A-
Neurovirulence was investigated by inoculating mice by the ic route. Compared to 
the parental NY99 strain with an icLD5o o f 30 PFU, three o f the mutant viruses,
NS 1 nos, NS 1 i3os/i75A/207A and NS 1 i30-i3isv/i75A/207A mutants did not have a significant 
difference in neurovirulence compared to the parental strain (i.e., icLDso o f 80,50 and 
50 PFU, respectively) (Table 4-2). In this study the most attenuated mutant for 
neurovirulence was the NS 1130-131SVmutant with an icLDso of 300 PFU.
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The mouse virulence study was repeated in a second group o f female 3-4 week old 
NIH Swiss mice with the NSloo-msv, NS1i3o-i3isv/i75a/207amutant viruses and 
compared to the parental NY99 and NS 1130A/175A/207A mutant virus (Table 4-3). The 
parental NY99 strain displayed an ipLD50 o f 10 PFU and an icLD5o o f 10 PFU while 
the NS 1 i3o-i3isvmutant showed an ipLD50 o f 300 PFU and an icLD5o o f >100 PFU. 
The NS 1130-13 isv/i75A/207A mutant showed the most attenuation with an ipLD50 of 
80,000 PFU and an icLDso o f 500 PFU. In this study the triple alanine mutant virus, 
NS 1130A/175A/207A, was more attenuated for neuroinvasiveness than the NSI 130-131SV 
mutant virus but less attenuated than the triple serine mutant virus, NS1 b o - 
i3isv/i75A/207A, that had an ipLDso o f 1,000 PFU. Overall, the results o f the two studies 
confirmed a high level o f attenuation o f mouse virulence for the mutant viruses 
compared to the parental NY99 strain.
4.2.5 Sequence analysis o f viral RNA isolatedfrom mouse brains
The brains o f mice that succumbed to infection following ip inoculation with the 
serine mutant viruses were collected, the nucleic acid extracted, and viral RNA 
subjected to RT-PCR and sequencing to analyze the NS 1 gene for mutations. The E 
gene was also analyzed due to the mutations in the E gene found in the brains o f mice 
that succumbed to NS 1i30a/17sa/207a following ip inoculation. Three brain samples 
were analyzed for each serine mutant virus at a  dose o f 1,000 or 100 PFU, except the 
NS 1 i3os/i75A/207Amutant virus for which only two mice succumbed to infection. No 
mutations, including reversions were seen in the NS 1 gene o f any of the serine mutant 
viruses at the engineered mutation sites and no mutations in the E protein were 
identified. However, all three mice that succumbed to infection following ip 
inoculation with the NS 1 nos mutant virus contained an A—>C change at nucleotide
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position 2589 that resulted in a glutamine to histidine (CAA—>CAC) amino acid 
mutation atNSUo (Fig 4-5).
Viral RNA isolated from the brains o f mice that succumbed to ip inoculation with the 
NS 1130A/175A/207A mutant virus used in these mouse virulence studies was also 
examined for mutations in the E and NS1 gene. All three samples analyzed showed 
the same reversion at the NS 1130 site and the same two mutations in the E gene (E204 
and E237) found in Chapter 3 section 3.2.4.2.
4.3 Discussion
In Chapter 3, the ablation of the three NS1 glycosylation sites consisted of changing 
each asparagine to an alanine. Although a high level o f attenuation of 
neuroinvasiveness was achieved, especially with the NS I130A/175A/207A mutant virus, 
reversion at the NS 1130 site as well as compensating mutations in the E protein were 
seen in viruses isolated from the brains o f mice that succumbed to infection following 
ip inoculation with this virus. Since several mice that succumbed to infection 
inoculated with the alanine triple mutant virus showed reversion at the NS 1 no residue, 
it was hypothesized that changing more than one amino acid in the first (NS 1130) 
glycosylation motif would result in a virus that would not readily revert to a virulent 
phenotype, and thus a more stable, attenuated virus. This was achieved by changing 
the NS 1130 asparagine to a serine and the NS 1131 asparagine to a valine (NNT-^SVT).
The NS 1 ]3os/i75A/207A and NS1130-132SV/175A/207 serine mutant viruses showed reduced 
multiplication in cell culture as well as a small plaque phenotype compared to the 
parental strain. Reduced infectivity titre and small plaque phenotype were associated 
with attenuation o f neuroinvasiveness in the mouse model (Fig. 4-2 and Tables 4-2
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and 4-3). Unlike the alanine mutants (Chapter 3), the serine mutant viruses displayed 
reduced infectivity titres in all three cell types examined with the most differences in 
mouse macrophage P388 D1 cells.
The protein blots showed a reduction in the secreted NS1 of the serine mutant viruses. 
The E control protein blot showed consistent bands between the parental NY99 and 
serine mutant viruses indicating the reduction in secreted NS1 was not due to an 
overall reduction in synthesis o f viral proteins. The exception to this was the NS 1bo- 
i3isv/i75A/207Amutant virus. The western blots for this protein samples indicated an 
overall loss o f viral protein that contributed to the reduction in secreted NS 1.
Neuroinvasive and neurovirulence phenotypes were determined in female 3-4 week 
NIH Swiss mice. All four o f the serine mutants proved to be attenuated for 
neuroinvasiveness to some extent compared to the parental NY99 strain. This was in 
contrast to the alanine mutants where only two of the seven engineered mutants were 
highly attenuated (NS1 b o a /207a  and NS1 i 30A/ i 75a /207a )  (Table 3-2). Interestingly, the 
single mutation at the NS 1 i3o residue, changing the asparagine to a serine (NS 1 bos) 
attenuated the virus 200-fold for neuroinvasiveness. This was unexpected since 
changing the NS 1 i3o residue to an alanine (NS 1 i3oa) did not significantly attenuate the 
virus. It is hypothesized that the serine mutation at this site is more stable than the 
alanine mutation and this is probably due to the similarity in molecular structure o f the 
asparagine and serine compared to alanine. Serine differs from alanine by a hydroxyl 
group that replaces one methyl group (Fig. 4-1 ) and is similar to the naturally 
occurring asparagine in that they are both hydrophilic amino acids while alanine is 
weakly hydrophobic. This similarity may explain why no reversions were seen in 
these mutants and consequently more attenuated mutants were achieved.
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It was noted that viral RNA isolated from the brains of mice that succumbed to 
infection with the NS1130s mutant virus contained an amino acid mutation at N SI40, a 
non-conserved site among flaviviruses (Fig 4-5). None of the other virus-infected 
mouse brains showed this mutation. It is unclear why the NS 1130s mutant was the 
only virus that showed a mutation in the NS 1 protein, however, the possibility of 
mutations elsewhere in the genome cannot be ruled out. Due to the volume of 
sequencing of both the E and NS1 genes, determining the nucleotide sequence o f the 
entire genome of vimses from several mice for all mutant viruses was not deemed 
feasible.
Two studies were conducted to determine the neuroinvasive and neurovirulence 
phenotype of these mutant viruses in mice. Although the LD50 for the serine mutant 
viruses, especially the NS1130-131SV/175A/207A, showed variability in mice, the parental 
virus remained consistent between experiments. Since reversion o f the NS 1 
glycosylation sites was not identified, restoration of the glycosylation site(s) cannot 
explain this variability. In fact, other than the mutation at N SI40 for the NS1130s 
mutant virus, no other mutations were found in the E or NS 1 protein genes of any 
mutant virus. This is in contrast to the alanine attenuated (NS 1130A/175A/207A) mutant 
where ablation o f the glycosylation sites resulted in either compensating mutations in 
the E protein and/or reversion at NS 1130 indicating that one or more glycosylation sites 
were needed for neuroinvasiveness.
Differences in the mice utilized may explain discrepancies between the two mouse
virulence studies, in particular the difference in results for the NS1130-131SV/175A/207A
mutant virus in the two studies. Due to the lack o f availability o f the mice, 3-4 week
old mice sets contained some weanling and post-weanling mice and varied between
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experiments. Age-dependent resistance to flavivirus infection in mice has been shown 
previously for West Nile and JE viruses (Hunsberger and Roehrig, 2006; Ogata et al, 
1991) and it has been shown that weanling mice display immature immune systems 
relative to adult mice (Holladay and Smialowicz, 2000). Since differences in the 
LD50’s were seen only in the NS1130-131SV/175A/207A mutant virus and not the parental 
NY99 strain, it is hypothesized that differences in the immune responses o f the mice 
towards these NS1 glycoslyation mutant viruses may affect their survival rate.
Further examination of this hypothesis was undertaken later in the thesis.
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Figure 4-1. Molecular structure o f asparagine and serine. Colors represent different 
atoms: Grey-carbon, white-hydrogen, red-oxygen and blue-nitrogen.
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Table 4-1 Temperature sensitivity of serine mutant viruses
V irus 37°C 39.5°C A (37°C-39.5°)
LoamPFU/mi Loam PFU/ml Loam PFU
N S I 130S 6.5 6.7 -0.2
N S1 -I30 -131SV 8.2 8.0 0.2
NS1130S/175A/207A 6.9 6.9 0
N S 1 130-131SV/175A/207A 6.2 4.6 1.6
1 1 2
Figure 4-3. Western blots o f the parental NY99 and serine mutants of the NS1 (A), E 
(B) and both protein blots overlaid (C).
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Figure 4-4 Multiplication o f serine mutants and the parental NY99 strain in Vero 
(A ), Neuro 2A (B) and P388 DI (C) cells. Each time point represents the mean 
+/- SD o f triplicate samples.
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Table 4-2. Mouse virulence phenotype o f serine mutant viruses and the parental NY99 
strain.
Virus
ipLDso
ÎPFU1 AST + SD* D-value
icLDsn
iPFU]
NY99 1 0 9.2 +1.1 N/A 30
NS1130A/175A/207A 500 10.5 + 1.7 >0.05 nd
NSI130S 2 ,0 0 0 9.5+ 0.7 >0.05 80
NS 1130-131SV 1,300 9.0 + 1.4 >0.05 300
NS1130S /175A/207A >10 0 ,0 0 0 > 2 1 <0.05 50
N S1130-132SV/175A/207A 80 9.2+ 0.8 >0.05 50
*AST ;LSD =  average survival time +  standard deviation at a dose o f  1,000 PFU  
nd= not determined 
N /A  = not applicable
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Table 4-3. Mouse neuroinvasiveness (ip) and neurovirulence (ic) of serine mutant viruses repeated.
Virus
ipLDso
iPFU) AST + SD* D-value
icLDsn
iPFUl
NY99 10 8.0 + 0 N/A 10
NS1130A/175A/207A 1,000 10.5 + 1.9 <0.05 nd
NS1130S nd nd nd nd
NS 1130-131SV 300 10.0 + 1.9 <0.05 >100
NS1130S/175A/207A nd nd nd nd
NS 1130-132SV/175A/207A 80,000 >21 <0.05 500
*AST +_SD = average survival time + standard deviation at a dose of 1,000 PFU 
nd= not determined 
N/A = not applicable
116
Fi
gu
re
 4
-5
. A
m
in
o 
ac
id
 a
lig
nm
en
t o
f t
he
 N
S1
 a
m
in
o 
te
rm
in
us
 o
f s
ev
er
al
 fl
av
iv
iru
se
s. 
H
ig
hl
ig
ht
ed
 a
m
in
o 
ac
id
s 
re
pr
es
en
t c
on
se
rv
ed
I
Vl
-T3<u
cs
tzj
£
W •—>
o
in
3
<D
£
co<D
I
CO
e
o
►*3 &H >  rtj O  Pi I (X 
>  H  CO P C  H  >  I M
iI
¡ ¿ ¡ ¿ W p( W ! 2  
O LQ L^_^ 0 > W
S
■
117
CHAPTER 5 : CHANGING NS1i30 TO A GLUTAMINE AND ALL 
THREE AMINO ACIDS IN THE GLYCOSYALTION MOTIF
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5.1 Introduction
West Nile virus NS1 protein contains three highly conserved glycosylation sites 
(NXT) beginning at residues NS1130, NS1175 and N SI207. The ablation of all three of 
these sites was examined in Chapter 3 by changing the asparagine o f the glycosylation 
motif to an alanine and resulted in a highly attenuated phenotype for mouse 
neuroinvasiveness. Mice that succumbed to infection, however, contained a reversion 
at NS 1 no that restored the first glycosylation site as well as two amino acid mutations 
in the E protein (E204 and E237).
To prevent reversion and increase mouse attenuation, the studies described in Chapter 
4 reported mutating the asparagine o f the NS 1130 glycosylation motif to a serine 
(NS 1130s, NS1130-131SV, NS 1130S/175A/207A and NS 1 b o -i 31sv/ i 75a/207a)- A s hypothesized, 
the serine mutants were more attenuated than the alanine mutant viruses.
Interestingly, even the single NS 1130 N—>-S change attenuated for mouse virulence at 
least as much as the most attenuated triple alanine mutant virus (NS1 boa/175a/207a)- 
Although reversion at NS 1130 site was not detected in the serine mutants, an amino 
acid mutation at NS 140 (glutamine to histadine [CAA—>CAC] ) was seen in all viral 
RNA samples isolated from the brains o f mice inoculated ip with the NS 1130s virus.
No other mutations were identified in either the E or NS1 genes o f the serine mutant 
viruses. Given that the glycosylation mutation remained, the difference in the alanine 
and serine mutants lies within the specific amino acid mutation. For example, the 
single alanine glycosylation mutant virus NS 1 boa was not attenuated in mice while 
the serine glycosylation mutant virus NS1 B 0 -i3 is v  showed a high level of attenuation 
o f mouse neuroinvasiveness, at least 200-fold, compared to the parental NY99 strain.
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The E and NS 1 gene sequences o f viral RNA isolated from the brains o f mice that 
succumbed to these viruses revealed no mutations other than those engineered, 
thereby suggesting that the amino acid at this site may contribute to the overall 
stability o f the virus.
Asparagine and serine are hydrophilic amino acids whereas alanine is hydrophobic. 
Although serine is more similar to asparagine than alanine, serine differs from 
asparagine by an amide group. The amino acid glutamine also contains this amide 
group and differs from asparagine by only one methyl group (Fig 5-1). Due to its 
similarity in molecular structure, glutamine was chosen to replace the asparagine in 
the N S I130 glycosylation site with the aim o f preventing the mutation at N SI40 seen in 
the serine mutant virus (NS 1130s) as well as reversion seen in the alanine mutants 
(NS1 i3oa/175a/207a)- Furthermore, it was hypothesized that changing asparagine to 
glutamine at the NS 1175 and N SI207 residues would generate a virus that was more 
attenuated for neuroinvasiveness in mice because o f the similarity o f the structure to 
that found in the wild type virus.
Six new mutant viruses were generated with one or more glutamine substitutions to
determine the affects o f changing the asparagine to glutamine. Two single site
glutamine mutants were generated, NS 1130Q and NS 1130Q/175A/207A- In addition, two
mutants were generated by changing all three amino acids in the glycosylation motif
such that the entire NS 1130 glycosylation motif was ablated where the two asparagines
at NS1 bo and NS1131 were both changed to glutamine and the threonine at NS1132 was
changed to an alanine (NNT—>QQA), which resulted in mutants NS1 i3o-i32Q QA and
NS 1130-132QQA/175A/207A- Studies in Chapter 4 demonstrated that the serine mutation at
NS 1 bo attenuated the virus (NS 1130s and NS1130-msv) compared to the parental NY99
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strain whereas the single alanine mutation (NS1 hoa) did not. Therefore, two more 
mutants were generated, NS1 i 75_i77QQA a n d  N S 12o7-209q q a -
5.2 Results
5.2.1 In vitro characterization of mutant viruses
The six mutant viruses were generated as described in Chapter 3 and harvested at five 
days post-transfection in Vero cells, samples frozen and then passaged once in Vero 
cells before subsequent experiments were performed. The viruses were titrated in 
Vero cells and plaque titration of the glutamine mutant viruses revealed a typical 
NY99 plaque morphology o f about 2mm for the NS 1 boq, NS 1130-132QQA, NS 1175-177QQA 
and NS I207-209QQA mutant viruses. However, the NS 1130Q/175A/207A and NSlno- 
132QQA/175 A7 0 7A mutant viruses exhibited small plaque morphology o f less than 1mm 
(Fig 5-2). A temperature sensitivity (ts) assay showed that none of the glutamine 
mutant viruses were ts at 39.5°C (Table 5-1). Three plaques were collected for all 
glutamine mutants at 39.5°C, the RNA extracted for RT-PCR and the NS1 gene was 
sequenced. No mutations were identified other than the engineered mutations.
5.2.2 Western blot analysis
All glutamine mutant viruses were used to infect Vero cells at a moi o f 0.1, the 
supernatant was collected at 48 hours post-infection and concentrated before 
performing a western blot. The parental NY99 strain was also used to determine 
whether or not there was an increase in migration o f the NS 1 mutants, thereby 
putatively showing a loss o f glycosylation (Fig 5-3B). The maximum amount of 
protein sample (25 pi) was used for each, and the blots were probed with a monoclonal
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NS1 antibody, 17NS1 (Chung et al., 2006), before chemiluminescence and 
audoradiography to detect the protein. Another PAGE gel was run in the same 
manner, but this time the blot was probed with a rabbit anti-recombinant polyclonal E- 
domain III antibody as a loading control (Fig. 5-3 A). Like the serine mutant viruses 
(Fig. 4-3), the NS1 o f the single site glutamine glycosylation mutant viruses migrated 
faster than that o f the parental NY99 virus, while the NS 1 o f the NS 1130Q/175A/207A and 
NS1130-132QQA/175A/207A migrated faster than the single site mutants. In addition, the 
triple NS1 mutants appeared to have reduced levels o f NS1 compared to the parental 
NY99 strain (Fig. 5-3B). The quantity o f E protein for all glutamine mutant viruses, 
except for the NS1130-132QQA/175A/207A mutant virus, appeared similar to the parental 
NY99 strain (Fig. 5-3A).
5.2.3 Multiplication kinetics in cell culture
Multiplication kinetics o f the NS 1130-132QQA and NS 1130-132QQA/175A/207A mutant viruses 
and the parental NY99 strain was determined in monkey kidney Vero, mouse 
macrophage P388 D l, and mouse neuroblastoma Neuro2A cells (Fig. 5-4A-C). These 
mutant viruses were chosen based on previous experiments where the N S  1130- 
131 sv/i 75A/207A mutant viruses showed the greatest reduction in infectivity titre 
compared to the parental NY99 strain (Fig. 4-4). In addition, there was little difference 
in multiplication kinetics between the N S  1130s, NS1 o o - m s v a n d  NSI130-131SV/175A/207A 
mutant viruses in mouse macrophage P388 D l cells (Chapter 4).
Cells were infected in triplicate at a moi o f 0.1, cell culture supernatants were 
collected at 12,24,48, 72 and 96 hours post-infection, frozen at -80°C and then 
infectivity titres were determined by plaque titration in Vero cells.
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5.2.3.1 Vero cells
The NS 1130-132QQ and NS 1130-132QQA/175A/207A mutant viruses, as well as the parental 
NY99 strain, showed peak infectivity titre at 48 hours post-infection with a subsequent 
drop in titre at later times post-infection in Vero cells. Both NS 1130-132QQ and NS 1130- 
132QQA/175A/207A mutant viruses showed a reduction in infectivity titre at 12 and 24 
hours post-infection compared to the parental NY99 strain, although only the NS1130- 
132QQA/175A/207A mutant virus displayed a difference at 48 hours post-infection. NS 1130- 
132QQ and NSI 130-132QQA/175A/207A mutant viruses showed some reduction in infectivity 
titre at 72 and 96 hours post-infection. The NS 1 i 3o- i 32QQa /17sa/207a  mutant virus 
showed the greatest difference compared to the parental NY99 strain with as much as 
a 3,000-fold reduction in infectivity titre at 24 hours post-infection (Fig. 5-4A).
5.2.3.2 P388 D1 cells
The parental NY99 strain increased in infectivity titre until 48 hours post-infection 
and subsequently reduced in infectivity titre at later times post-infection. The mutant 
viruses NS 1 130-132QQA and NS 1 i 30-132q q a /17sa/207a  showed reduction (up to 30-fold) in 
infectivity titre compared to the parental NY99 strain (Fig 5-4B). Although the 
infectivity titre o f the NS 1 130-132QQA mutant virus was only slightly increased over 
NS 1 130-132QQA/175A/207A, this virus did not reach peak infectivity titre until 7 2  hours 
post-infection. The NSI 130-132QQA/175A/207Amutant virus displayed the greatest 
reduction in infectivity titre compared to the parental NY99 strain and followed the 
same curve as NY99 virus with a peak in infectivity titre 48 hours post-infection.
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5.2.3.3 Neuro 2A cells
Multiplication kinetics of WNV in the mouse neuroblastoma Neuro2A cell line were 
slower, and did not show a rapid increase and subsequent decrease in infectivity titre, 
as seen in the Vero or P388 D1 cells lines. The N S  1130-132QQA/175A/207A mutant virus 
showed the greatest reduction in infectivity titre with a 10-fold decrease at 24 ,48,72 
and 96 hours post-infection compared to the parental NY99 strain (Fig 5-4C). Both 
the parental NY99 and the NSI130-132QQA/175A/207A viruses showed a peak infectivity 
titre at 72 hours post-infection, while that N S  1130-132QQA mutant virus showed a peak 
infectivity titre at 48 hours post-infection; although there were little differences in the 
infectivity titres between the 48 and 72 hour time points.
5.2.4 Mouse virulence phenotype o f mutant viruses
All six glutamine mutants were inoculated into female 3-4 week outbred NIH Swiss 
mice by the ip route (to determine neuroinvasiveness) and by the ic route (to 
determine neurovirulence). Serial 10-fold dilutions o f each virus including, N S 1 i 30q , 
N S  1 130- 132QQA5 N SI175-177Q Q A , NSI207-209QQA, N S  1 130Q/175A/207A a n d  N S I1 3 0 -  
132QQA/175A/207A were inoculated into mice. The LDso’s and average survival times 
(AST’s) were calculated and compared to two controls: the parental N Y 9 9  strain and 
N S  1130A/175A/207A mutant to determine the level of attenuation (Tables 5-2 and 5-3).
5.2.4.1 Neuroinvasiveness and neurovirulence o f mutant viruses
The NS 1 no glutamine mutants exhibited a high level o f attenuation in mice with at 
least a 30-fold attenuation o f neuroinvasiveness compared to the parental NY99 strain. 
The NS I 130Q mutant showed an ipLD50 of 5,000 PFU and the NSlno-mQQA mutant
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showed an ipLD5o o f 300 PFU compared to the parental NY99 strain, which had an 
ipLDso o f 10 PFU. Neither o f these viruses was significantly attenuated for 
neurovirulence compared to the parental strain with icLDso’s for the NY99, NSI 130Q 
and NS 1130-132QQA o f 30, 50 and 20 PFU respectively. In comparison, the 
NS 1130Q/175A/207A and NS 1 no-132QQA/175A/207A mutants were greatly increased in 
attenuation compared to the NS 1130A/175A/207A mutant for both neuroinvasiveness and 
neurovirulence. The ipLD50 for NS1 130Q/175A/207Awas >10,000 PFU with an icLD50 of 
500 PFU, while the NS 1130-132QQA/175A/207A mutant was also highly attenuated with an 
ipLDso o f >500,000 PFU and also showed the greatest attenuation for neurovirulence 
with an icLDso o f 800 PFU (Table 5-2).
The NS 1175-177QQA and N S I207-209QQA mutant viruses were attenuated for 
neuroinvasiveness but not for neurovirulence. The NSI 175-177QQAmutant virus showed 
an ipLDso of 200 PFU while the NS I207-209QQA mutant virus showed a  more modest 
attenuation with an ipLDso of 50 PFU compared to the parental NY99 strain that 
showed an ipLDso of 10 PFU for this experiment (Table 5-2).
In a  repeat experiment (Table 5- 3) ,  the NS 1130-132QQA and NS 1 i3o-132QQa /175a /207a  
mutants maintained a highly attenuated phenotype for both neuroinvasiveness and 
neurovirulence. As in the first experiment, the parental NY99 strain had an ipLDso 
and icLDso o f 10 PFU. The NS 1130-132QQA mutant virus displayed an ipLDso of 500 
PFU, similar to the previous experiment and an icLDso of 500 PFU, which was more 
attenuated than seen in the previous experiment. The NS 1130-132QQA/175A/207A mutant, on 
the other hand, showed consistent ip and ic LD50 values with an ipLDso o f > 1,000,000 
PFU and an icLDso o f 800 PFU (Table 5- 3) ,  nearly identical to the previous 
experiment (Table 5-2) .
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5.2.4.2 Sequence analysis o f viral RNA isolatedfrom mouse brains
The brains o f mice that succumbed to ip inoculation with NS1 i30q, NS1130-132QQA,
N S  1 i 30-132q q a / i 75a/207Aj N S 1175-177QQAand NSI207-209QQA were homogenized and viral 
RNA was extracted followed by RT-PCR and sequencing of the E and N S 1 genes. 
Mice inoculated with the N S  1130Q/175A/207A mutant virus, however, did not show 
morbidity or mortality, and therefore, no brains from this group were analyzed. For 
two viruses, N S 1 i 3oq and N S 1130-132QQA/175A/207A, no sequence was obtained due to the 
lack o f RT-PCR product for these samples. For the other viruses, N S 1130-132QQA, 
N S li75_i77QQAand NSI207-209QQA, 2-5 brain samples were analyzed for each virus 
mutant. No mutations were identified in the E and N S 1 genes, other than the 
engineered mutations (Table 5-4).
5.3 Discussion
Previous experiments in Chapters 3 and 4 described ablating the glycosylation sites in 
the N S 1 protein by mutating the asparagine at the N S 1130 site to an alanine (Chapter 3) 
or a serine (Chapter 4), and the NSI175 andNSl207 sites by changing the asparagine to 
an alanine (Chapter 3 and 4). Although some mutants were attenuated for both 
neuroinvasiveness and neurovirulence in mice, it was clear that the particular amino 
acids in the glycosylation motif were very important and could lead to instability 
and/or tendencies to either revert or cause putative compensatory mutations at other 
residues. This led to the hypothesis that particular changes in the glycosylation motif 
would result in a more ‘stable’ virus and further attenuate the virus for mouse 
virulence. Therefore, the asparagine in the glycosylation motif was mutated to a 
glutamine due to its similarity in molecular properties to asparagines (Figure 5-1).
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Western blot analyses o f the glutamine mutant viruses revealed a decrease in secreted 
NS1 protein o f all mutant viruses compared to the parental NY99 strain in Vero cells. 
Other than for the NS1130-132QQA/175A/207A mutant, this result was not due to the overall 
decrease in viral protein since the quantity o f E protein appeared similar for all 
glutamine mutant viruses and the parental NY99 strain. The NS 1130-132QQA and 
NS1130-132QQA/175A/207A mutant viruses did not show considerable differences in 
multiplication kinetics in Vero cells at later time points although differences were seen 
at all time points in P388 D1 cells and modest differenced in the Neuro2A cells . 
Overall these data suggests a deficiency in NS1 production and viral replication. The 
greatly reduced multiplication o f the NS 1130-132QQA/175A/207A mutant (Fig 5-4) is 
consistent with the reduced quantity o f E and NS1 proteins in the western blots (Fig 5- 
3) compared to the other mutants and NY99 infected Vero cells.
Interestingly, changing all three amino acids in the glycosylation motif o f both the 
NS 1175 and NS 1207 sites attenuated these viruses similar to changing each asparagine 
to an alanine only as undertaken in previous experiments in Chapter 3. The NS 1175. 
177QQA mutant showed a 20-fold attenuation compared to the parental NY99 strain.
This was not entirely surprising as the N S 1 n 5A mutant virus did show attenuation 
compared to the parental NY99 strain, although the level o f attenuation was much less 
than some o f the other mutants. The N S I2 0 7 A  mutant was not attenuated compared to 
the parental NY99 strain, while the N S  I207-209QQA mutant was only weakly (5-fold) 
attenuated and was not considered attenuated. The N S I 1 7 5  glycosylation site is only 
present in the JE serogroup, except for JE virus itself, and this study indicates that this 
site is also important for virulence whereas the N S I2 0 7  site alone does not appear to 
greatly affect the mouse virulence phenotype.
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Significantly, no revertants, or any other amino acid mutations in the E or NS 1 
proteins, were seen in any o f the mice that succumbed to infection. This was in 
contrast to the alanine triple mutant (NS I130A/175A/207A mutant) that reverted at the 
NS 1 n o  site and contained compensating mutations at E204 and E237, and the serine 
mutant where a glutamine to histadine mutation at NS140 was found in viral RNA 
isolated from the brains o f mice that succumbed to infection with the NS 1130s mutant 
virus.
In the absence of X-ray crystallographic or NMR structure o f the NS1 protein, it is 
unclear how these mutations affect the structure and/or conformation o f this protein. 
Although little details are available for the structure and function o f this protein, it can 
be surmised from these data that not only are the highly conserved glycosylation sites 
in the NS1 protein essential, but the specific amino acids, especially at the NS1130-132 
residues, are also very important, and may indicate a greater importance for this region 
such as a conformation needed for proper folding.
As hypothesized, the glutamine mutant viruses were overall more attenuated than 
either the alanine or serine mutant viruses and the mouse virulence phenotype o f the 
mutant viruses was reproducible. Here it was shown that mutations in the 
glycosylation motif using amino acids that closely resembled those that were to be 
replaced, in this case asparagine to glutamine, resulted in a virus that was replication 
competent in cell culture yet was completely attenuated for neuroinvasiveness, highly 
attenuated for neurovirulence, and did not revert or cause mutations in viruses isolated 
from the brains o f mice that succumbed to infection.
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Figure 5-1. Molecular structure o f asparagine and glutamine. Colors represent atoms 
in the amino acid; white-hydrogen, grey-carbon, blue-nitrogen, red-oxygen.
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Table 5-1. Temperature sensitivity of glutamine mutant viruses
37°C 39.5°C A (37°-39.5°l
LoamPFU/ml LoamPFU/ml LoamPFU
N S 1 - I3 0 Q 5.1 5.1 0
N S 1130-132QQA 6.9 6.7 0.2
N S1175-177Q Q A 6.2 5.8 0.4
N S1207-209Q Q A 7.1 7 0.1
NS1130Q/175A/207A 6 5.9 0.1
N S  1130-1 32QQA/175A/207A 6.8 5.9 0.9
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Figure 5-3. Western blot of Vero-infected culture supernatant o f all glutamine mutant 
viruses and the parental NY99 strain o f the E (A) and the NS1 (B) proteins.
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Figure 5-4 Multiplication kinetics o f glutamine mutant viruses compared to the 
parental NY99 strain in Vero (A), P388 DI (B) and Neuro2A (C) cells. Each time 
point represents the mean +/- SD of triplicate samples.
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Hours post-infection
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Table 5-2. Mouse virulence phenotype of glutamine mutant
viruses.
Virus ioLD^n AST + SD* D-valuet icLD™
(PFU) (PFU)
NY99 10 9.2 ± 1.1 N/A 30
NSIboq 5,000 >21 <0.05 50
NSI 130-132QQA 300 8.0 ± 0 >0.05 20
NS 1175-177QQA 200 9.2 ± 0 .8 >0.05 50
NS 11207-209QQA 50 8.0 ± 0 >0.05 30
NSI 130A/175A/207A 500 10.5 ± 1 .7 >0.05 nd
NSI 130Q/175A/207A >10,000 >21 <0.05 500
N SI 130-132QQA/175A/207A >500,000 >21 <0.05 800
* Average survival time +_ standard deviation at a dose of 1,000 PFU 
t  P-value determined by Student’s T-test 
nd= not determined
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Table 5-3. Repeated mouse virulence study of attenuated glutamine mutant viruses.
V irus ¡dLD50 AST + SD* D -v a l u e f icLD50
(PFU) ÎPFU1
NY99 10 8.0 ± 0 N/A 10
N S Iooq nd nd nd nd
N S I  130-132QQA 500 S.5±  0.6 >0.05 500
N S  1175-177QQA nd nd nd nd
N S 1207-209QQA nd nd nd nd
N S  1130A /175A/207A 1,000 10.5 ± 1 .9 <0.05 nd
N S I  130Q/175A/207A nd nd nd nd
N S I  130- 132QQA/175A/207A >1,000,000 >21 <0.05 800
* Average survival time +_ standard deviation at a dose of 1,000 PFU 
t  P-value determined by Student’s T-test 
nd= not determined
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CHAPTER 6 : CHARACTERIZATION OF MULTIGENIC 
GLYCOSYLATION MUTANTS: ADDITION OF THE E 
GLYCOSYLATION SITE MUTATION TO THE 
ATTENUATED NSI GLYCOSYALTION MUTANT VIRUSES
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6.1 Introduction
Previously, Chapters 3 ,4  and 5 discussed the ablation o f the glycosylation site(s) in 
the NS 1 protein and the affects o f these mutations in terms of multiplication kinetics 
in cell culture and in vivo, as well as the mouse virulence phenotype compared to the 
parental NY99 strain. These mutant viruses proved to be replication competent in 
cell culture and highly attenuated in mice. However, in order to achieve a viable live- 
attenuated vaccine candidate, attenuating mutations in more than one gene are 
necessary to ensure a reversion event at one site does not lead to a vaccine revertant. 
Therefore, a mutation in the envelope gene, at E i54s (N~>S), ablating the E protein 
glycosylation site o f WNV, was added to the attenuated triple NS1 glycosylation 
mutant viruses.
Our laboratory has previously shown that the E i54S mutation attenuates WNV mouse 
neuroinvasiveness compared to the parental NY99 strain (Beasley et al., 2005). Serine 
was chosen given that it is the naturally occurring mutation at this site for other WNV 
strains. In these studies, the E is4s mutant virus showed a 12-fold reduction in 
infectivity titre in monkey kidney Vero cells and was shown to be attenuated by 100- 
fold for neuroinvasiveness in mice compared to the parental NY99 strain.
A total o f  three new mutant viruses were generated including E154S/N S11 30a/ i 75 A/207A, 
Ei54s/NS 1 i30-i3isv/i75A/207A and E is4s/NS 1130-132QQA/175A/207A- Multiplication kinetics in 
cell culture and in vivo, as well as mouse virulence experiments, were undertaken to 
determine the difference in the phenotypes o f these viruses compared to the parental 
NY99 strain. The triple NS 1 glycosylation mutant viruses, NS 1130A/175A/207A and
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NS1 i 3o -i3 is v / i75A/20 7A, were also used as control viruses in some experiments. The 
E 154S mutant virus was not utilized as the triple NS1 mutant viruses displayed greater 
differences, overall, compared to the parental NY99 strain in multiplication kinetics 
and mouse virulence in previous studies (Beasley et al., 2005).
6.2 Results
6.2.1 In vitro characterization o f mutant viruses
The E/NS1 mutant viruses were sequenced around the mutation sites following 
transfection to ensure the engineered mutations remained. Viruses were passaged 
once and plaqued in Vero cells before subsequent experiments were performed. 
Interstingly, the E154S/NSI130A/175A/207A and E 154S/NSI130-131SV/175A/207 mutants 
displayed high infectivity titre, but the E i 54s/ N S 1 i 3o-i 32q q a / i 75a /207a  mutant virus 
showed reduced infectivity with an infectivity titre o f only 4 logio PFU/ml, even after 
passage. The E 15 4 s/N S1130A/175A/207A mutant virus displayed a minor reduction in 
plaque size (1.5 mm), whereas the E154s/NSli3o-i3isv/i75AA>07Aand Ei54s/N Sli30- 
132QQA/175A/207A mutant viruses showed a small plaque phenotype (<1 mm) compared to 
the parental NY99 strain (2 mm) (Fig. 6-1). A temperature sensitivity (ts) assay was 
performed with the E 154S/NS1130A/175A/207A, E 154S/NS1130-131SV/175A/207 and E154S/NS1130- 
132QQA/175A/207A mutant viruses. None o f these viruses were ts at 39.5°C (Table 6-1) 
and three plaques collected from each virus at 39.5°C did not reveal any mutations in 
the NS 1 gene other than the engineered mutations after viral RNA extraction, RT- 
PCR and sequencing. Given that putative compensating mutations previously seen in
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the E gene (E204 and E237, Chapter 3) correlated with a reversion at NS1130, the E gene 
was not sequenced.
6.2.2 Western blot analysis o f  mutant viruses
Western blotting was used to determine the relative amounts o f E and NS1 protein, 
and putative loss o f glycosylation, for the E i54s/NS1 130A/175A/207A, E i54S/NS1 b o - 
13 1SV/175A/207 and E i54S/NS1 i 30-i32q q a /175a /207a  mutant viruses. Confluent Vero cell 
monolayers were infected at a moi o f 0.1 with either the parental NY99 or mutant 
viruses, the supernatant collected 48 hours post-infection and concentrated before the 
western blot was performed. The whole cell lysates were also collected concurrently.
The whole cell lysates showed similar E and NS1 protein levels in the NY99 and 
Ei54S/NSl i3oa/i75A707amutant viruses while the Ei54s/NSli3o-i3isv/i75A/207Aand 
E154S/NS1 i3o-i 32QQA/175A/207A mutant viruses showed reduced levels of E and NS1 
proteins (Fig 6-2A). The faster migration o f the NS1 protein for the E/NS1 mutant 
viruses indicated a loss o f glycosylation (Fig. 6-2A). The loss o f glycosylation in the E 
protein was not as evident due to a lack o f sensitivity o f  the PAGE to detect a 
migration difference from the loss o f only one carbohydrate residue versus the loss of 
all three glycosylation sites in the NS1 protein. The E and NS1 proteins were reduced 
in the supernatant for the E 154/ N S1130-131SV/175 a/207a, Ei54s/NS1 i3o-i32Qqa/i75a/207a and to 
a lesser extent E154s/NS1 1 3oa/i75a/207a mutants compared to the NY99 virus (Fig. 6-2B).
6.2.3 Multiplication kinetics o f  mutant viruses
The multiplication kinetics in monkey kidney Vero and mouse macrophage P388 D1 
cells were determined for the E i54s/NS1i3oa/i75A/207a and E i54s/N S1 i3o-i3isv/175a/207
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mutant viruses and in mouse neuroblastoma Neuro 2  A cells for the NS 1 130- 
131SV/175A/207 mutant virus. The parental NY9 9  strain was used as a control to determine 
the differences in multiplication kinetics of the mutant viruses in each cell line. Since 
the triple serine mutant virus, NSI130-131SV/175A/207Ashowed significant differences 
compared to the parental NY9 9  strain in all three cell lines (Chapter 5, Fig 5-4), this 
virus was also used as a control to determine differences in the multiplication between 
it and the Ei54s/NS 1 130-13 isv/i75A/207- Due to the lack of differences of the 
NS1 130A/175A/207A in Vero cells and minimal differences in P3 8 8  D1 cells compared to 
the parental NY9 9  strain (Chapter 3 , Fig. 3 -2 ) this virus was not used as a control.
The E 154S/NSI130-132QQA/175A/207mutant virus was not included due to the low 
infectivity titre, approximately 4 logio PFU/ml o f this virus, even after passage in Vero 
cells. Cells were infected at a moi o f 0.1 with either mutant virus or the parental 
NY99 strain in triplicate, the supernatant collected at 12,24, 36,48 and 72 hours post­
infection for the E154S/NSI i3oa/i75a/207amutant virus and at 12, 24,48, 72 and 96 hours 
post-infection for the E 154S/NSI130-131SV/175A/207A mutant virus, and the infectivity titre 
was determined in Vero cells.
6.2.3.1 Vero cells
The parental NY99 strain displayed a peak titre at 48 hours post-infection while the 
E i5 4 s /N S  1130A/175A/207A mutant virus increased in infectivity titre until 72 hours post- 
infection(Fig 6-3A). The E 154S/NSI130A/175A/207A mutant virus showed up to a 10-fold 
reduction in infectivity titre compared to the parental NY99 strain at two different 
time points, 24 and 48 hours post infection, and notably showing a lag of 
multiplication at the 12 hour time point (Fig. 6-3 A).
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The Ei54s/NSli3o-i3isv/i75A/207A mutant virus displayed a peak in infectivity titre of 
approximately 8 logio PFU/ml at 72 hours post-infection compared to the parental 
NY99 strain, which had a peak titre at 48 hours post-infection (Fig 6-4A). Differences 
(up to 75-fold reduction) were seen between the E i54s/NS1i3o-i3isv/i75a/207a mutant 
virus and the parental NY99 strain at the 24 and 48 hour time points. No differences 
were seen between the NSI130-131SV/175A/207A and E154S/NSI130-131SV/175A/207A mutant 
viruses (Fig. 6-4A).
6.2.3.2 P388D1 cells
Multiplication kinetics o f the E i54s/NS l i3<w i75a/207a mutant virus and the parental 
NY99 virus in P388 D1 cells followed a similar trend, with a peak titre at 36 hours 
post-infection, however, the E is 4s/ N S 1  i 3oa/175a /207a mutant virus showed reduction in 
infectivity titre (up to 100-fold) from NY99 virus at each time point (Fig. 6-3B).
The Ei54s/NSli3o-i3isv/i75A/207A mutant, NS 1 i 3<m 31s v / i 75a /207a mutant and the parental 
NY99 viruses showed a similar trend in multiplication kinetics (Fig 6-4B). All three 
viruses displayed peak titre at 48 hours post-infection. Interestingly, the NS1130. 
131SV/175A/207A mutant virus showed the greatest reduction in infectivity titre, up to 
10,000- fold compared to the parental NY99 strain. The E i  54s/NS 1130-131 sv/i i s a j iq i a  
mutant virus showed up to 75-fold reduction in the infectivity titre compared to the 
parental NY99 strain at the 24-96 hour time points. (Fig. 6-4B).
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6.2.3.3 Neuro 2A cells
Since the NS 1130-131SV/175A/207A mutant virus showed a high level o f attenuation of 
neurovirulence (see Chapter 4, Table 4-3), the Ej 54s/NS1130-131 sv/i75A/207A virus was 
examined in mouse neuroblastoma Neuro 2A cells and compared to the triple serine 
NS I 130-131SV/175A/207A mutant virus and the parental NY99 strain. The NS 1130- 
i3isv/i75A/207mutant and the parental NY99 viruses showed a peak infectivity titre at 72 
hours post-infection while the E i54s/NS1 130-131SV/175A/207Amutant virus did not peak 
until 96 hours post-infection. Although the Ei 54S/NS1130-131 sv/i 75A/207A mutant vims did 
not show any difference in the infectivity titre at 12 hours post-infection from the 
parental NY99 strain, this mutant showed up to a 100-fold reduction in infectivity at 
all other time points examined (Fig. 6-4C). Similar to the multiplication kinetics in 
P388 D1 cells (Fig 6-4B), the E154s/NS1130-131SV/175A/207a mutant virus displayed a 
higher infectivity titre than the NS 1130-131SV/175A/207A mutant virus at all time points (Fig 
6-4C).
6.2.4 Virulence phenotype and multiplication o f mutant viruses in mice
All three E/NS1 mutant viruses ( E i 54s/ N S 1 i 3oa/175a/207a , E i 54s/ N S 1 i 3o-i 3is v / i 75a/207a  and 
E ,5 4 s/N S 1  i 30-132qqa / i 75a/207a )  were inoculated into 3-4 week female outbred NIH Swiss 
mice by the ip route (to determine neuroinvasiveness) and by the ic route (to 
determine neurovirulence) and compared to the NS1 triple mutant viruses 
(NS1 130A/175A/207A» NS1 i3i-i3isv/i75A/207A and NS1 i 30-i 32QQa / 175a /207a )  and the parental 
NY99 strain. The AST’s and LDso’s were calculated at 21 days post-inoculation 
(Table 6-2).
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Multiplication kinetics of the E i54s/NS1i3oa/i75a/207a mutant, NS1i30a/i75a/207a mutant 
and the parental NY99 viruses in mice were examined by serial bleeds two and three 
day post-inoculation by the ip route. The serum collected was analyzed by plaque 
titration in Vero cells to determine viraemia (Table 6-3).
6.2.4.1 Neuroinvasiveness and neurovirulence o f mutant viruses
The Ei54s/NSli30A/175A/207A, Ei54s/NSli30-131SV/175A7207 and E154S/NSI130-132QQA/175A/207A 
mutant viruses all showed complete attenuation for neuroinvasiveness at the highest 
possible dose o f virus with ipLDso values o f >100,000, >100,000 and >1,000 PFU, 
respectively, and were at least 100-fold attenuated for neuroinvasiveness compared to 
the parental NY99 strain, which had an ipLD5o value o f 10 PFU (Table 6-2). 
Repeated experiments with the E i54S/NS1i3oa/175a^ 07a mutant virus demonstrated the 
same result (data not shown). Due to the low infectivity titre of the E 154S/NSI130- 
132QQA/175A/207A mutant virus, the highest inoculum dose was not as high as the other 
two viruses; therefore the E 154S/NSI130-132QQA/175A/207A mutant virus showed the least 
apparent attenuation of the three E/NS1 mutant viruses. The NS1 triple mutants 
NS1 130A/175A/207A and NS1 i30-i3isv/i7SA/207A that had ipLDso values of 1,000 and 80,000 
PFU, respectfully, were further attenuated for neuroinvasiveness by the addition of the 
E154S mutation. It was not possible to determine if  the NSI130-132QQA/175A/207A mutant 
virus was further attenuated by the addition o f the E154s mutation as the NS1 mutant 
had an ipLDso value o f >1,000,000 PFU while the E i54s/NS1i3o-i32Qqa/17sa/207a mutant 
grew to low titer and was attenuated > 100-fold.
The addition o f the E154S mutation further attenuated the triple alanine mutant virus for
neurovirulence; the NS1 i30a/175a/207a and Ei54S/NS1 130A/175A/207A mutant viruses
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displaying icLD50 values o f 20 and 100 PFU, respectively while the 
Ei54s/NS 1 i3oa/175a/207a virus was attenuated 10-fold compared to the parental NY99 
strain (which had an icLDso value o f 10 PFU). The other two E/NS1 mutant viruses,
El54s/NSl 130-131SV/175A/207A and Ei54s/NSli30-l32QQA/175A/207A, which had icLDso values of
126 an d  <100 PFU, resp ectively , w e re  le s s  attenuated for neuroviru len ce than th e N S 1 
triple m u tan t v iru ses NSI130-131SV/175A/207A and.NSli3o-i32QQA/i75A/207A that had  icLD so  
v a lu es o f  500 and 800 PFU, re sp ectiv e ly  (Table 6-2).
6 . 2 . 4 . 2  Multiplication of E /^ N S l 130A / 175A / 207A  mutant virus in mice
Mice were bled on days two and three post inoculation to determine the viraemia 
(PFU/ml) in the serum (Table 6-3). The virus doses chosen for the NY9 9 , 
NSI Bon75A/207A and Ei54sNSli30Ai75A^ 07A viruses were selected to contain groups that 
survived as well as succumbed to infection, hence the difference in the inoculum titres 
chosen for these viruses. Groups o f five mice were inoculated with NY9 9  virus at 
doses o f  10 and 100 PFU of virus, NSI130A/175A/207A at doses o f 100 and 1,000 PFU, 
and Ei54s/NSli30A/i75A/207A virus at doses o f 1,000 and 10,000 PFU. All mice 
inoculated with the NY9 9  parental strain, with one exception, succumbed to infection 
and revealed a viraemia o f at least 2,000 PFU/ml and up to 300,000 PFU/ml on either 
day two or three post-inoculation. In comparison, three mice succumbed to infection 
inoculated with the attenuated N S 1 mutant virus ( N S 1i 3oa/175A/207a )  where all mice 
inoculated at a dose of 100 PFU showed no detectable viraemia on days 2 and 3 post­
infection while two o f five mice inoculated at a dose o f 1,000 PFU showed vireamia at 
three days post-infection comparable to the NY9 9  inoculated mice o f >1,000 PFU/ml;
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however, these mice contained a reversion at NS 1130 and two mutations in the E 
protein at E207 and E237 (described in Chapter 3). The addition o f the E 154S mutation 
reduced vireamia considerably as the E i54s/N S1 i3oa/i75a/207A infected mice exhibited 
little or no detectable viraemia on days 2 and 3 post-infection at a dose as high as 
10,000 PFU.
6.2.5 Induction o f protective immunity in mice inoculated with the 
Ej54s/NSl I30A/I75A/207A mutant virus
Due to the phenotypes o f high infectivity titre in cell culture, consistent lack of 
neuroinvasivess, and little to no detectable viraemia, the E 154S/NS11 30a/ i 75A/207A mutant 
virus was examined for induction o f neutralizing antibodies and a protective immune 
response against challenge with NY99 virus. Groups o f five mice were inoculated 
with serial 10-fold doses o f either the mutant or parental NY99 viruses and at 21 days 
post-inoculation, the surviving mice were challenged ip with a lethal dose (100 PFU) 
of parental NY99 virus. The 50% protective dose (P D 50) was calculated from the 
mice that survived this challenge. The parental NY99 mice did not survive lethal 
challenge; therefore, P D 50 was not calculable. The Ej 54s/NS 1130A/175A/207A mutant 
showed a PD50 of 50 PFU.
In a separate experiment, the neutralizing antibody titre was determined by assaying 
sera collected 21 days post ip inoculation. The whole blood was left at room 
temperature to coagulate, the blood centrifuged and the serum collected. The serum 
was then stored at -80°C until a plaque reduction neutralization test was performed. 
Neutralizing antibody titres were represented by the dilution o f the antibody able to 
reduce the NY99 infectivity titre by 50 percent (Table 6-4).
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Since no mice succumbed to ip inoculation with the E i 54S/N S 1 i30a/175a/207a  mutant 
virus, groups o f five mice at each dose (1 to 100,000 PFU) were tested for induction 
of neutralization antibodies by this virus. The parental NY99 virus, on the other hand, 
had only two surviving mice at a dose o f 1 PFU; one mouse had a low neutralization 
titre (80) while the other had a high titre (20,480). The five mice inoculated with 1 
PFU o f the E 154S/NSI130A/175A/207A mutant showed neutralization titres ranging from 20 
to 1280. This variation is presumably a reflection that the mice are outbred. All five 
E iW N S l 130A/175A/207Ainfected mice inoculated with a dose o f 1,000 PFU showed high 
levels o f  neutralizing antibodies (at least 320) while mice inoculated with the highest 
dose o f virus (100,000 pfu) had neutralization titres o f 1,280 to 10,240. Interestingly, 
although there was no detectable viraemia for the E i 54s/N S 1 130A/175A/207A infected mice 
at a dose o f 10,000 PFU (see section 6.2.4.2), high levels of neutralizing antibodies 
were detected (320-5,120) in all five mice similarly infected (Table 6-4).
6.3 Discussion
Previously it was shown that the ablation o f the glycosylation sites in the NS 1 protein 
attenuated neuroinvasiveness, up to > 100,000-fold, compared to the parental NY99 
strain (Chapters 3, 4 and 5). Although highly attenuated, some mice inoculated with 
NS I 130A/175A/207A virus at doses of 10 to 1,000 PFU succumbed to infection due to a 
reversion at the NS 1130 site. Although changing amino acids in the unstable NS 1130 
site to either a serine or glutamine further attenuated the virus by preventing reversion, 
an attenuating mutation in more than one gene is necessary for a live-attenuated 
vaccine candidate; hence the mouse attenuated E i54S mutation was chosen for study.
147
The addition of the E i54s mutation in the E i54s/NS1i3oa/i75a/207a and E i54s/N S1130_ 
i3isv/i75A/207A mutant viruses reduced the infectivity titre compared to the parental 
NY99 strain. However, these viruses remained replication competent in cell culture 
with a peak infectivity titre up to 8 logi0 PFU/ml. The E 154S/NS1 oo-i32q q a / i75a /207a  
mutant, on the other hand, showed a deficiency in multiplication with an infectivity 
titre o f  4 logio PFU/ml, even after one passage in Vero cells. Notably, the addition o f 
the E i54s mutation appeared to increase the infectivity titre o f the Ei54s/N Sli3o- 
i3isv/i75A/207A mutant virus when compared to the triple serine (N SI130-131SV/175A/207A) 
mutant virus indicating a stabilization o f the virus due to the addition of this mutation. 
Interestingly, the E i54S/NS1i3oa/i75a/207a did not display a small plaque phentotype 
similar to the E/NS1 (Ei54s/NSli3o-i3isv/i75A/207A and E i54s/NS1i3o-i32qqa/175a/207a) and 
NS1 (NS1 i30-i3isv/i75A/207A and NS1 i30-i32qqa/175a/207a) mutant viruses. Since both the 
E154S/NSI130A/175A/207A and NS1i3oa/i75a/207a mutant (see chapter 3) viruses resembled 
the parental NY99 plaque phenotype, the small plaque phenotype appeared to be due 
to mutations in the NS1 protein. Although all mutant viruses showed a reduction in 
viral infectivity titre, this reduction did not necessarily correlate with a reduction in E 
or NS1 protein detectable by western blotting. The E154S/N S1, 30a/ i 75 A/207A mutant 
virus had protein levels comparable to the parental NY99 strain while the other two 
mutant viruses showed a reduction in both the E and NS1 proteins as detected by 
western blotting from the whole cell lysates. These data suggest that the asparagine to 
alanine change in the NS1 protein may be less disruptive than the serine or glutamine 
at the NS 1 no site.
Mouse virulence experiments showed that the addition o f the E is4s mutation further 
attenuated the viruses for neuroinvasiveness for the E]54s/NS1 i3oa/17sa/207a and
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Ei54s/NSli3o-msv/i75A/207A, but not the E i5 4 s /N S  1 130-132QQA/175A/207A mutant virus. The 
E154S/NSI130-132QQA/175A/207A mutant virus showed reduced multiplication in cell culture 
and high titres o f this virus was not available for the mouse virulence studies. Given 
that the NSI130-132QQA/175A/207A mutant virus was the most attenuated N S 1 
glycosylation mutant virus, the addition o f the E 154S mutation may have caused the 
virus to become over-attenuated.
Interestingly, no mice succumbed to ip infection at any dose o f any o f the mutant 
viruses tested. This is in contrast to the NSI130A/175A/207A mutant virus where some 
mice did not survive infection due to a reversion at NS1 i30, plus mutations at E204 and 
E237 seen in the viral RNA isolated from the brains o f mice that succumbed following 
ip inoculation. The addition o f the E i54S mutation to the NS 1 130A/175A/207A mutant virus 
further attenuated the virus for neuroinvasiveness and no mice succumbed to infection 
suggesting no reversions or compensating mutations in the E gene were generated. 
Although no brains were sequenced, it is hypothesized that compensating mutation or 
reversion did not occur since no mice succumbed to infection. Therefore, it is 
hypothesized that the E and NS1 mutations interact synergistically, and by adding a 
mutation in the E gene, the mutations in the NS 1 gene were stabilized. Interstingly, 
however, although the addition o f the E 154S mutation further attenuated the mouse 
neuroinvasuveness o f the NS1 mutants, there was no further increase in the 
attenuation o f neurovirulence. There is no obvious explanation for this result other 
than to confirm that neuroinvasiveness and neurovirulence appear to be encoded by 
different molecular determinants in the WNV genome, and that it is very likely that 
both phenotypes are multigenic.
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Finally, the E 154S/NS1 bo a / i 75A/207A did not show detectable viraemia at two or three 
days post-infection in most mice inoculated ip with 10,000 PFU of the virus. 
Nonetheless, mice inoculated with this dose of virus were protected from subsequent 
lethal challenge and elicited a high neutralizing antibody response. These data, 
combined with the fact that no mice succumbed to infection suggests, such a mutant 
may have potential as a live-attenuated vaccine candidate.
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Table 6-1. Temperature sensitivity of the E/NS1 mutant viruses
37°C 39.5°C A (37°-39.5°)
Loq^PFU/ml LociinPFU/ml LoamPFU
E1 54s/N S 1130A/175A/207A 7.4 7.6 -0.2
E154S/NS1130-131SV/175A/207A 6.0 6.3 -0.3
E154S/NS1130-132QQA/175A/207A 4.6 4.0 0.6
152
Figure 6-2. Overlay of E and NS 1 western blots from virus-infected Vero lysates (A) 
or supernatant (B).
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Figure 6-3. Multiplication kinetics of the E i54s/NS1 i30a/i75a/207a mutant and parental 
NY99 viruses in Vero (A) and P388 DI (B) cells. Each time point represents the mean 
+/- SD o f triplicate samples.
A
—♦— NY99
- m -  E154S/NS1130A/175A/207A
- • — NY99
E1 5 4 S /N S 1 130A/175  
A/207A
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Figure 6-4. Multiplication kinetics o f the E i54S/NS1 i30-msv/i75A/207A mutant and 
parental NY99 viruses in Vero (A), P388 DI (B) and Neuro 2A (C) cells. Each time 
point represents the mean +/- SD of triplicate samples.
A
—♦— NY99
—-— MSI 1 30-
131 SW1 75A/207A  
—a— E 1 54S/NS1 1 30-
131 SV/1 75A/207A
N Y99
N S  1130-131S  V/175A/207A
E154 /N S113- 
131 OS V/17 5A/207A
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Table 6-2. Mouse neuroinvasiveness (ip) and neurovirulence (ic) of E/NS1 mutant 
viruses.
Virus
ipLDsn
(PFU)
AST + SD* D-value
icLDsn
(PFU)
NY99 10 8.25 ±0.5 N/A 10
N S  1130A/175A/207A 1,000 10.5 + 1.9 <0.05 20
NS1130-131SV/175A/207A 80,000 >21 <0.05 500
NS1130-132QQA/175A/207A >1,000,000 >21 <0.05 800
E 1 5 4S /N S1130A/175A/207A >100,000 >21 <0.05 100
E i 5 4 s /N S l 130-131SV/175A/207A >100,000 >21 <0.05 126
E 1 5 4S /N S1130-132QQA717 5 A/207A >1,000 >21 <0.05 <100
* Average survival time + standard deviation at a dose of 1,000 PFU
p-value determined by Student’s t-test
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Table 6- 3. Viraemia at two and three days post-ip infection with either parental 
NY99, NS 1130A/175A/207Aor Ei54s/NSl 130A/175A/207Amutant viruses
NY99 NS 1130A/175A/207A Ei54s/NSl 130A/175A/207A
(10 PFU ip) (100 PFU ip) (1,000 PFU ip)
2dpi 3dpi 2 dpi 3 dpi 2dpi 3 dpi
(PFU/ml) (PFU/ml) (PFU/ml) (PFU/ml) (PFU/ml) (PFU/ml)
Mouse
1 <50 15,000* <50 <50 <50 <50
2 <50 <50 <50 <50* J <50 <50
3 2,000 150,000* <50 <50 <50 <50
4 4,000 50,000* <50 <50 <50 <50
5 2,500 300,000* <50 <50 <50 <50
NY99 NS 1130A/175A/207A E,54S/NS1130A/175A/207A
(100 PFU ip) (1,000 PFU ip) (10,000 PFU ip)
2dpi 3dEi 2 dpi 3 dpi 2dpi 3 dpi
(PFU/ml) (PFU/ml) (PFU/ml) (PFU/ml) (PFU/ml) (PFU/ml)
Mouse
1 5,000 2,000* 50 <50 <50 100
2 6,500 3,000* 100 100 <50 <50
3 10,000 5,000* <50 <50 <50 <50
4 4,000 10,000* 50 4,500*$ <50 50
5 <50 12,500* 400 1,500*$ <50 <50
* mice that succumbed to infection
J Reversion at NS1130 seen in viral RNA isolated from the brains
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CHAPTER 7 : LOSS OF THE PRM GLYCOSYLATION SITE 
AND A VACCINE CANDIDATE INCLUDING MUTATIONS 
IN THE PRM, E, NS1 AND NS4B PROTEINS
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7.1 Introduction
West Nile virus contains one putative N-linked glycosylation site in the prM protein at 
asparagine prMi5. Other flaviviruses, including JE, SLE, YF, DEN-2, USU and TBE, 
contain at least one putative glycosylation site in the prM protein (Fig. 7-1). Chapters 
3 to 6 described how the ablation o f the E and NS 1 protein glycosylation sites 
significantly attenuated WNV. Consequently, it was hypothesized that the loss o f the 
prM glycosylation site would also attenuate WNV.
Although the role o f this glycosylation site has not been elucidated, previous studies 
have investigated changes in the levels o f E protein due to the loss o f prM 
glycosylation. These studies, however, involved the use o f either virus-like particles 
(VLP) or subviral particles (SVP), rather than infectious virus (Goto et al., 2005; 
Hanna et al., 2005). The loss of the prM glycosylation site o f a TBE VLP resulted in 
an increase o f intracellular E protein but a decrease in E protein secretion (Goto et al, 
2005), whereas the loss o f the prM glycosylation site for a WNV SVP resulted in a 
decrease o f E protein secretion (Hanna et al, 2005). A mutation in the glycosylation 
site o f  the prM protein as it relates to the phenotype o f WNV or any other flavivirus 
has not been previously characterized. Therefore, this chapter describes the affects of 
this mutation in terms o f multiplication kinetics and mouse virulence phenotypes. The 
glycosylation site was ablated by changing the asparagine o f the glycosylation motif 
to a serine (prMis N—>S). Serine was chosen since it is the naturally occurring 
mutation for the E glycosylation site for WNV strains.
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In terms o f vaccine development, to further reduce the potential o f reversion to a 
virulent phenotype, attenuating mutations in more than two genes may prove more 
advantageous. Therefore, multiple mutations in up to four genes, including the prM, 
E, NS1 and NS4B, were examined for mouse virulence. Along with the prM 15s 
mutation, attenuating mutations in the E/NS1 mutant virus ( E i 54S/N S 1  i 3oa/ 175a /207a )  
that were described in chapter 6 were also included since this virus was replication 
competent in cell culture, displayed low or no detectable viremia in mice, and elicited 
a high neutralizing antibody response. The NS4B mutation encompasses a mutation 
in the central domain o f the NS4B protein at NS4B io2 changing a conserved cysteine 
to a serine ( N S 4 B io2s)  and has been previously shown to attenuate WNV mouse 
neurovirulence compared to the parental NY99 strain (Wicker et al., 2006). This 
NS4B mutation along with the mutations in the prM, E and NS1 were combined to 
determine mouse virulence phenotype o f the mutant virus containing the mutations in 
all four proteins (prMi5s/Ei54s/NSli30A/i75A^07A/NS4Bi02s).
A total o f  three prM mutant viruses were examined for mouse virulence, including 
prM ^s to determine the affects o f this mutation alone, prMiss/Ei54s to determine the 
virulence affects o f mutations in the two structural protein glycosylation sites, and 
prM i ss/Ei 54S/NS1130A/1 75a/207a/NS4B 102s to determine the attenuation level o f a virus 
containing mutations in four proteins. The prMjss mutant was also examined for 
multiplication kinetics in cell culture to determine the affects o f this mutation alone in 
terms o f infectivity titre compared to the parental NY99 strain.
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7.2 Results
7.2.1 Generation o f the prM] 5S mutant virus
As with mutant viruses described in chapters 3 to 6, the prMi5S mutant virus was 
generated by site-directed mutagenesis and transfected into Vero cells. The resulting 
virus was harvested and passaged once before subsequent experiments were 
performed. The viral RNA was extracted, RT-PCR was performed and the prM 
region sequenced for verification o f the mutation. Due to the lack o f availability o f an 
anti-prM antibody at the time of these studies, the loss o f glycosylation could not be 
monitored by western blotting.
7.2.2 Multiplication o f the prM] 5s mutant in cell culture
Only the prMiss mutant virus was examined in cell culture to determine the 
multiplication kinetics compared to die parental NY99 strain, since mutations in the 
prM glycosylation site had not been previously characterized. Both viruses were used 
to infect either monkey kidney Vero cells or mouse macrophage P388 D1 cells at a 
moi o f  0.1 in triplicate and supernatant was harvested at 12,24,48, 72 and 96 hours 
post-infection. Infectivity titres were determined by plaque titration in Vero cells.
7.2.2.1 Vero cells
Both the prM ^s mutant virus and the parental NY99 strain displayed similar 
multiplication kinetics in Vero cells with a peak infectivity titre at 48 hours post­
infection and subsequent decrease. Although the prM ^s mutant virus and the 
parental NY99 strain showed similar infectivity titres at the 48, 72 and 96 hour time
points, at the earlier 12 and 24 hour time points, the prMi5S mutant virus displayed a
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higher infectivity titre, up to 10-fold, compared to the parental NY99 strain (Fig. 7- 
2A).
7.2.2.2 P388D1 cells
Since the NS 1 glycosylation mutant viruses (see chapters 3 to 5) showed the greatest 
differences in multiplication kinetics in mouse macrophage P388 D1 cells, this cell 
line was used to determine differences between the multiplication kinetics o f the 
prMiss mutant virus and the parental NY99 strain. Indeed, greater differences were 
seen in this cell line than the Vero cells between the mutant and parental viruses. The 
parental NY99 virus showed a peak infectivity titre at 72 hours post-infection while 
the prMiss virus did not peak in infectivity titre until 96 hours post-infection. 
However, the prMi5S mutant virus showed up to 100-fold greater infectivity titre at all 
time points compared to the parental strain (Fig. 7-2B).
7.2.3 Mouse virulence phenotype o f the prM\ ss mutant viruses
Female 3-4 week old outbred NIH Swiss mice were inoculated with the mutant 
viruses either by the ip route to determine neuroinvasiveness or by the ic route to 
determine neurovirulence. The parental NY99 strain was used as a control for both 
the ip and ic route.
7.2.3.1 Mouse virulence phenotype o f the prM} 5s and prMi 3S/E i54S mutant virus
Since previous chapters showed that NS1 glycosylation mutant viruses were more
attenuated for neuroinvasiveness than neurovirulence (see chapters 3 to 6) only the
neuroinvasive phenotype was initially examined for the prMi5$ and prMi5s/Ei54s
mutant viruses. The prMiss mutant virus displayed an ipLDso value o f 5 PFU, which
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was similar to the parental NY99 strain with an ipLD5o value o f 10 PFU. The addition 
o f the E 154S mutation (prMi5s/Ei54s), thereby ablating both the structural protein 
glycosylation sites, resulted in a mutant with an ipLD50 value o f >1,000 PFU, and was 
attenuated at least 100-fold compared to the parental NY99 strain (Table 7-1).
7.2.3.2 The addition o f the attenuating E, NS1 and NS4B mutations
The privies and prMi5S/E i54S/NSI i3oa/i75a/207a/NS4B102s mutant viruses were 
examined for mouse virulence and compared to several control viruses including 
NS4Bi02s, NS 1130A/175A/207A and NS1130A/175A/207A/NS4B102S mutant viruses. For the 
neuroinvasive phenotype, the NS 1130A/175A/207A mutant virus has an ipLD50 value of 
800 PFU whereas the parental NY99 strain was 5 PFU, while the 
NS 1 i30a/i75a/207a/NS4B io2s showed complete attenuation for neuroinvasiveness with 
an ipLDso value o f >10,000 PFU. Since the N S4B102s mutant was highly attenuated for 
neurovirulence (by the ic route) (Wicker et al, 2006), this virus along with the 
NS 1 i30a/175a/207a/NS4Bio2s and prMi5$/Ei54s/NS 1130A/1 75a/207a/NS4B102s mutants were 
examined for neurovirulence (Table 7-2). The mouse neuro virulence phenotype o f 
the NS1 i30a/175a/207a/NS4Bio2s mutant virus was highly attenuated with an icLD5o of 
2,000 PFU while the NS4B io2s virus was also attenuated and had an icLD50 o f 800 
PFU. In comparison, the parental NY99 virus was neurovirulent with an icLD50 of 10 
PFU. A quadruple gene mutant virus containing the prM, E, NS1 and NS4B 
mutations (prMi5s/Ei54s/NSli30A/i75A/207A/NS4Bi02s) was examined for mouse 
neuro virulence and the icLDso value for this virus was 30 PFU.
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7.3 Discussion
The affects o f  the loss o f prM glycosylation by changing the asparagine o f the 
glycosylation motif to a glutamine have previously been described for West Nile and 
TBE viruses, however, these studies were limited and utilized either subviral particles 
or virus-like particles (Goto et al., 2005; Hanna et al., 2005). Both studies showed a 
decrease in either the secretion o f E protein or the subviral particle, but one study 
found an increase in the amount o f intracellular E protein. Mutations in the prM 
glycosylation site have not been previously described for infectious virus.
Unfortunately, there were no WNV anti-prM antibodies available at the time o f these 
studies and therefore, the loss o f glycosylation could not be monitored by western 
blotting. However, western blots in chapter 3 to 6 showed that the loss o f E and NS1 
glycosylation was achieved by mutating the asparagine in the glycosylation motif to 
either an alanine, glutamine or serine. There was, however, indirect evidence of an 
amino acid change by altered phenotype o f the prMiss mutant in terms o f increased 
multiplication kinetics in cell culture, as determined by infectivity titre, compared to 
the parental NY99 strain (Figure 7-2). This was unexpected since previous studies 
showed that the loss o f the glycosylation site(s) for the E and the NS 1 proteins 
decreased the multiplication kinetics compared to parental NY99 virus (see chapters 3 
to 6). Clearly, further studies are warranted to investigate this result.
A potential explanation for this result may involve an increase in the ability of the 
virus to attach and infect cells. The glycosylation residues for both the structural 
proteins (prM and E) o f WNV have been shown to affect cellular tropism by 
increasing the susceptibility o f cells to infection through the binding o f the C-type
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lectin attachment factor dendritic cell specific intercellular adhesion molecule 3- 
grabbing nonintegrin (DC-SIGN or DC-SIGNR) (Davis et al., 2006). All SIGN 
members contain carbohydrate recognition domains (CRDs) that have been shown to 
bind glycosylation residues present on the surface o f pathogens (Koppel et al., 2005). 
Specifically, DC-SIGN has been shown to be a HTV-1 receptor able to capture and 
disseminate HIV-1 to enhance infection through the binding of the envelope 
glycoprotein gpl20 (Getjtenbeek et al., 2002). In fact, DC-SIGN and DC-SIGNR 
have been shown to increase infectivity in vitro for several viruses including Ebola, 
Marburg, dengue, hepatitis C, Sindbis, SARS-CoV and human cytomegalovirus 
(Alvarez et al., 2002; Halary et al., 2002; Jeffers et al., 2004; Klimstra et al., 
2003,;Lozach et al., 2004; Navarro-Sanchez et al., 2003; Tassaneetrithep et al., 2003). 
One study comparing the cellular attachment and infection rates o f WNV found the N- 
linked glycan on the prM alone could enhance WNV infection through DC-SIGNR 
attachment (Davis et al., 2006). Since the ability o f the E glycosylation site alone to 
increase infection through the attachment to DC-SIGNR or DC-SIGN was not 
undertaken, it is unclear how the absence o f the prM glycosylation residue would 
affect the binding o f these attachment factors. Although prM is cleaved before release 
of the mature virus, it has been shown that significant levels of prM are associated 
with the infectious virus (Guirakhoo et al., 1991; Keelapang et al., 2004; Wengler and 
Wengler, 1989). One hypothesis for the increase in infectivity titre seen by the prMiss 
mutant is that the ablation o f the prM glycosylation site allowed for the increased 
efficiency of the E glycan binding resulting in the higher infectivity titre seen in the 
P388 D1 and to a lesser extent Vero cells.
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Previous studies have investigated mutations in the prM at prM63 for TBE virus, the 
prM/E cleavage site for TBE virus and the C-prM signal sequence for YF virus and 
the affects o f these mutations in cell culture and for mouse neurovirulence (Yoshii et 
al., 2004; Elshuber et al., 2003; Lee et al., 2000). Overall, these studies found a 
reduction in infectious particles, lack o f infectious particles or attenuation for mouse 
neuro virulence. To date, published data regarding the function o f the prM protein 
utilizing prM mutants showed that the prM is necessary for entry, assembly and 
maturation o f the virus and mutations in various portions o f the prM protein 
negatively affect these functions. The mutation in the prM glycosylation site 
(prMiss) could affect one or more o f these functions, including increasing exposure of 
the fusion peptide. It is known that the prM masks the E protein fusion peptide 
(Zhang et al., 2003) and therefore, it is important to consider differences for the 
various prM functions for future studies. In fact, one study found that a mutation in 
the M protein increased infectivity titre in cell culture, but not neurovirulence in mice 
(Maier et al., 2007). This mutant virus was not inactivated at pH levels higher than 
those that would inactivate the parental virus suggesting enhanced replication was the 
result o f increased fusion and uncoating. Since the prM protein may also involve in 
this process, fusion assays may provide useful information in understanding the 
affects o f  mutations in the prM.
The ablation o f the prM glycosylation site alone did not attenuate mouse virulence and 
the L D 5o was similar to the parental NY99 strain. The addition o f the E i54s mutation 
(prMi5s/Ei54s) resulted in a virus that was attenuated >100-fold for mouse 
neuroinvasiveness compared to the parental NY99 strain. These results suggest that, 
contrary to the results in cell culture (Fig. 7-2), the prMi5S mutation may not
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significantly increase infectivity in vivo. Interestingly, the mutant containing the 
prM i5s mutation along with other established attenuating mutations in the E, NS1 and 
NS4B proteins (prMi5s/Ei54s/NSli30A/i75A/207A/NS4Bio2s) was not attenuated for 
mouse virulence suggesting that these mutations do not act synergistically. Since the 
NS1/NS4B (NS1i3oa/175A/207a/NS4Bio2s) mutant virus was highly attenuated for 
neurovirulence (Table 7- 2), it was surprising that the addition o f the prMi5s/Ei54S 
mutations resulted in the prMi5s/Ei54s/NSl i3oa/i75a/207a/NS4Bio2S mutant that was not 
highly attenuated. Since these mice were inoculated by the ic route, brains were not 
collected for sequence analysis. Further analyses o f these viruses, including ip 
inoculations and sequencing of viral RNA in the brains o f mice that succumbed to 
infection, may prove that a combination of these mutations result in instability o f the 
virus. Also, the loss of glycosylation o f all three (prM, E and NS1) proteins may have 
contributed to the loss o f  attenuation when all four prM, E, NS1 and NS4B mutations 
were combined, suggesting that one or more glycosylation sites were necessary for 
overall stability. Previously, in chapter 3, it was shown that mutations in the E 
protein were found in the triple NSI glycosylation mutant virus collected from mouse 
brains, but not in cell culture. This suggests selective pressure of these mutations in 
mice and a possible interaction between the E and NS1 proteins. It is, therefore, 
feasible that a functioning glycosylation site on at least one protein is necessary and 
the loss o f  all three protein glycosylation residues is not well tolerated in mice.
Further experiments examining the affects o f these mutations in greater detail may 
answer the question of how these prM mutants affect entry in to cells, assembly and 
release o f  virus from cells.
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Overall, these data showed that the prMiss mutation increased the efficiency of 
multiplication in cell culture and did not attenuate the mouse virulence phenotype o f 
WNV. In lieu o f these results, it was determined that the prMiss mutation would not 
be advantageous to include as an attenuating mutation for a WNV vaccine candidate.
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Figure 7-2. Multiplication kinetics in Vero (A) and P388 DI (B) for the prMi5S mutant 
virus and the parental NY99 strain. Each time point represents the mean +/- SD of 
triplicate samples.
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Table 7-1. Mouse virulence of the prMiss mutant viruses
Virus iDl_D,n ÎPFU1 AST + SD* P-valuet
NY99 10 9.2 +1.1 N/A
prM-iss 5 8.0 ±0.8 >0.05
prM/E154s >1,000 >21 <0.05
* AST= average survival time + standard deviation of mice inoculated with 1,000 PFU of virus 
t  p-value determined by Student’s t-test 
N/A= not applicable
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Table 7-2. Mouse virulence o f the viruses containing mutations in prM, E, NS1, 
and/or NS4B.
¡d LD50
(P FU )
NY99 5
N S 4 B io2s nd
N S 1 130A/175A/207A 800
NS1130A/175A/207A+N S4B i02S 10,000
prMi5s/Ei54s/NS1 130A/175A/207a / 
N S 4 B io2S nd
icLD50
A S T  + SD* D -v a lu e t ÎPFU)
7 .5+  0.6 N/A 10
N/A N/A 800
9.0 +1.0 <0.05 nd
>21 <0.05 2,000
N/A N/A 30
nd= not determined
* AST= average survival time + standard deviation of mice inoculated with 1,000 PFU of virus 
t  p-value determined by Student's t-test 
N/A= not applicable
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CHAPTER 8 : IN VITRO CELLULAR LOCALIZATION OF THE 
E AND NS1 PROTEINS AND ULTRASTRUCTURAL 
ANALYSIS OF THE PARENTAL NY99 AND ATTENUATED 
GLYCOSYLATION MUTANT VIRUS-INFECTED VERO
CELLS
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8.1 Introduction
Previous chapters discussed mutations within the glycosylation motifs o f the NS 1 
protein that proved to be highly attenuated for mouse neuroinvasiveness and 
neurovirulence while maintaining replication competence in cell culture (see chapters 
3 to 6). Many o f these mutant viruses also showed attenuation markers in cell culture, 
such as reduced infectivity titer compared to the parental strain as well as small plaque 
phenotype. Also, a decrease in the level o f secreted NS1 was shown by western 
blotting independent o f E protein levels indicating the reduction in NS1 was not the 
result o f  reduced viral multiplication.
In an effort to better understand the affects o f these mutations in cell culture, confocal
microscopy and electron microscopy (EM) were used to visualize the localization of
the E and NS1 proteins in the mutant virus-infected cells compared to the parental
NY99 virus-infected cells. Colocalization o f the E and NS1 proteins has been shown
for MVE, KUN, JE, WN and KOK virus-infected cells by indirect
immunofluorescence (Blitvich et al., 1995; Mackenzie et al., 1996; Westaway et al.,
1997). The colocalization o f the E and NS 1 proteins has not been previously studied
by EM o f virus-infected cells for any flavivirus and therefore, the colocalization of the
E and NS1 proteins in WNV-infected Vero cells were visualized by transmission
immuno-EM (TIEM). Furthermore, transmission EM (TEM) was also utilized for the
ultrastructural analysis o f the parental NY99 and attenuated NS1 i30-i32QQA/i75A/207A
mutant virus-infected Vero cells. The NS 1130-132QQA/175A/207A mutant virus was used
since it showed the greatest attenuation for mouse neuroinvasiveness and
neurovirulence o f all the NS 1 mutant viruses as well as having a small plaque
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phenotype, and decreased infectivity titre and decreased levels o f secreted NS1 protein 
in cell culture (see chapter 5). It was hypothesized that mutations in the NS 1 
glycosylation sites would alter the intracellular localization o f either NS 1 or E, or both 
proteins. In addition, it was hypothesized that comparison o f the ultrastructure by 
TEM o f parental and mutant virus-infected cells would provide further insight to the 
affects o f  the NS 1 glycosylation mutations in cell culture.
8.2 Results
8.2.1 Confocal microscopy
Coverslips containing a  confluent monolayer o f Vero cells were infected at an moi o f 
0.1 with either NS 1130-132QQA/175A/207A mutant or parental NY99 strain. At forty-eight 
hours post-infection the cells were fixed in a 50:50 acetonermethanol mixture, then air 
dried before subsequent staining. Published studies indicated that the NS 1 protein 
colocalized with the E protein in virus-infected for several flaviruses (Blitvich et al., 
1995; Mackenzie etal., 1996). Therefore, in an effort to better understand the 
mechanism o f attenuation for the highly mouse attenuated NS1 glycosylation mutants; 
both the E and NS1 proteins were utilized to visualize the staining pattern o f these two 
proteins for several mutant viruses. The coverslips were double-stained using mouse 
anti-NSl (17NS1) monoclonal antibody and rabbit polyclonal anti-E protein domain 
III antiserum. Secondary anti-mouse Fluorescein (FITC) and anti-rabbit Texas Red 
labeled antibodies were utilized to visualize the staining pattern o f each o f the two 
proteins and the merged view to determine colocalization by confocal microscopy. 
Mock-infected cells were stained and appeared similar to the virus-infected cells with
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very little background or nonspecific staining with either anti-E or -NS1 antibodies 
(Fig. 8- 1).
8.2.1.1 Localization o f the E and NS1 proteins for mutant and parental NY99 
viruses
Similar to previous studies, the E and NS1 proteins colocalized in NY99 virus- 
infected Vero cells. Although these previous studies found colocalization o f the E and 
NS1 proteins in cell culture, discrepancies in the localization o f these two proteins in 
limited areas o f the cell were noted (Blitvich et al., 1995; Mackenzie et al., 1996; 
Westaway and Goodman, 1987). Some examples o f apparent lack o f colocalization 
were also seen in this study, however, it is important to note that two different 
antibodies were utilized and the dilutions o f these antibodies differed somewhat. 
Therefore, these areas can only be concluded as having differing amounts o f E and 
NS1 protein. Overall, increased intensity o f the E protein fluorescence did correlate to 
increased intensity o f the NS1 fluorescence. Both proteins illustrated diffuse 
cytoplasmic staining with areas o f intense fluorescence in a circularized, vesicle-like, 
staining pattern (Fig.8-1).
The E j54s mutant was used as it was previously determined to have decreased 
infectivity titre compared to the parental NY99 strain (Beasley et al., 2005) and, 
therefore, was used to visualize differences in the E and NS1 proteins staining pattern 
for a mutant virus without changes in the NS 1 protein. Interestingly, the antibody 
staining pattern was very similar to the parental NY99 strain, having no obvious 
differences and showed diffuse cytoplasmic staining o f both E and NS 1 proteins as
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well as vesicle-like staining. Again, the E and NS1 proteins displayed overall 
colocalization (Fig. 8-1).
The NS 1 no.]32qqa/175a/207a mutant virus showed major differences in the staining 
pattern o f both the E and NS1 proteins compared to the parental NY99 stain. The 
parental NY99 strain had diffuse cytoplasmic staining, while the NSI130- 
132QQA/175A/207A mutant showed less intense vesicle-like NS1 protein staining in the 
absence o f diffuse staining. Although areas o f intense E protein staining correlated to 
intense NS1 protein staining in many areas, there were also significant numbers o f 
areas o f NS1 protein fluorescence without apparent E protein fluorescence (Fig. 8 -1).
The attenuated E 154s/NS1130A/175A/207A mutant showed a pattern o f E protein 
fluorescence with diffuse cytoplasmic staining, which was more similar to the parental 
NY99 strain and E154S mutant virus than the N S li3o-i32QQA/i75A«07Amutant virus. The 
most notable difference was the reduced fluorescence o f the NS1 protein compared to 
the parental NY99 strain, even though cells had been infected at the same moi with 
both viruses (Fig. 8-1).
Since flaviviruses have been previously shown to associate with the endoplasmic 
reticulum (ER), virus-infected Vero cells were probed with a mouse anti-ER 
polyclonal antibody and visualized with a FITC conjugated antibody. Since this anti- 
ER antibody was only available as a mouse antibody, dual staining with the mouse 
derived NS1 antibody was not possible. The confocal microscopy images for the 
mock-infected cells showed a diffuse staining pattern indicating ER was located 
throughout the cell. The NY99 virus-infected cells showed many areas o f circularized 
vesicle-like staining pattern as did the mutant NS 1i 30-i 32qqa/175a/207A virus-infected
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cells, albeit to a lesser extent, suggesting that WNV infection induced large ER vesicle 
formations (Fig. 8-2).
8.2.2 Electron microscopy
Since the confocal studies with the NS 1130-132QQA/175A/207A mutant virus-infected cells 
showed the greatest reduction in intracellular E and NS1 proteins, this mutant virus 
was used to study the ultrastructural differences o f mutant virus-infected cells 
compared to the parental NY99 strain virus-infected cells using electron microscopy. 
Vero cells were infected at a moi o f 0.1 with one o f the two viruses and cells were 
fixed at 48 hours post-infection before subsequent staining for EM studies. Both the 
attenuated and parental strains were prepared for both TEM and TIEM staining (see 
Materials and Methods 2.10). Immuno-staining utilized the same primary antibodies 
used in the confocal study, namely a rabbit anti-E protein domain III and a mouse 
anti-NSl (17NS1) monoclonal antibody with secondary gold-labeled antibodies. 
Mock-infected Vero cells were prepared in parallel as a control to determine the 
ultrastructure o f uninfected cells and as a  background control for the TIEM 
experiment.
8.2.2.1 Transmission EM
Transmission EM involved the procedures of fixing, staining and embedding virus- 
infected and mock-infected cells before thin sections o f the embedded cells were 
observed under high voltage and high magnification. This technique allowed for the 
visualization o f individual compartments within the cell in detail as well as virus 
particles by contrast staining lipids within the cell.
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Compared to the mock-infected Vero cells, the NY99 virus-infected cells showed 
differences in the ultrastructure within the cell characteristic o f previously described 
flavivirus infection-induced changes including swollen endoplasmic reticulum (ER), 
vesicle packets (VP), smooth membrane structures (SMS), pararystalline arrays (PC) 
and convoluted membranes (CM) (Leary and Blair 1980; Hase etal., 1987; Chu and 
Westaway 1992; Westaway et al., 1997) (Fig 8-3). The parental NY99 virus-infected 
cells showed that the CMs were commonly found in close proximity to the nucleus 
and SMS were heavily associated around these CM structures. The small spherical 
shaped SMS were approximately 45-80 nm in diameter and although virus was not 
found within these SMS, vesicle packets (VP) containing SMS did contain virus.
Paracrystalline arrays (PC) are hexagon shaped CM-like structures, sometimes 
indistinguishable from CM and it has been suggested that the PC dissociates into CM 
late in KUN virus infection o f Vero cells (Ng and Hong, 1989). The SMS were found 
with or without the presence o f CM or PC, and differed in location in the presence or 
absence o f the CM. The CM and PC appeared to change quite drastically in size as 
well as the amount o f SMS associated with these structures depending on the cell.
The virus induced ultrastructural changes differed from cell to cell, from cells that 
contained no CM or PC and generalized SMS throughout the cell, to cells with well 
defined CM with localized SMS near the CM. Also, some cells displayed small CM 
with associated PC, while others displayed multiple CM foci (Fig. 8-4).
The N S1130-132QQA/175A/207A mutant virus-infected cell ultrastructure was somewhat 
different than that of the parental NY99 virus-infected cells. First, many cells did not 
contain CM structures whereas these structures were found in almost every NY99 
virus-infected cell. Interestingly, the SMS were frequently more abundant than the
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CM structures and in fact, SMS were commonly found without the presence o f CM 
yet virus particles in these cells were also common (Fig. 8-5). Another major 
difference from the NY99 virus-infected cells was the size and shape o f the SMS, 
which varied from small round to larger tubular shape o f about 20-150 nm in diameter 
(Fig. 8-6).
8.2.2.2 Immuno-EM
Transmission EM and TIEM differ in that TIEM involved probing with antibodies 
after the cells were embedded and thin sections were prepared. Gold particles were 
used at either 10 nm or 5 nm for the anti-mouse NS1 antibody and 15 or 5nm for the 
anti-rabbit E antibody. Different sized gold particles were used because the larger 
gold particles were easier to identify than the 5 nm particles within heavier stained 
areas o f  the cell. This technique is very different from confocal microscopy, including 
the use o f thin sections of the cell, the ability to use higher magnification and the 
ability to visualize individual compartments in detail through contrast staining lipids 
with in the cell. Mock-infected cells were prepared in parallel to the virus-infected 
cells and showed minimal background staining with the anti-E and -NS1 antibodies 
(Fig. 8-7).
In cells infected with NY99 virus, the localization o f the E protein by staining with 
anti-E 15 nm gold particles was determined to be throughout the cell, within vesicles, 
associated with virus and within the CM. The mutant NS 1130-132QQA/175A/207A virus- 
infected cells showed a similar staining pattern (Fig. 8-8). An example o f a tubular 
proliferated membrane (TPM) was also observed in the NS 1130-132QQA/175A/207A mutant- 
infected cells. This structure has been previously characterized as an ER proliferated
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membrane structure and was identified in WNV-infected mosquito cells at early time 
points (Girard et al, 2005) (Fig. 8-8). Colocalization using the 5 nm anti- mouse gold 
particle (NS1 protein) was difficult to identify in these cells due to the difference in 
particle size.
In cells stained with anti-NSl 10 nm gold particles, the localization o f the NS1 and E 
protein were more easily identified. The NY99 virus-infected cells showed NS1 
protein within vesicles and throughout the cell. The NS1 protein was also found 
associated with virus particles and often colocalized with the E protein. Not 
surprisingly, much less NS1 was found in the NS1130-132QQA/175A/207A mutant infected 
cells. Nonetheless, the E and NS1 proteins appeared to colocalize within vesicles and 
in cells (Fig. 8-9). Interestingly, the NS1 protein often localized around the CM but 
not within the CM.
8.3 Discussion
Previous chapters focused on the affects o f mutations in the NS 1 glycosylation site(s) 
in cell culture and in mice. Many mutant viruses proved to be highly attenuated for 
neuroinvasiveness and neurovirulence, showed decreased infectivity titre and sp 
phenotype, although the mechanism of these affects was not clear (see chapters 3-6).
Although several o f these viruses showed reduced levels o f secreted NS1 compared to 
the parental NY99 strain, the decreased levels o f NS1 protein were not consistently 
related with a reduction in virus infectivity as determined by plaque assay. This was 
evident by western blotting where the E protein levels o f tile NS1 mutants were 
comparable to the NY99 virus-infected cells although levels o f NS1 protein were 
decreased compared to the parental NY99 strain (see chapters 4 to 6). Confocal
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images confirmed this result. The E i54S/NS 1130A/175A/207A mutant virus-infected cells 
showed intense diffuse cytoplasmic staining o f the E protein but reduced, focal 
staining o f the NS 1 protein, while the E154S virus-infected cells showed cytoplasmic 
staining o f E and NS1 proteins similar to the parental NY99 strain, although both of 
these viruses previously showed a  reduction in infectivity titre compared to the 
parental NY99 strain. These results suggest that a reduction in the NS 1 protein was 
independent o f the reduction in multiplication. It was previously shown (Mackenzie 
et al., 1996; Westaway and Goodman 1987) that the E and NS1 proteins did not 
exclusively overlap, however, close inspection o f the confocal and TIEM images in 
this study showed E protein was commonly found with NS1 protein in vesicles and 
with the virus. Interestingly, intense staining of the NS1 protein also correlated with 
more intense E protein staining even in the mutant-infected cells, indicative of 
colocalization.
In an effort to better understand and compare the differences between the parental 
NY99 strain and mutant infection in cell culture, TEM and TDEM were utilized and 
identified many differences in the structures and E and NS1 protein localization within 
cells infected with these viruses. Transmission EM of both the parental NY99 and 
NS 1130-132QQA/175A/207A virus-infected cells showed the presence o f a  CM was not 
always present in virus-infected cells since SMS and virus particles were seen without 
a CM structure. It has been suggested that the CM is made up o f ER (Mackenzie et 
al, 1999). Since the SMS were often contained within ribosome studded vesicles, it is 
possible that the CM is made from the dissociation o f the SMS containing vesicles. It 
is speculated that virus-infected cells without CM are at different stages o f viral 
replication and the CM structure have not yet formed. The CMs have been proposed
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as the proteolytic process site due to the colocalization o f the protease NS3 and 
cofactor NS2B proteins (Mackenzie et al., 1997). Interestingly, the E protein (but not 
the NS 1 protein) was found associated with the CM structures indicating a wider use 
of these structures. Smooth membrane structures (SMS) in the absence o f CMs were 
generally found throughout the cell whereas SMS in cells with CMs were generally 
found in close proximity to the nucleus, indicating a necessity o f the CM to be in close 
proximity to the nucleus. Most cells infected with the NY99 strain showed evidence of 
viral infection due to a change in the ultrastructure whereas these differences were not 
as easily found for the NS 1 130-132QQA/175A/207Avirus-infected cells. For example, there 
was little CM in the mutant N S1130-132QQA/175A/207A infected cells compared to the 
parental NY99 virus-infected cells. Also TPM was found in the mutant NS 1130- 
132QQA/175A/207A virus-infected cells, which has been previously described for early 
WNV-infected mosquito cells (Girard et al., 2005). From these data, it is 
hypothesized that the SMS are formed early in infection, relocate in close proximity to 
the nucleus where CM are subsequently formed. A larger experiment, including a 
time-course experiment with these viruses may give more insight into this hypothesis.
Besides the apparent decrease in observed CM structures, the most striking difference 
between the ultrastructure o f the parental NY99 and NS 1130-132QQA/175 A/207A viruses in 
infected Vero cells was the size and shape o f the SMS. The SMS in the mutant 
NS1130-132QQA/175A/207 virus-infected cells differed from small spherical shape to larger 
tubular shape whereas the parental NY99-infected cells showed only spherical shaped 
SMS. Interestingly, tubular shaped SMS have been previously described for WNV- 
infected mosquito cells (Girard et al., 2005). Mosquito cells modify N-linked 
glycosylation residues different from mammalian cells as mosquito cells lack the
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enzymes required for the addition o f complex carbohydrates (Jarvis and Finn 1996). 
The NS1 no for DEN-2 and MVE viruses and NS1175 for MVE virus glycosylation 
sites have been shown to contain complex carbohydrate residues while the NS 1207 site 
for DEN-2 virus was demonstrated as having high mannose type carbohydrate (Pryor 
and Wright, 1994; Blitvich e t a l ,  2001). Therefore, it is hypothesized that the 
discrepancy in the shape of the SMS was the result of the loss o f NSI glycosylation. 
Studies need to be undertaken in a second cell line to confirm the differences obtained 
in virus-infected monkey kidney Vero cells.
These data suggest that the NS 1 protein is involved in SMS structure or formation; 
however, differences in the SMS were not the only dissimilarities between the 
parental NY99 and NS 1 i30-B2qqa/175a/207a mutant virus-infected cells. Many NS1i30- 
B2QQA/175A707A virus-infected cells did not contain CMs but showed evidence of 
infection having SMS and virus. It is hypothesized that NS1 also directs the SMS 
towards the nucleus for subsequent function o f CM/PC required for the viral 
replication cycle, consequently, reduced multiplication may be the result if  this defect. 
Although only mutations in the glycosylation sites caused these results, it is possible 
that glycosylation residues function in many ways. In fact, N-linked chains related to 
glycoproteins have been shown to affect protein folding, secretion rate, intracellular 
trafficking, cell surface expression, intracellular stability, enzyme or cytokine activity, 
receptor signal transduction, susceptibility to protease or dénaturants, recognition by 
antibodies and targeting to specific cell types (Varki, 1999). Since the NS 1 protein is 
not expressed on the surface o f the virion, some o f these functions would be unlikely, 
such as cell surface expression or receptor signal transduction. However, the NS 1 is a 
secreted protein and therefore many o f these putative functions for the carbohydrate
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residues associated with proteins cannot be dismissed. The NSI glycosylation 
mutants displayed a decrease in intracellular and extracellular NS1 by confocal and 
western blot (see chapters 4 to 6), respectively, and well-defined rather than diffuse 
localization compared to the parental NY99 strain. Since nonglycosylated NS1 was 
still secreted from the cells, it is likely that the reduction in the secreted NS1 was a 
direct result o f the reduction in intracellular NS 1. Therefore, it is hypothesized that 
the NS 1 protein for the nonglycosylated NS1 mutant viruses may be more susceptible 
to dénaturation, accounting for the reduction o f this protein, which directly affects the 
function of the protein proposed to be vesicle transport o f  the SMS to the nucleus 
where CM (which are necessary in the replication cycle) are formed .
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Figure 8-1. Localization of the E and NS1 proteins by confocal microscopy in mock- 
(A) and WNV-infected (B-E) Vero cells. The E protein was identified by red (Texas 
Red) fluorescence and the NS1 protein by green (FITC) fluorescence. Both N Y 99 - (B) 
and mutant E154S- (C), NSI130-132QQA/175A/207A- (D) and E154S/NSI130A/175A/207A- (E) 
infected Vero cells displayed a high degree o f colocalization indicated by the overlap of 
the E and NS1 protein stains.
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Figure 8-2. Localization o f the ER by confocal microscopy in mock- versus 
WNV- infected Vero cells. White arrows illustrate areas o f vesicle-like staining.
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Figure 8-3. TEM ultrastructural comparison o f mock- and NY99-infected Vero 
cells. Virus-infected cells show swollen mitochondria (Mi), smooth membrane 
structures (SMS), paracrystalline arrays (PC) and convoluted membranes (CM). 
Scale bar 500 nm for mock- and NY99-infected cells.
Mock NY99
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Figure 8-4. Ultrastructure differences in NY99-infected Vero cells may indicate 
a progression in stages of infection. TEM images o f the parental NY99-infected 
Vero cells depicting differences in the location and arrangement of virus- 
induced structures cell to cell showing no apparent CM with diffuse SMS 
structures (A), PC and CM localized to the nucleus (B), More defined CM with 
SMS located between two CM foci (C) and well defined large CM structure 
with localized SMS (D). Scale bar 500 nm.
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Figure 8-5. Ultrastructure comparison o f the parental NY99- and attenuated 
NS 1 i 3o-132q q a / 175a/207a  mutant virus-infected Vero cells. Both parental and 
attenuated infected cells show convoluted membranes (CM) near the nucleus 
(Nu) with associated smooth membrane structures (SMS). Swollen 
endoplasmic reticulum (ER) and mitochondria (Mi) evident in NY99 infected 
cells. Scale bar represents 500 nm.
NY99 N S 1130-132QQA/175A/207A
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Figure 8-6. Ultrastructure o f NSI130-132QQA/175A/207A mutant virus- 
infected Vero cells. Smooth membrane structures (SMS) within vesicle 
packets (VP) containing virus (V) throughout the cell. A paracrystalline 
structure (PC) also appears but no convoluted membranes (CM) were 
within this cell. Scale bar represents 500 nm.
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Figure 8-7. Transmission immuno-EM of mock- and NY99-infected Vero cells 
labeled with anti-E and anti-NSl antibodies. Both mock- and virus-infected Vero 
cells labeled with 5 nm E anti-rabbit and 10 ran NS1 anti-mouse antibodies. 
Significant differences (p<0.01) in the level of E and NS1 were determined from 
the background of the mock-infected Vero cells compared to the NY99-infected 
Vero cells by Student’s t-test. Scale bar 1 pm.
Mock NY99
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Figure 8-8. Localization of the E protein to convoluted membrane (CM) 
structures and vesicle associated virus. E protein localized to virus particles 
(V), CM and tubular membrane structures (TMS). Mitochondria (Mi). Scale 
bar 100 nm.
E within CM E within vesicles and localized to the 
virus
NY99
N S 1 13o-
132QQA/175A/207A
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Figure 8-9 Colocalization o f the E and NS1 proteins in the NY99- and NSlno- 
132QQA/175A/207A mutant virus-infected Vero cells. E protein labeled with 5 nm 
gold particles and NS1 with 10 nm gold particles. Scale bar 100 nm.
NY99 NS1 130-132QQA/17 5 A/207A
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CHAPTER 9 : CYTOKINE EXPRESSION OF VIRULENT NY99 
AND ATTENUATED NSI GLYCOSYLATION MUTANT 
VIRUSES IN MOUSE SERUM
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9.1 Introduction
Previous chapters examined the ablation o f the NS1 glycosylation sites and the affects 
of these mutations in cell culture and in mice. Several mutant viruses were highly 
attenuated for neuroinvasiveness and neurovirulence in mice. The most attenuated 
NS1 glycosylation mutant virus in mice proved to be NS1 i30-i32Qqa/175a/207a, which 
also showed decreased infectivity titre compared to the parental NY99 strain. This 
virus was stable in cell culture and in mice given that no reversions or putative 
compensating mutations were identified and the mouse experiments were highly 
reproducible.
The NS 1130A/175A.207A mutant virus also proved highly attenuated for neuroinvasiveness 
in mice although the infectivity titre in cell culture was comparable to the parental 
NY99 strain. Interestingly, a reversion at NS 1130 and putative compensating mutations 
in the E protein were routinely observed in the viral RNA from brains o f mice that 
succumbed to ip infection, but not in cell culture. Unlike the NS 1130-132QQA/175A/207A 
mutant, however, the NS I130A/175A/207A mutant virus was not ftdly attenuated for mouse 
neurinvasiveness.
Previous experiments also indicated that the levels of intracellular and secreted NS1 
protein (see chapters 5 and 8) and viraemia (see chapter 3) were reduced for the 
attenuated mutants compared to the parental NY99 strain. In order to better 
understand the mechanism for attenuation in vivo, cytokine assays were utilized to 
determine which, if  any, cytokines were up-regulated or down-regulated in the 
parental NY99- and attenuated mutant-infected mice versus the mock-infected mice. 
Initially, the serum of parental NY99 virus-infected mice was screened using a
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cytokine membrane to determine if  there were differences in the levels o f the 
cytokines between the infected and uninfected serum samples. A larger experiment 
involved the use o f the Bioplex system to screen secreted cytokines in the serum of 
NS 1130A/175A/207A5 NS1130-132QQA/175A/207A, parental NY99 and mock-infected mice at 
three days post-ip inoculation.
Since it was also previously shown that the NS 1130A/175A/207A mutant virus showed 
variable ipLDso values, it was hypothesized that the age o f the mice may have 
contributed to this discrepancy. Due to the lack o f available mice, the ages of the mice 
varied somewhat. Therefore, smaller groups o f mice were obtained containing 3- 
week-old weanling and 5- week-old adult mice. The ipLD50 o f the NS1 b o a /175a/207a  
and NS 1 i 30- i 32q q a /175a /207a  mutants and parental NY99 strain were examined for both 
age groups. At the same time, the sera o f these mice were collected at one and three 
days post-ip infection for use with a cytokine Bioplex screening assay to determine 
any differences in cytokines secreted in the sera o f weanling or adult mice.
9.2 Results
9.2.1 Cytokine membrane
Initial cytokine experiments involved the use o f RayBiotech cytokine arrays and 
female 3-4 week old outbred mice. These arrays involved the use of a 62 cytokine 
coated membrane (see Material and Methods Fig. 2-2). Mouse blood was collected at 
one and two days post-ip infection from either parental NY99 virus- or mock-infected 
mice. The blood was allowed to coagulate at room temperature before centrifugation 
and collection o f the serum, which was placed at -80°C before subsequent use. This 
serum was added to the cytokine membranes, incubated overnight before strepdavidin
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incubation and chemiluminescence development o f membranes. The cytokine levels 
were determined by a densitometer and significance (p < 0.05 by Students t-test) o f 
each cytokine calculated.
9.2.1.1 New York 99- vs. Mock- infected
In this preliminary study, the effects on cytokines in the serum of mice following 
NY99 virus infection was determined by comparison o f virus-infected versus mock- 
infected mice bled on one and two days post-infection. These time points were 
examined in this experiment since previous studies showed that high viraemia for 
NY99 virus-infected mice occurred on either one or two days post-ip infection, with 
total clearance from the serum by the fourth day (see chapter 3).
Interestingly, at one day post-infection there were no statistical differences between 
the NY99 virus-infected and mock-infected serum samples. At two days post- 
infection, the NY99 virus-infected serum samples showed significant cytokine 
differences compared to the mock-infected serum samples, including: eotaxin, 
interleukin 1 beta(IL-lp), interleukin 9 (IL-9), interleukin 17 (IL-17), lymphocyte 
adhesion molecule 1 (L-selectin), lymphotactin, macrophage inflammatory protein 1 
gamma (MIP-ly), macrophage inflammatory protein 3 alpha (MIP-3a) and soluble 
interferon receptor type 2 (sIFNrll). Although most o f these cytokines were up- 
regulated in the virus-infected serum sample, one, eotaxin, was down-regulated 
compared to the mock-infected cells (Table 9-1).
199
9.2.2 Bioplex
The Bioplex technology differs from the cytokine membranes in that the antibodies 
used for the Bioplex are identified by laser capture rather than chemiluminescence. 
Real time fluorescence o f each antibody tagged ‘bead’ is read for each antibody in the 
assay. These studies used either a mouse 23-plex kit or 32-plex (23-plex plus 9-plex) 
kit so that all cytokines could be assayed at one time (see Materials and Methods 
Table 2-3). In this larger study, all five mice in groups inoculated with either the 
parental NY99, NS 1130A/175A/207A or NS 1 130-132QQA/175A/207A viruses were utilized to 
determine statistical (p < 0.05) differences in secreted cytokines between the virus- 
infected and mock-infected mice.
9.2.2.1 3-5-week-old mice
The initial Bioplex assay examined the extracellular cytokine expression in female 
outbred mice inoculated by the ip route with a dose of 1,000 PFU for the parental 
NY99 and NS 1130A/175A/207A viruses and a higher dose o f 10,000 PFU for the NS 1130- 
132QQA/175A/207A virus. Due to the lack o f availability o f mice, 3-5-week-old mice were 
utilized. The blood from these mice was collected at three days post-infection only 
and the serum collected for the cytokine assay. Various virus doses were chosen for 
multiple reasons. Since all mice given 1,000 PFU of the parental NY99 succumbed to 
infection, this dose was chosen to determine the cytokine expression in mice infected 
with the virulent strain at the time point o f high viraemia but before clearance o f the 
virus (see Table 3-3 and Figure 3-4A). A dose o f 1,000 PFU was chosen for 
NS1 130A/175A/207A -infected mice since it was previously shown that mice inoculated 
with this dose resulted in some mice succumbing to infection while others survived
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infection (see Table 3-3). It was hypothesized that differences in cytokines may be 
identified between mice that succumbed or survived infection. A higher dose of 
NS 1130-132QQA/175A/207A virus was chosen since the ipLDso o f this virus was higher than 
the other two viruses.
Similar to the preliminary cytokine membrane data, the initial Bioplex experiment 
revealed both up-regulation and down-regulation o f various cytokines including: IL-9, 
IL-12p20, IL-12p40, IL-13, IL-17, monocyte chemotactic protein-1 or monocyte 
chemoattractant protein -1 (MCP-1) and cytokine induced neutrophil chemoattractant 
(KC) (Table 9-2). O f these, IL-12p20 was up regulated in NS1130A/175A/207A, NS1130- 
132QQA/175A/207A and the parental NY99 virus-infected serum samples. In comparison 
interluekin-9 (IL-9), IL-13 and IL-17 were up-regulated only in the sera from NS 1130- 
i32QA/i75A^07A-infected mice, KC was up-regulated in the NY99 samples and MCP-1 
was up-regulated in the sera from NY99 and NS 1130A/175A/207A virus-infected mice. 
Down-regulation o f cytokines was also demonstrated for IL-12p70 for the NS1i30. 
132QA/175A/207A mice and for IL-17 for the NS 1130A/175A/207A and NY99 serum samples.
The infectivity titres for the mouse serum samples used for this experiment were 
determined by plaque titration (Table 9-3). All five mice inoculated with the parental 
NY99 strain succumbed to infection and displayed infectivity titres o f 4,500 to 11,000 
PFU/ml. Similarly, the NS 1130A/175A/207A mutant infected mouse serum had infectivity 
titres o f  1,000 to 4,500 PFU/ml and all but one mouse succumbed to infection. The 
NS1130-132QQA/175A/207A mutant-infected serum samples, on the other hand, had no 
detectable viraemia and none o f the mice succumbed to infection.
2 0 1
One mouse inoculated with the NS I130A/175A/207A mutant virus survived infection 
although the vireamia was high (Table 9-3). This mouse did show one significant 
difference in cytokine expression, a 4-fold increase o f IL-10, compared to other serum 
samples from all viruses.
9.2.2.2 Weanling versus adult mice
Due to the lack of availability o f mice, some o f the previous mouse experiments 
utilized a mixture o f weanling and adult mice. Since there was some variability in the 
LDso’s between mouse experiments, it was hypothesized that this discrepancy was 
likely due to the differences in the immune response to infection. To test this 
hypothesis, 21 day (3 week) old weanling and 35 day (5 week) old adult mice were 
inoculated by the ip route with either N S 1 i 30a/ i 75a /207a , N S 1 i 3o- i 32q q a /175/V207a  or 
parental N Y 99 virus (Table 9- 4). The N Y 99 virus-infected 3-week and 5-week-old 
mice showed similar ipLD50 values o f 10 and 5 PFU, respectively. There was also 
agreement for the NSI130-132QQA/175A/207A virus-infected 3- and 5-week-old mice with 
an ipLDso value o f 100,000 and >500,000 PFU, respectively. The N S  1130A/175A/207A 
virus-infected mice, on the other hand, showed different ipLD50 values for the 3- and 
5-week-old mice o f 20 and 2,000 PFU, respectively. The sera from these mice were 
collected and used for subsequent Bioplex experiments. This time the 32-plex was 
used due to assay nine newly available cytokines; these nine cytokines were combined 
with the previously used 23 cytokines.
Since the NS1130A/17SA/207A mutant virus showed differences in the ipLDso between the 
3- and 5-week-old mice, the 100 PFU dose was selected for Bioplex cytokine 
screening to determine differences between mice that either succumbed or survived
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infection. At this dose, four out o f five 5-week-old mice survived infection whereas 
only one out o f five 3-week-old mice survived infection. A higher dose o f 10,000 
PFU for the NS1130-132QQA/175A/207A inoculated mice was also chosen. Although highly 
attenuated in both the weanling and adult mice, three out o f five 3-week-old mice 
survived infection whereas all o f the 5-week-old mice survived infection. A dose o f 
1,000 PFU was chosen for the NY99 parental strain.
Due to the large sample volume required to test multiple time points, only the one and 
three day time points were utilized for the 5-week-old infected mice whereas only the 
three day time point was used for the 3-week-old infected mice. The time points were 
chosen since previous studies showed that low and high viraemia was correlated to 
one and three days post-infection, respectively, and the three day time point showed 
greater differences in preliminary studies (Figure 3-4A and Table 9-1).
O f the 32 cytokines examined in this study, 21 showed significant (p< 0.05)
differences compared to the mock-infected serum samples including: IL -la , IL-lp,
IL-2, IL-3, IL-5, IL-9, IL-10, IL-12p40, IL-15, IL-17, IL-18, macrophage colony-
stimulating factor (M-CSF), monokine induced by interferon gamma (MIG),
macrophage inflammatory protein 2 (MIP-2), vascular endothelial growth factor
(VEGF), eotaxin, MCP-1, MIP-ip, granulocyte colony-stimulating factor (G-CSF),
granulocyte macrophage colony-stimulating factor (GM-CSF) and M IP-la (Table 9-
5). Interestingly, all o f these cytokines were down-regulated in the parental NY99
virus-infected 5-week-old mice at one day post-inoculation. The 5-week-old
NS1 130A/175A/207A and NS li30-i32QQA/i75A/207A infected mouse serum samples at one day
post-inoculation also showed that many cytokines down-regulated compared to the
mock-infected mouse serum samples, including IL -la , IL-3, IL-9, IL-10, IL-15, IL-
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17, M-CSF, MIG, MIP-2, VEGF, MCP-1, M IP-ip and M IP-la. At this time point, 
cytokines that were down-regulated in both the attenuated N S li30A/i75Ay207A and 
NS 1130-132QQA/175A/207A mice were also down-regulated in the parental NY99 mice. By 
three days post-inoculation, the NY99 virus-infected 5-week-old mouse serum 
samples still showed down-regulation o f most cytokines compared to the mock- 
infected mouse serum samples. The NS I130A/175A/207A virus-infected mouse sera, 
however, did not down-regulate any cytokines but there was up-regulation o f IL-ip. 
At this time point, the NS 1 i 3o-132qq a /175A/207a  serum samples showed down-regulation 
of the IL-15 and G-CSF and up-regulation o f M-CSF compared to the mock-infected 
serum samples.
As stated above, the sera from 3-week-old virus-infected mice was only examined at 
the three day time point. At this time point, the parental NY99 strain showed only 
three down-regulated cytokines (IL-17, IL-18 and M IP-la) and one up-regulated 
cytokine (M-CSF) compared to the mock-infected mouse serum samples. The 
NS 1 i 3o a/i 75a /207a  virus-infected 3-week-old mouse serum samples also showed a 
combination o f up- and down-regulated cytokines, including IL-15, M-CSF and MIG 
that were up-regulated, and IL-18 that was down-regulated. The NS 1 i30. 
132QQA/175A/207A mutant virus showed only one difference in cytokine levels compared 
to the mock-infected mouse serum samples, namely M-CSF, which was up-regulated.
The mfectivity titres for the serum samples used for this experiment were not 
determined in order to preserve the samples for future use to confirm these differences 
using other assays.
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9.3 Discussion
Previous experiments showed that mutations in the NS1 glycosylation sites attenuated 
WNV for both neuroinvasiveness and neurovirulence in mice. These mutants showed 
decreased intracellular and secreted NS1 protein in cell culture and reduced vireamia 
in mice (chapters 3 to 6, 8). The NS1 protein has been implicated in severe dengue 
infections, including a link has been identified between high levels o f circulating NS1 
and life-threatening dengue hemorrhagic fever (Green and Rothman, 2006; Libraty et 
al., 2002). Since some o f the WNV NS1 mutants showed decreased levels of 
secreted NS1 protein in cell culture and reduced mortality in mice, it was 
hypothesized that levels o f cytokine expression may reveal differences between the 
virulent and attenuated strains compared to mock-infected mice, and may contribute to 
the differences observed in the mouse neuroinvasive phenotype.
Cytokine expression showed several similarities among the parental NY99,
NS1 i 30A/175A207A and NS 1130-132QQA/175A/27A mouse serum samples in separate 
experiments and demonstrated reproducible results. Some o f these cytokines, such as 
MCP-1 and IL-12p40, were up-regulated in one experiment but down-regulated in 
another experiment. Since changes in the levels o f these cytokines were identified in 
different experiments using different mice, these cytokines may be potentially 
important, and it is hypothesized that differences in vireamia or viral load may be, in 
part, due to the variability in cytokine expression. In fact, differences in cytokine 
expression was seen in mouse sera collected at different time points and between 
weanling mice, which were highly susceptible to infection, and adult mice, which 
were less susceptible to NS1 mutant virus infection. Although the infectivity titres 
were not determined for the Bioplex study o f 3-and 5-week old mice, previous
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infectivity titres o f mouse serum samples demonstrated a correlation between vireamia 
and mortality where high vireamia was seen in mice that subsequently succumbed to 
infection and low or undetectable vireamia was seen in mice that survived infection 
(Table 3-3 and Table 9-3).
Other cytokines, such as IL-17, were consistent among different experiments 
suggesting its importance for WNV infection. Using mock-infected mouse serum 
samples as a baseline, IL-17 displayed down-regulation o f expression in NY99 and 
NS 1130A/175A/207A virus-infected mice, but not sera from NS 1130-132QQA/175A/207A virus- 
infected mice. Since the NS1130A/175A/207A mutant virus showed high vireamia in all 
mice (Table 9-3) and mice that succumbed to infection often contained a reversion at 
NS 1130, it is hypothesized that this virus mimics virulent NY99 infection in mice that 
succumb to infection. Recently, IL-17 has been associated with a new subset o f T 
helper (Th) cells eliciting a pro-inflammatory response against extracellular pathogens 
not efficiently cleared by Thl or Th2 immunity (Bettelli et al., 2007). Since both the 
NY99 and N S I130A/175A/207A, but not NS 1 i30-i 32qqa/175a/207a  virus-infected mice showed 
down-regulation o f IL-17, the expression of this cytokine may be suppressed by WNV 
infection. Unfortunately, these data do not allow conclusion that the difference in the 
down-regulation in the NY99-infected sera and the up-regulation o f this cytokine in 
the NS 1130-132QQA/175A/207A sera (Table 9-2) was due to the loss o f secreted NS 1. 
However, IL-17 may be an important factor in the clearance o f this virus and, 
therefore, further work is needed to investigate the role o f this cytokine.
Differences in the cytokine expression were seen between the 5-and 3-week-old mice. 
Interestingly, the 3-week-old mice did not have many changes in cytokine expression 
compared to the mock-infected samples despite the fact that the attenuated mutant
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viruses were more lethal in the weanling mice than the adult mice. A comparison of 
neonate and adult mice showed that young mice have limited T-cell response 
including reduced ability to produce cytokines that are required for immune activation 
until adulthood is reached (Holladay and Smialowicz, 2000). It is, therefore, 
hypothesized that possible differences in the immune response to WNV in weanling 
and adult mice contributed to the limited immune response in the weanling mice.
One cytokine, IL-18, was down-regulated in both the virus-infected weanling and 
adult mice. This cytokine corresponded with a poor outcome since only groups of 
mice where at least four out o f five mice succumbed to infection showed this down- 
regulation (Table 9-5). Interleukin-18 has been shown to induce Langerhans cell 
migration to the draining lymph node for the accumulation o f dendritic cells and the 
reduction o f major histocompatibility complex (MHC) class II (Cumberbatch et al., 
2001). Therefore, WNV may down-regulate IL-18 as a way of reducing the antigen 
presenting function o f these cells, which triggers activation o f T- and B-cells that may 
allow for immune evasion.
Although studies o f cytokine expression for flavivirus infection have focused on the 
up-regulation o f cytokines and their affects on the clearance o f the virus, down- 
regulation o f cytokines has also been noted. Down-regulation o f IL-10, an anti­
inflammatory cytokine, was seen in the brains o f JE virus-infected mice, hypothesized 
to be the result o f an overwhelming pro-inflammatory response (Swarp et al., 2007). 
Down-regulation o f IL-10 and IL-8 was seen by real time PCR o f the RNA isolated 
from white blood cells o f cynomolgus macaques infected with DEN-1 and DEN-4, but 
attributed to fluctuations in the normal response (Swarup et al., 2007). Neither o f 
these studies determined the affects o f treatment with these cytokines. Interleukin-10
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was down-regulated for the parental NY99, NS1 i30A/i75A/207Aand NS 1130- 
132QQA/175A/207A infected 5-week-old mice one day post-infection and for the parental 
NY99 strain three days post-infection indicating it may be down-regulated in virus- 
infected mice early in infection and also important in the progression o f infection 
since mice that survived infection did not show down-regulation o f this cytokine at the 
later time points (Table 9-5). Also, a 4-fold increase in IL-10 was seen in the one 
mouse that survived NS1130A/175A/207A infection although having high viraemia (Table 
9-3). These data suggest that IL-10 may be important for the progression o f lethal 
WNV infection and experiments examining the treatment with this cytokine may be 
effective in clearance o f the virus.
Interestingly, many of the cytokines examined showed no changes in the attenuated- 
infected mice samples. Since previous experiments found that the attenuated mutant 
viruses do not produce high viraemia, the lack o f cytokine changes may be a direct 
result o f the reduction in the multiplication o f the vims in the blood. Again, this may 
indicate the importance of the virus to down-regulate cytokines to allow for efficient 
multiplication.
Although these studies did not confirm the interaction o f secreted NS1 protein with
cytokine expression, there was evidence that the cytokines respond differently to
virulent and attenuated viruses. Also, these data showed that WNV infection results in
the down-regulation o f many cytokines. Published studies have focused on the up-
regulated cytokines and their possible role in the clearance if  WNV infection
(Diamond et al., 2003; Fredericksen et al, 2004). Here it is suggested that WNV can
suppress cytokines levels that allows for effective infection and that secreted NS1 may
be involved either indirectly or directly in this process. Although no purified WNV
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NS1 protein was available, future experiments examining the cytokine expression 
changes in mice inoculated with NS1 protein may reveal some of these changes.
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Table 9-1. Cytokine changes in the parental NY99 virus-infected mouse serum 
samples compared to mock-infected 3-5-week-old mice at one and two days post­
inoculation with 1,000 PFU using a cytokine membrane assay
Cvtokine 1dpi 2dpi p-value
Eotaxin-2 nc Î 0.02
IL-1 (3 nc 1 0.04
IL-9 nc 1 0.004
IL-17 nc 4 0.04
L-selectin nc 4 0.03
Lymphotactin nc 1 0.04
MIP-1y nc 4 0.02
MIP-3a nc 4 0.04
STNF-rll nc 4 0.04
Green= up-regulated and red= down-regulated, 
compared to mock-infected mice 
dpi= days post-infection
*p-value o f 2dpi of NY99 versus mock-infected serum
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Table 9-3. Infectivity titres (PFU/ml) in sera o f 3-5-week-old mice infected with either 
NY99, NS 1130A/175A/207A or NS1 i3o-i32QQA/i75A/207A viruses at three days post infection.
Mouse 1
Virus
NY99 10,000*
NS1130A/175A/207A 4,000*
NS1130-132QQA/175A/207A <50
* Succumbed to infection
2 3 4 5
4,500* 8,000* 4,500* 11,000
4,000 1,000* 4,500* 1,500*
<50 <50 <50 <50
2 1 2
Table 9-4. Lethality (ipLDso) ofNY99, NSli30A/i75A/207AandNSli30-i32QQA/i75A/207A_ 
infected 3-and 5-week-old mice.
Lethalitv in 3- 
week-old 
mice
(PFU/LD™)
AST + 
SD*
Lethalitv in 
5-week-old 
mice
(PFU/LD^ AST + SD
NY99 10 8.2 + 0.9 5 9 + 1.5
NS1130A/175A/207A 30 9.3 + 1.4 2,000 10 M .3
NS1130- 
132QQA/175A/207A 100,000 12.3 + 4.1 >500,000 15 + 0
♦Average survival time in days ^standard deviation
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CHAPTER 10 : GENERAL DISCUSSION
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West Nile virus is a mosquito-bome flavivirus and the causative agent o f the highest 
numbers o f human neuroinvasive cases in the United States in recent years (CDC, 
2007). Before 1999, WNV was found in Europe, Asia, the Middle East and Africa 
(Hayes, 1989). In the summer o f 1999, WNV was confined to the New York area. 
Subsequently, this virulent strain o f WNV has spread across the United States, 
Canada, the Caribbean, Mexico and South America and has been responsible for 
thousands o f human and animal deaths (Gubler, 2007). To date, no vaccine or 
antiviral is available for human use.
In order to develop a vaccine candidate or therapeutic target, it is necessary to 
understand the WNV replication cycle to effectively develop countermeasures to one 
or more o f these steps. The flavivirus NS1 protein is a highly conserved glycoprotein 
whose function has not yet been fully determined; however, several studies suggest 
that the NS1 protein may be involved in various steps o f  the replication cycle 
(Lindenbach and Rice, 1997; Mackenzie et al., 1996; Westaway et al., 1997). The 
NS1 protein has also been shown to be associated with the cell membrane, within the 
cell and secreted from the cell (Winkler et al., 1988). All mosquito-bome, tick-borne 
(TBE) and no known vector-borne (ENT) flaviviruses contain glycosylation sites in 
the NS 1 protein, most o f which are highly conserved, suggesting their importance for 
the function o f the NS1 protein (Dalgamo et al., 1986; Pryor and Wright 1994; 
Flamand et al., 1992; Kuno et al., 2006). Therefore, mutations in the WNV 
glycosylation sites were characterized, with the hypothesis that these mutations would 
attenuate the virus, lead to a  better understanding o f the function o f this protein and 
potentially lead to advances in vaccine development.
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The ablation o f  the N S 1 glycosylation sites o f  W N V  was used to generate a panel o f  
mutants, none o f which were temperature sensitive. Some o f the mutant viruses 
displayed reduced replication in cell culture and attenuation in mice. Interestingly, an 
alanine, serine or glutamine substitution at the N S 1 130 glycosylation site combined 
with an alanine substitution at N S  1 175 and NSI207 resulted in mutants 
(N SI 130A/175A/207A, N S I 130S/175A/207A, N S I 130Q/175A/207A, N S 1 ]30-131SV/175A/207A&nd N S 1 130. 
132qqa/175a/207a) that displayed variable multiplication kinetics in cell culture and 
attenuation in mice compared to the parental N Y 9 9  strain. When the asparagine o f  
the N S  1 Bo glycosylation m otif was changed to an alanine in combination with the 
NSI175 a n d N S l207 mutations (N S 1 i3oa/i75a/207a), this virus was replication competent 
in cell culture, comparable to the parental N Y 9 9  strain, and highly attenuated in mice, 
although a reversion to asparagine or mutation to an aspartic acid at N S  1 130 as well as 
two mutations in the E  protein at E204 and E237 were commonly found in mice that 
succumbed following ip infection. These mutations were hypothesized to affect 
selective pressure since reversion and compensating mutations were found to be 
associated with mice that succumbed to ip inoculation, but were not found in cell 
culture. Also, the N S  1130 reversion to asparagine was commonly, but not exclusively, 
associated with the E mutations, while the E  mutations were not found without the 
reversion at N S  1 130. A n  alanine to aspartic acid at N S  1 130 was also seen in two mice 
that succumbed to N S 1 130A/175A/207A infection. Aspartic acid differs from alanine by  
the replacement o f  one hydrogen with a carboxylic acid and differs from asparagine 
by one amide group, again suggesting that these mutations were the result o f  
instability o f  the virus and not an artifact from the mutagenesis process.
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This instability was not seen in any of the serine or glutamine mutant viruses and these 
mutants were also attenuated for mice at least 100-fold more that the N S 1 i 30a / i 75A/207a  
mutant virus, although the only difference was the amino acid at NS 1130 that resulted 
in loss o f  the glycosylation site. Disparate results o f NS1 glycosylation mutant 
viruses were seen in separate studies for the related flavivirus dengue-2 (DEN-2) 
virus. Mutant viruses that contained an asparagine to glutamine change in the two 
NS1 glycosylation motifs o f  DEN-2 virus showed reduced replication and multiple 
compensating mutations in cell culture whereas changing the asparagine o f the 
glycosylation motifs to an alanine in a chimeric DEN/TBE virus showed reduced 
replication competence, enhanced virulence and attenuation in mice (Crabtree et al., 
2005; Pletnev et al., 1993). Although these studies did not compare mutant viruses 
with different amino acids at the NS1 glycosylation sites, the results described in 
previous chapters o f this PhD thesis suggest that the disparities in the previous studies 
could be due to the differences in the amino acid substitutions used in these studies 
and the variable stability o f the different amino acids, especially at the NS1 no site.
Ablation o f the glycosylation sites in the NS1 protein proved to be important for the 
virulence phenotype o f WNV and is the first study to demonstrate that mutations in 
the NS 1 protein attenuated the virus for neuroinvasiveness. In fact, these mutations 
completely attenuated for neuroinvasiveness in mice at the highest possible dose used 
and highly attenuated for mouse neurovirulence.
The NS1 glycosylation mutant viruses were highly attenuated and have potential for 
inclusion in candidate live attenuated vaccines; however, live-attenuated vaccine 
candidates should contain multiple attenuating mutations in several proteins to ensure 
reversion cannot occur. Therefore, mutations in the prM, E and NS4B proteins,
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together with the NS1 mutations, were characterized. The prM mutant (prMi5S) 
contained a mutation at the prM glycosylation site that had not been previously 
described for WNV, whereas the E and NS4B mutations had previously been 
described as attenuating mutations for WNV (Beasley et al, 2005; Wicker et al, 
2006). Interestingly, the mutant containing mutations in all four proteins 
(prMi5s/Ei54s/NSli30A/i75A207A/NS4Bio2s) was not attenuated in mice although some of 
the combinations o f these mutations were found to be highly attenuated, indicating a 
delicate balance o f attenuating mutations required for a successfully attenuated virus. 
Also o f interest was the lack o f attenuation following the ablation o f the conserved 
prM glycosylation site, especially since the E and NSI glycosylation mutant viruses 
were highly attenuated.
The ablation o f the glycosylation site in the prM protein enhanced infectivity titre in 
cell culture and did not attenuate the virus in mice whereas the loss o f glycosylation in 
the E and NS1 proteins reduced infectivity titre in cell culture and was attenuated in 
mice. It is unclear if  this was the result o f increased binding efficiency to cell 
receptor(s), fusion or assembly. Since WNV has been previously shown to interact 
with DC-SIGN, the prMj5 mutant may be used in similar studies to determine the 
affects o f this mutation related to DC-SIGN binding. Also altering the pH in cell 
culture is often an effective way to investigate mutations that affect the fusion process.
Another interesting finding was in the addition o f the E 154S glycosylation mutation. 
Variable degrees o f attenuation were seen in the mutants containing the E154S 
glycosylation mutation in combination with the triple NS1 mutant viruses
(E154s/NS 1 130A/175A7207A, E154S/NSI130-131SV/175A/207A and Ei54s/NSl 130-132QQA/175A/207A)-
Similar to the NS1 mutant viruses, the E/NS1 mutant virus with an asparagine to
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alanine substitution at the NS1 no glycosylation motif appeared less attenuated than the 
E/NS1 mutant with an asparagine to glutamine substitution at the NS loo site. 
Although the E 154S/NSI130A/175A/207A mutant virus was completely attenuated for 
neuroinvasiveness in mice at a dose >100,000 PFU, the E i54S/NS1 130-132QQA/175A/207A 
did not multiply to >1,000 PFU/ml in cell culture indicating these mutations rendered 
the virus over-attenuated. These results also confirm that the amino acids at the 
NS 1 i3o site contribute to the overall fitness o f the virus since these were the only 
amino acids different in these viruses.
The data in this thesis also suggest a possible interaction o f the E and NS1 proteins. 
The NS 113oa/ i 75A/207A mutant showed reversion and mutations in the E protein in mice, 
yet none o f the E/NS1 mutant viruses showed reversions or putative compensating 
mutations. In fact, the addition of the E 154S mutation appeared to stabilize these 
mutations in mice in that no mice succumbed to infection even at high doses. Further 
studies are necessary to identify this possible interaction.
The glycosylation of the NS1 clearly affected the virulence o f WNV; however, the 
functions) o f this protein is(are) still unclear. Confocal microscopy showed that the 
intracellular NS1 was decreased in the attenuated NS1 glycosylation mutant virus 
infected Vero cells. Western blotting showed that secreted NS1 was also decreased 
independent o f secreted E protein for mutant viruses that also showed the greatest 
reduction in infectivity titre in cell culture and attenuation in mice. Others have 
shown that there is a delay in the secretion o f the NS 1 protein compared to the release 
of the virus particle in cell culture (Macdonald et al., 2005). These results suggest that 
the NS1 protein may not be involved in the release o f the virus.
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NS1 has been shown to colocalize with dsRNA and, therefore, is speculated to be a 
part o f  the replication complex (Mackenzie et al, 1996). The deletion o f the NS 1 
gene is lethal and therefore, the protein is necessary for replication o f the virus, 
however, the NS 1 protein may be supplied in trans which may indicate its function is 
independent o f other proteins (Lindenbach and Rice, 1997). Since the NS 1 protein 
showed differences in cell culture indicated by immunofluorescence, electron 
microscopy was used to further understand the affects o f the NS1 glycosylation 
mutations in cell culture. Transmission EM of cells infected with the highly mouse 
attenuated N S1 glycosylation mutant virus, N S 1 i 3o-i 32q q a / 175a /207a ,  showed many 
differences in the ultrastructure from that seen in the parental NY99-infected Vero 
cells. The most notable difference was the size and shape o f the smooth membrane 
structures (SMS), previously described as flavivirus induced vesicles that contain the 
replication complex (Westaway et al., 1997). West Nile virus-infected mosquito cells 
showed similar shaped SMS (Girard et al., 2005). Since mosquito cells lack the 
enzymes required for the addition o f complex carbohydrates, it is likely that the loss o f 
NS 1 glycosylation resulted in the changes o f the SMS seen in Vero cells. This was 
the first study to identify a link in the formation o f the SMS and the NS 1 protein. 
Another interesting finding was the reduction in the presence of convoluted 
membranes (CM) and paracrystaliine arrays (PC) in the N S I13 0 -13 2 Q Q A /17 5 A /2 0 7Amutant- 
infected Vero cells. Although these membranes have been previously described in 
flavivirus-infected cells, no definitive function for these structures has been identified. 
The CM structures have been found to contain the protease NS3 and cofactor NS2B, 
and hypothesized to be the site o f proteolytic cleavage (Mackenzie et al., 1998). 
Immuno-EM o f the E protein revealed the presence o f this protein within the CM, 
suggesting a wider function for this structure (see chapter 8). The CMs were
2 2 1
consistently found in close proximity to the nucleus and hypothesized to be the site of 
virus assembly. Perhaps its location near the nucleus is necessary for assembly, and 
the capsid protein translocation to the nucleus may be necessary to perform assembly 
at this [perinuclear] location. Paracrystalline arrays are sometimes found in 
association with the CM and are hypothesized to be intermediate structures formed by 
the concentration o f SMS that dissociate into CM. Given these data, the current 
hypothesis for virus replication in cells culture are as follows: 1) virus entry 2) fusion 
and disassembly 3) translation 4) formation o f SMS by the NS1 protein that contains 
the replication complex 5) transport o f the SMS in close proximity to the nucleus 6) 
localization o f SMS near the nucleus and formation o f PC 7) dissociation o f PC into 
CM 8) virus assembly 9) maturation and release o f the virus 10) secretion o f NS1.
Since the NS 1 protein is secreted from the cell after the release o f the virus, this 
protein may not be involved in maturation or release o f the virus. The function o f this 
protein may be in the formation o f SMS and transport of the replication complex in 
close proximity to the nucleus where assembly occurs. It is unclear why there would 
be a delay in the secretion o f the NS1 protein, however, studies have shown that the 
majority o f the NS 1 remains intracellular while only a small fraction is released from 
the cell (Macdonald et al., 2005).
A larger TEM study is necessary to understand the ultrastructural changes caused by 
the NS 1 mutations. Other cell lines should be used to confirm the changes in the SMS 
structures. Also, other NS1 glycosylation mutant viruses should be used to confirm 
that the results seen in Chapter 8 were the result o f the loss o f glycosylation and not 
due to reduction in efficiency o f virus replication. At the same time, various time 
points in the replication cycle o f the parental NY99 and attenuated strains may also
2 2 2
elucidate if  the ultrastructural changes are seen early and late in infection. This study 
may be extended to include changes in other proteins. Previous studies have shown 
that NS4A and NS4B proteins may be involved in the formation o f virus-induced 
structures (Egger et al., 2002; Roosendaal et al., 2006; Miller et al., 2007). Therefore, 
including mutations in the NS1 and other NS proteins may lead to greater changes in 
the ultrastructure and could lead to a greater understanding o f the synergy between 
proteins.
Recently the NS 1 protein has been implicated in complement activation resulting in 
vascular leakage, which can lead to lethal dengue hemorrhagic fever (DHF) 
(Avirutnan et al., 2006). It has been known for some time that the NS 1 protein elicits 
a protective immune response probably due to the complement binding capabilities o f 
NS1 antibodies (Schlesinger et al., 1986; Schlesinger et al., 1987; Chung et al., 2006). 
West Nile virus-infected hamsters have been shown to secrete NS1 similar to the in 
vitro findings in that the secretion o f the protein occurs after the release o f mature 
virus and only a fraction o f the NS1 was found extracellularly (Macdonald et al., 
2005). This systematic secretion o f the NS 1 protein after the release o f the virus was, 
therefore, hypothesized to have a functional role, possibly immunomodulatory, rather 
than an accidental release o f the protein due to cell damage (Macdonald et al., 2005). 
NS1 has been shown to play a  role in antibody dependent cellular cytoxicity and 
complement fixation (reviewed by Gibson et al., 1988), which is consistent with a role 
in the immune response. Since WNV does not cause vascular leakage like DHF, the 
NS1 protein may be involved in various aspects o f the immune response. The NS1 
glycosylation mutant viruses described in chapters 4 to 6 showed reduction o f the 
secretion o f the NS1 protein and were attenuated in mice. Viraemia studies showed
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that the highly attenuated NS1 glycosylation mutant viruses displayed reduced or no 
viraemia, however, these viruses were replication competent in cell culture. The NS 1 
glycosylation mutant viruses did show a greater difference in the multiplication 
compared to the parental NY99 strain in the macrophage P388 D1 cells than the 
mammalian Vero cells, which may indicate multiple factors contributing to the 
attenuation o f these viruses, including an immunomodulatory role. Cytokine 
expression assays o f the parental NY99 and attenuated NS1 glycosylation mutant 
viruses in mice showed up- and down-regulation o f several cytokines. Far more 
publications report the up-regulation o f cytokine and their affects on the control o f the 
virus than report down-regulation o f cytokines. Chapter 9 explored the expression of 
secreted cytokines in the serum of infected mice and found that far more cytokines 
were down-regulated compared to the mock-infected mice. Some down-regulated 
cytokines corresponded with a poor outcome and therefore, it is hypothesized that 
WNV can suppress the immune response to infection, which may contribute to lethal 
infection. Although the down-regulation o f these cytokines cannot be directly 
associated with the secretion, or lack of, o f the NS1 protein, it is possible that the 
reduction o f secreted NS1 did contribute to the cytokine expression.
In order to further understand the immunomodulatory capabilities o f the NS 1 protein, 
it is important to first determine that immune changes are the result of the NS1 
protein. Mice given the NS 1 protein alone may show some changes in the cytokine 
expression determined using the same assays described in Chapter 9 and inoculation 
of various knockout strains o f mice with the NS1 mutants may help understand the 
interaction o f NS1 with the immune system. Since mice inoculated with the 
attenuated strain did not show viraemia, the level o f  secreted NS1 cannot be
224
determined in these mice. However, it is hypothesized that the reduction o f secreted 
NS1 resulted in inefficient replication and faster clearance o f the virus. If correct, the 
induction o f NS1 protein (in trans) simultaneous with infection o f the attenuated NS1 
mutant virus should result in increased mortality. Studies combining the attenuated 
mutant virus with wild-type NS1 protein may lead to a better understanding of the 
mechanism of attenuation for these mutant viruses.
These data indicate that the NS1 protein functions in various ways necessary for the 
replication of the vims and may have immunomodulatory capabilities. In light o f 
these results, the NS1 protein may be a good therapeutic target for treatment of not 
only WNV, but also other flavivirus infections, such as DHF where high levels of 
circulating NS1 have been linked to a poor outcome. Finally, the ablation of the NS1 
glycosylation sites in combination with the ablated E glycosylation site was 
replication competent in vaccine-certified Vero cells, mice showed little to no 
viraemia, even when inoculated with high doses o f the virus, and were protected from 
subsequent challenge with a lethal dose o f the parental strain, even in mice that were 
inoculated with low doses o f mutant virus. In conclusion, these viruses proved to be 
effective components o f future vaccine candidates.
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